

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACDR1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	OCT 04	Precision of EMBASE searching enhanced with new chemical name field
NEWS	3	OCT 06	Increase your retrieval consistency with new formats or for Taiwanese application numbers in CA/CAPLUS.
NEWS	4	OCT 21	CA/CAPLUS kind code changes for Chinese patents increase consistency, save time
NEWS	5	OCT 22	New version of STN Viewer preserves custom highlighting of terms when patent documents are saved in .rtf format
NEWS	6	OCT 28	INPADOCDB/INPAFAMDB: Enhancements to the US national patent classification.
NEWS	7	NOV 03	New format for Korean patent application numbers in CA/CAPLUS increases consistency, saves time.
NEWS	8	NOV 04	Selected STN databases scheduled for removal on December 31, 2010
NEWS	9	NOV 18	PROUSDDR and SYNTHLINE Scheduled for Removal December 31, 2010 by Request of Prou Science
NEWS	10	NOV 22	Higher System Limits Increase the Power of STN Substance-Based Searching
NEWS	11	NOV 24	Search an additional 46,850 records with MEDLINE backfile extension to 1946
NEWS	12	DEC 14	New PNK Field Allows More Precise Crossover among STN Patent Databases
NEWS	13	DEC 18	ReaxysFile available on STN
NEWS	14	DEC 21	CAS Learning Solutions -- a new online training experience
NEWS	15	DEC 22	Value-Added Indexing Improves Access to World Traditional Medicine Patents in CAPLUS
NEWS	16	JAN 24	The new and enhanced DPCI file on STN has been released
NEWS	17	JAN 26	Improved Timeliness of CAS Indexing Adds Value to USPATFULL and USPAT2 Chemistry Patents
NEWS	18	JAN 26	Updated MeSH vocabulary, new structured abstracts, and other enhancements improve searching in STN reload of MEDLINE
NEWS	19	JAN 28	CABA will be updated weekly
NEWS	20	FEB 23	PCTFULL file on STN completely reloaded
NEWS	21	FEB 23	STN AnaVist Test Projects Now Available for Qualified Customers
NEWS	22	FEB 25	LPCI will be replaced by LDPCI
NEWS	23	MAR 07	Pricing for SELECTing Patent, Application, and Priority Numbers in the USPAT and IFI Database Families is Now Consistent with Similar Patent Databases on STN
NEWS	24	APR 26	Expanded Swedish Patent Application Coverage in CA/CAPLUS Provides More Current and Complete Information
NEWS	25	APR 28	The DWPI (files WPINDEX, WPIDS and WPIX) on STN have been enhanced with thesauri for the European Patent Classifications

NEWS 26 MAY 02 MEDLINE Improvements Provide Fast and Simple Access to DOI and
Chemical Name Information
NEWS 27 MAY 12 European Patent Classification thesauri added to the INPADOC
files, PCTFULL, GBFULL and FRFULL
NEWS 28 MAY 20 PATDPA database updates to end in June 2011
NEWS 29 MAY 23 STN biosequence searches with enhanced performance
NEWS 30 MAY 23 Free Trial of the Numeric Property Search Feature
in PCTFULL on STN

NEWS EXPRESS 17 DECEMBER 2010 CURRENT WINDOWS VERSION IS V8.4.2 .1,
AND CURRENT DISCOVER FILE IS DATED 24 JANUARY 2011.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial
gateways, or use of CAS and STN data in the building of commercial
products is prohibited and may result in loss of user privileges
and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:52:54 ON 25 MAY 2011

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.23	0.23

FILE 'REGISTRY' ENTERED AT 09:53:16 ON 25 MAY 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAY 2011 HIGHEST RN 1299596-13-6
DICTIONARY FILE UPDATES: 24 MAY 2011 HIGHEST RN 1299596-13-6

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH January 14, 2011.


Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdnc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10598281FOAM1.str



```
chain nodes :
10 17 18 19 20 21 22 23 24 25 26
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16
chain bonds :
2-25 3-24 4-20 5-26 9-10 10-11 14-17 17-18 17-19 20-21 21-22 21-23
ring bonds :
1-2 1-6 1-9 2-3 3-4 4-5 5-6 6-7 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16
exact/norm bonds :
1-9 6-7 7-8 8-9 17-18 17-19
exact bonds :
2-25 3-24 4-20 5-26 9-10 10-11 14-17 20-21 21-22 21-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
```

```
Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS
```

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 09:53:36 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 215 TO ITERATE
100.0% PROCESSED 215 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 3421 TO 5179
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 196.35 U.S. DOLLARS
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
FULL SEARCH INITIATED 09:53:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4548 TO ITERATE

100.0% PROCESSED 4548 ITERATIONS 18 ANSWERS
SEARCH TIME: 00.00.01

L3 18 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 196.86 197.09

FILE 'CAPLUS' ENTERED AT 09:53:51 ON 25 MAY 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 May 2011 VOL 154 ISS 22
FILE LAST UPDATED: 24 May 2011 (20110524/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2011
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2011

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>



This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3
L4 1 L3

=> d ibib abs

L4 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2005:1042216 CAPLUS
DOCUMENT NUMBER: 143:347050
TITLE: Preparation of
4-(5-(aminomethyl)indole-1-ylmethyl)benzamide
derivatives as opioid receptor antagonists for the
treatment of obesity
INVENTOR(S): Benesh, Dana Rae; Blanco-Pillado, Maria-Jesus
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2005090303	A1	20050929	WO 2005-US7702	20050309
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2558030	A1	20050929	CA 2005-2558030	20050309
EP 1751103	A1	20070214	EP 2005-725070	20050309
EP 1751103	B1	20090114		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2007529523	T	20071025	JP 2007-503959	20050309
AT 420858	T	20090115	AT 2005-725070	20050309
ES 2318472	T3	20090501	ES 2005-725070	20050309
US 20070155793	A1	20070705	US 2006-598281	20060823
PRIORITY APPLN. INFO.:			US 2004-553176P	P 20040315
			WO 2005-US7702	W 20050309
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):			CASREACT 143:347050; MARPAT 143:347050	
GI				



AB Title comps. represented by the formula I [wherein X1 = CH2, CH or N; X2 = CH or N; R1, R2 = independently H, alkyl(aryl), alkenyl, etc.; R3, R3' = independently H, alkyl, alkynyl, etc.; R4, R5 = independently H, (halo)alkyl, aryl, etc.; m = 0-2; n = 0-2; p = 0-2; and pharmaceutically acceptable salts, solvates, prodrugs, enantiomers, racemates, diastereomers and diastereomeric mixture thereof] were prepared as opioid receptor antagonists. For example, II was provided in a multi-step synthesis starting from the reaction of 5-formylindole with 4-bromomethylbenzonitrile. I were tested for antagonistic activity of mu-, gamma- and delta-opioid receptor in SPA-based GTPyS binding assay, and their pharmaceutical formulations were also presented. Thus, I and their pharmaceutical comps. are useful as opioid receptor antagonists for the treatment of obesity (no data).

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.72	200.81
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.87	-0.87

FILE 'REGISTRY' ENTERED AT 09:54:29 ON 25 MAY 2011
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAY 2011 HIGHEST RN 1299596-13-6
 DICTIONARY FILE UPDATES: 24 MAY 2011 HIGHEST RN 1299596-13-6

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH January 14, 2011.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10598281FOAM1a.str




```
chain nodes :
10 11 12 13 14
ring nodes :
1 2 3 4 5 6 7 8 9 15 16 17 18 19 20
chain bonds :
9-10 10-16 11-12 12-13 12-14
ring bonds :
1-2 1-6 1-9 2-3 3-4 4-5 5-6 6-7 7-8 8-9 15-16 15-20 16-17 17-18 18-19
19-20
exact/norm bonds :
1-9 6-7 7-8 8-9
exact bonds :
9-10 10-16 11-12 12-13 12-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 15-16 15-20 16-17 17-18 18-19 19-20
```

Match level :

```
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 23:Atom
```

=> d l5
 L5 HAS NO ANSWERS
 L5 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l5 sss sam
 SAMPLE SEARCH INITIATED 09:57:04 FILE 'REGISTRY'
 SAMPLE SCREEN SEARCH COMPLETED - 8867 TO ITERATE

100.0% PROCESSED 8867 ITERATIONS 0 ANSWERS
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**
 PROJECTED ITERATIONS: 171695 TO 182985
 PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L5

=> s l5 sss full
 THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 196.35 U.S. DOLLARS
 DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y
 FULL SEARCH INITIATED 09:57:13 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 176794 TO ITERATE

100.0% PROCESSED 176794 ITERATIONS 30 ANSWERS
 SEARCH TIME: 00.00.01

L7 30 SEA SSS FUL L5

=> file caplus
 COST IN U.S. DOLLARS

SINCE FILE TOTAL
 ENTRY SESSION

FULL ESTIMATED COST	198.90	399.71
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-0.87

FILE 'CAPLUS' ENTERED AT 09:57:16 ON 25 MAY 2011
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 May 2011 VOL 154 ISS 22
 FILE LAST UPDATED: 24 May 2011 (20110524/ED)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2011
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2011

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l7

L8 9 L7

=> d ibib abs hitstr 1-9

L8 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2010:1400899 CAPLUS
 DOCUMENT NUMBER: 153:596083
 TITLE: S1P3 receptor inhibitors for treating conditions of the eye
 INVENTOR(S): Donello, John E.; Dibas, Mohammed I.; Beard, Richard L.
 PATENT ASSIGNEE(S): Allergan, Inc., USA
 SOURCE: PCT Int. Appl., 108pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010129553	A1	20101111	WO 2010-US33553	20100504
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG,				

ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2009-175763P P 20090505


OTHER SOURCE(S): MARPAT 153:596083

AB Disclosed herein are compns. and methods for treating conditions of the eye using S1P3 receptor inhibitors.

IT 1254474-63-9 1254474-64-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (S1P3 receptor inhibitors for treating conditions of eye)


RN 1254474-63-9 CAPLUS

CN 1H-Indole-3-carboxamide, N-[(3,4-difluorophenyl)methyl]-5-[(ethylamino)methyl]-2-(1-methylethyl)-1-(phenylmethyl)- (CA INDEX NAME)



RN 1254474-64-0 CAPLUS

CN 1H-Indole-3-carboxamide, N-[(3,4-difluorophenyl)methyl]-2-(1-methylethyl)-1-(phenylmethyl)-5-[(propylamino)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2009:1163615 CAPLUS

DOCUMENT NUMBER: 151:396098

TITLE: S1P3 receptor inhibitors for treating inflammation

INVENTOR(S): Donello, John E.; Dibas, Mohammed I.

PATENT ASSIGNEE(S): Allergan, Inc., USA

SOURCE: PCT Int. Appl., 91 pp.

DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 1 English
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009117335	A2	20090924	WO 2009-US37219	20090316
WO 2009117335	A3	20091210		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2009225747	A1	20090924	AU 2009-225747	20090316
CA 2718705	A1	20090924	CA 2009-2718705	20090316
EP 2262497	A2	20101222	EP 2009-722947	20090316
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, RS			
JP 2011514385	T	20110506	JP 2011-500883	20090316
US 20110009453	A1	20110113	US 2010-922629	20100914
PRIORITY APPLN. INFO.:			US 2008-37250P	P 20080317
			WO 2009-US37219	W 20090316

OTHER SOURCE(S): MARPAT 151:396098


AB Disclosed herein are compns. and methods for treating inflammation using sphingosine-1-phosphate S1P3 receptor inhibitors.

IT 1040027-53-9 1040027-54-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (selective sphingosine-1-phosphate S1P3 receptor inhibitors for treating inflammation)


RN 1040027-53-9 CAPLUS

CN 1H-Indole-3-carboxamide, N-[(3,4-difluorophenyl)methyl]-6-[(ethylamino)methyl]-2-(1-methylethyl)-1-(phenylmethyl)- (CA INDEX NAME)



RN 1040027-54-0 CAPLUS

CN 1H-Indole-3-carboxamide, N-[(3,4-difluorophenyl)methyl]-2-(1-methylethyl)-1-(phenylmethyl)-6-[(propylamino)methyl]- (CA INDEX NAME)



L8 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2008:889426 CAPLUS

DOCUMENT NUMBER: 149:176179

TITLE: Preparation of 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor agonist and/or antagonist biological activity

INVENTOR(S): Beard, Richard L.; Yuan, Haigang

PATENT ASSIGNEE(S): Allergan, Inc., USA

SOURCE: PCT Int. Appl., 57pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008089015	A1	20080724	WO 2008-US50695	20080110
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2008206495	A1	20080724	AU 2008-206495	20080110
CA 2674946	A1	20080724	CA 2008-2674946	20080110
KR 2009101307	A	20090924	KR 2009-7016762	20080110
EP 2125723	A1	20091202	EP 2008-727502	20080110
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR				
JP 2010515750	T	20100513	JP 2009-545669	20080110
US 20080171772	A1	20080717	US 2008-13239	20080111
AU 2008347006	A1	20090716	AU 2008-347006	20080710
CA 2711815	A1	20090716	CA 2008-2711815	20080710
WO 2009088531	A1	20090716	WO 2008-US69648	20080710
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 2238109 A1 20101013 EP 2008-870363 20080710

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS

KR 2011005679 A 20110118 KR 2010-7017718 20080710

MX 2009007334 A 20090715 MX 2009-7334 20090707

IN 2009DN04500 A 20100514 IN 2009-DN4500 20090709

CN 101668741 A 20100310 CN 2008-80007131 20090904

MX 2010007588 A 20100806 MX 2010-7588 20100709

IN 2010DN05120 A 20110225 IN 2010-DN5120 20100715

PRIORITY APPLN. INFO.: US 2007-884470P P 20070111

WO 2008-US50695 W 20080110

US 2008-13239 A 20080111

WO 2008-US69648 W 20080710

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 149:176179; MARPAT 149:176179

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compound I [R1-4 independently = H, alkyl, alkenyl, alkynyl, etc.; X and X1 independently = NR5, O or S; R5 = H, alkyl, cycloalkyl, Ph or alkylphenyl; Y = carbocyclic aryl or heterocyclic aryl; Z = O or S; n = 0-5; m = 0-3; p = 0-3; each q independently = 0-1; A, A1 and A2 independently = alkyl, cycloalkyl, alkenyl, alkynyl, etc.; B = H, OR6, COOR7, NR8R9, etc., wherein R6-9 independently = H, (un)substituted alkyl, alkenyl, alkynyl, carbocyclic hydrocarbon or heterocyclyl], and their pharmaceutically acceptable salts having sphingosine-1-phosphate receptor agonist and/or antagonist biol. activity, are prepared Thus, e.g., II was prepared by condensation reaction of 1-iodobutane with 1-benzyl-N-(3,4-difluorobenzyl)-6-hydroxy-2-isopropyl-1H-indole-3-carboxamide which was prepared from Me 6-methoxy-1H-indole-2-carboxylate with benzyl bromide in 7 steps. I were assessed for their ability to activate or block activation of the human S1P receptor in T24 cells. From the assay, I were found to have the activity to inhibit S1P receptor, e.g., II demonstrated IC50 of 3 nM with 100% inhibition. I should prove useful for treating a disease or condition selected from the group consisting of glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, and wound healing.


IT 1040027-53-9P 1040027-54-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of indolecarboxamides as sphingosine-1-phosphate (S1P) receptor agonists and/or antagonists)

RN 1040027-53-9 CAPLUS

CN 1H-Indole-3-carboxamide, N-[(3,4-difluorophenyl)methyl]-6-[(ethylamino)methyl]-2-(1-methylethyl)-1-(phenylmethyl)- (CA INDEX NAME)






RN 1040027-54-0 CAPLUS
 CN 1H-Indole-3-carboxamide, N-[(3,4-difluorophenyl)methyl]-2-(1-methylethyl)-1-(phenylmethyl)-6-[(propylamino)methyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L8 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2007:196791 CAPLUS
 DOCUMENT NUMBER: 146:441968
 TITLE: Synthesis of N-Protected Staurosporinones
 AUTHOR(S): Wada, Yasuhiro; Nagasaki, Hideo; Tokuda, Masao; Orito, Kazuhiko
 CORPORATE SOURCE: Laboratory of Organic Synthesis, Division of Molecular Chemistry, Graduate School of Engineering, Hokkaido University, Sapporo, 060-8628, Japan
 SOURCE: Journal of Organic Chemistry (2007), 72(6), 2008-2014
 CODEN: JOCEAH; ISSN: 0022-3263
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 146:441968
 GI



- AB I [R = H, 2,6-Me2C6H3CH2, 2,4,6-(MeO)3C6H2CH2; R1 = H, PhCH2] are prepared from N-benzyl-3-indoleacetonitrile and 3-indolemethyltrimethylammonium iodide using a sequential acid- and oxidant-mediated cyclocondensation and a palladium-catalyzed oxidative cyclocarbonylation as the key steps. Lithiation of N-benzyl-3-indoleacetonitrile and coupling to 3-indolemethyltrimethylammonium iodide yields a bisindole which cyclizes in trifluoroacetic acid and undergoes dehydrogenation with DDQ to yield indolocarbazolecarbonitrile II (R2 = CN); the use of either palladium-catalyzed cyclocondensation conditions or oxidation with chloranil followed by oxidative cyclocondensation with iodine and air yields II (R2 = CN) in significantly lower yields. Cobalt-mediated reduction of II (R = CN) to the amine II (R = NH2CH2) and reductive amination with benzaldehydes R3CHO [R3 = 2,6-Me2C6H3, 2,4,6-(MeO)3C6H2] provides II [R2 = R3NHCH2; R3 = 2,6-Me2C6H3, 2,4,6-(MeO)3C6H2]. Oxidative cyclocarbonylation of II [R2 = 2,6-Me2C6H3CH2NHCH2, 2,4,6-(MeO)3C6H2CH2NHCH2] with copper (II) acetate in the presence of palladium acetate in refluxing toluene or DMSO at 110° gives I [R = 2,6-Me2C6H3CH2, 2,4,6-(MeO)3C6H2CH2; R1 = PhCH2] in 15-50% yields; cleavage of the N-benzyl protecting groups of I [R = 2,6-Me2C6H3CH2, 2,4,6-(MeO)3C6H2CH2; R1 = PhCH2] with aluminum trichloride and anisole yields I (R = R1 = H) in 71-99% yields. Two isoindolinones III (R4 = PhCH2, 2,6-Me2C6H3CH2) are prepared in 67% and 31% yields, resp., by oxidative carbonylation of PhCH2NHR4 (R4 = PhCH2, 2,6-Me2C6H3CH2) with copper (II) acetate in the presence of palladium acetate in refluxing toluene.
- IT 934506-85-1P 934506-86-2P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of staurosporinones using oxidative acid-mediated cyclocondensation and oxidative cyclocarbonylation reactions as key steps)
- RN 934506-85-1 CAPLUS
- CN Indolo[2,3-a]carbazole-5-methanamine,
 N-[(2,6-dimethylphenyl)methyl]-11,12-dihydro-12-(phenylmethyl)- (CA INDEX NAME)



RN 934506-86-2 CAPLUS
 CN Indolo[2,3-a]carbazole-5-methanamine,
 11,12-dihydro-12-(phenylmethyl)-N-[(2,4,6-trimethoxyphenyl)methyl]- (CA
 INDEX NAME)



OS.CITING REF COUNT: 19 THERE ARE 19 CAPLUS RECORDS THAT CITE THIS
 RECORD (19 CITINGS)
 REFERENCE COUNT: 135 THERE ARE 135 CITED REFERENCES AVAILABLE FOR
 THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L8 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2011 ACS on SIN

ACCESSION NUMBER: 2005:1103733 CAPLUS

DOCUMENT NUMBER: 143:386930

TITLE: Preparation of 2-amino- and 2-thio-substituted
 1,3-diaminopropanes as β -secretase inhibitors for
 treating Alzheimer's disease and other diseases
 characterized by deposition of A β -peptide
 INVENTOR(S): Hom, Roy; Tucker, John; John, Varghese; Shah, Neerav
 PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn
 Company

SOURCE: PCT Int. Appl., 365 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005095326	A2	20051013	WO 2005-US9920	20050325
WO 2005095326	A3	20051110		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
 SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

CA 2560773 A1 20051013 CA 2005-2560773 20050325
 US 20050267199 A1 20051201 US 2005-90520 20050325
 US 7544717 B2 20090609
 EP 1751091 A2 20070214 EP 2005-741943 20050325


R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,
 HR, LV, MK, YU

BR 2005009186 A 20070828 BR 2005-9186 20050325
 JP 2007530583 T 20071101 JP 2007-505201 20050325
 MX 2006010899 A 20061215 MX 2006-10899 20060922

PRIORITY APPLN. INFO.:

US 2004-556461P P 20040325
 WO 2005-US9920 W 20050325

OTHER SOURCE(S): MARPAT 143:386930
 GI



II

AB Title compds. of formula Z-X-NHCH(R1)CH(Q)C(R2)(R3)N(R15)(Rc) (I) [Q = SH and derivs., NH and derivs.; Z = H, (un)substituted cycloalkylalk(en/yn)yl, cycloalkyl; X = CO, SO2; R1 = (un)substituted alkyl; R2, R3 = independently H, F, (un)substituted alk(en/yn)yl, hetero/aryl, etc.; R2CR3 = 3-7 membered carbocyclic ring with 1-3 C atoms optionally replaced by O, S, SO2, CO, NH and derivs.; R15 = H, (un)substituted alkyl, alkoxy, etc.; Rc = (un)substituted (CH2)n-cycloalkyl, etc.; n = 0-3] were prepared. Compds. disclosed herein are inhibitors of the β -secretase enzyme (no data) and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal (no data). For example, II was prepared, in 4 steps, by reacting benzyl 4-amino-6-ethyl-3,4-dihydroquinoline-1(2H)-carboxylate with [(1S)-2-(3,5-difluorophenyl)-1-((2S)-oxiran-2-yl)ethyl]carbamate, followed by Boc-deprotection, acetylation in the presence of N,N-diacetyl-O-methylhydroxylamine/CH2Cl2, and Cbz-deprotection.

IT 1044707-53-0 1044707-54-1


RL: PRPH (Prophetic)

(Preparation of 2-amino- and 2-thio-substituted 1,3-diaminopropanes as β -secretase inhibitors for treating Alzheimer's disease and other diseases characterized by deposition of A β -peptide)

RN 1044707-53-0 CAPLUS


CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.




RN 1044707-54-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Relative stereochemistry.




IT 676137-42-1P 676137-48-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(drug candidate; preparation of 2-amino- and 2-thio-substituted
1,3-diaminopropanes as β -secretase inhibitors for treating
Alzheimer's disease and other diseases characterized by deposition of
 $\text{A}\beta$ -peptide)
RN 676137-42-1 CAPLUS
CN Acetamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[2,3-dihydro-5-(2-
methylpropyl)-1-(phenylmethyl)-1H-indol-7-yl]methyl]amino]-2-
hydroxypropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 676137-48-7 CAPLUS
 CN Acetamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[5-(2-methylpropyl)-1-(phenylmethyl)-1H-indol-7-yl]methyl]amino]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (12 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2005:1042216 CAPLUS
 DOCUMENT NUMBER: 143:347050
 TITLE: Preparation of 4-(5-(aminomethyl)indole-1-ylmethyl)benzamide derivatives as opioid receptor antagonists for the treatment of obesity
 INVENTOR(S): Benesh, Dana Rae; Blanco-Pillado, Maria-Jesus
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090303	A1	20050929	WO 2005-US7702	20050309



W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2558030	A1	20050929	CA 2005-2558030	20050309
EP 1751103	A1	20070214	EP 2005-725070	20050309
EP 1751103	B1	20090114		
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
JP 2007529523	T	20071025	JP 2007-503959	20050309
AT 420858	T	20090115	AT 2005-725070	20050309
ES 2318472	T3	20090501	ES 2005-725070	20050309
US 20070155793	A1	20070705	US 2006-598281	20060823

PRIORITY APPLN. INFO.:

US 2004-553176P	P	20040315
WO 2005-US7702	W	20050309

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): CASREACT 143:347050; MARPAT 143:347050
 GI



AB Title compds. represented by the formula I [wherein X1 = CH2, CH or N; X2 = CH or N; R1, R2 = independently H, alkyl(aryl), alkenyl, etc.; R3, R3' = independently H, alkyl, alkynyl, etc.; R4, R5 = independently H, (halo)alkyl, aryl, etc.; m = 0-2; n = 0-2; p = 0-2; and pharmaceutically acceptable salts, solvates, prodrugs, enantiomers, racemates, diastereomers and diastereomeric mixture thereof] were prepared as opioid receptor antagonists. For example, II was provided in a multi-step synthesis starting from the reaction of 5-formylindole with 4-bromomethylbenzonitrile. I were tested for antagonistic activity of mu-, gamma- and delta-opioid receptor in SPA-based GTPgammaS binding assay, and their pharmaceutical formulations were also presented. Thus, I and their pharmaceutical compns. are useful as opioid receptor antagonists for the treatment of obesity (no data).


IT 865542-83-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of 4-(5-(aminomethyl)indole-1-ylmethyl)benzamide derivs. as
opioid receptor antagonists for treatment of obesity)

RN 865542-83-2 CAPLUS

CN Benzamide, 4-[[5-[[[2-(2-thienyl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]-
(CA INDEX NAME)



IT 865542-80-9P 865542-84-3P 865542-85-4P

865542-86-5P 865542-87-6P 865542-88-7P

865542-89-8P 865542-90-1P 865542-91-2P

865542-92-3P 865542-93-4P 865542-94-5P

865542-95-6P 865542-96-7P 865542-97-8P


865542-98-9P 865542-99-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of 4-(5-(aminomethyl)indole-1-ylmethyl)benzamide derivs. as
opioid receptor antagonists for treatment of obesity)


RN 865542-80-9 CAPLUS

CN Benzamide, 4-[[5-[[[3-methylbutyl]amino]methyl]-1H-indol-1-yl]methyl]-
(CA INDEX NAME)




RN 865542-84-3 CAPLUS

CN Benzamide, 4-[[5-[[[3,3-dimethylbutyl]amino]methyl]-1H-indol-1-yl]methyl]-
(CA INDEX NAME)




RN 865542-85-4 CAPLUS

CN Benzamide, 4-[[5-[[[2,3-dihydro-5-[[[2-(2-thienyl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]-
(CA INDEX NAME)




RN 865542-86-5 CAPLUS

CN Benzamide, 4-[[2,3-dihydro-5-[(3-methylbutyl)amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-87-6 CAPLUS

CN Benzamide, 4-[[5-[[[(3,3-dimethylbutyl)amino]methyl]-2,3-dihydro-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-88-7 CAPLUS

CN Benzamide, 4-[[5-[(hexylamino)methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-89-8 CAPLUS

CN Benzamide, 4-[[5-[[[(3-phenylpropyl)amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-90-1 CAPLUS

CN Benzamide, 4-[[5-[[[2-(2-fluorophenyl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-91-2 CAPLUS

CN Benzamide, 4-[[5-[[[2-(2-hydroxyethyl)amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-92-3 CAPLUS

CN Benzamide, 4-[[5-[[[2-(4-methoxyphenyl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-93-4 CAPLUS

CN Benzamide, 4-[[5-[[[2-(2-chloro-6-fluorophenyl)methyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-94-5 CAPLUS


CN Benzamide, 4-[[5-[[[2-(3-pyridinyl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-95-6 CAPLUS
 CN Benzamide, 4-[[5-[[2-(2-ethoxyphenyl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-96-7 CAPLUS
 CN Benzamide, 4-[[5-[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)



RN 865542-97-8 CAPLUS
 CN Benzamide, 4-[[5-[[2-(1-cyclohexen-1-yl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-98-9 CAPLUS
 CN Benzamide, 4-[[5-[[2-(3-fluorophenyl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)



RN 865542-99-0 CAPLUS

CN Benzamide, 4-[[5-[[[(2-ethylbutyl)amino]methyl]-1H-indol-1-yl]methyl]- (CA
INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2004:252298 CAPLUS

DOCUMENT NUMBER: 140:287268

TITLE: Preparation of ring-containing N-acetyl
2-hydroxy-1,3-diaminoalkanes as β -secretase
inhibitors for treating Alzheimer's disease and other
diseases characterized by deposition of
A β -peptide

INVENTOR(S): Maillard, Michel; Baldwin, Eric T.; Beck, James T.;
Hughes, Robert; John, Varghese; Pulley, Shon R.;
Tenbrink, Ruth

PATENT ASSIGNEE(S): Elian Pharmaceuticals, Inc., USA; Pfizer, Inc.;
Pharmacia & Upjohn Company, LLC

SOURCE: PCT Int. Appl., 459 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004024081	A2	20040325	WO 2003-US28503	20030910
WO 2004024081	A3	20050623		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2498248	A1	20040325	CA 2003-2498248	20030910
AU 2003267132	A1	20040430	AU 2003-267132	20030910
US 20040180939	A1	20040916	US 2003-658959	20030910
US 7244725	B2	20070717		
BR 2003014188	A	20050809	BR 2003-14188	20030910
EP 1565443	A2	20050824	EP 2003-749607	20030910
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1694870	A	20051109	CN 2003-824988	20030910
CN 100384824	C	20080430		
JP 2006504793	T	20060209	JP 2004-571986	20030910
NZ 539095	A	20070427	NZ 2003-539095	20030910
TW 336320	B	20110121	TW 2003-125081	20030910


NO 2005001239	A	20050606	NO 2005-1239	20050310
MX 2005002695	A	20050908	MX 2005-2695	20050310
KR 2006057520	A	20060526	KR 2005-7004161	20050310
IN 2005KN00409	A	20060421	IN 2005-KN409	20050314
IN 225649	A1	20081121		
ZA 2005001991	A	20050309	ZA 2005-1991	20051020
US 20070293483	A1	20071220	US 2006-447789	20060606
US 7645780	B2	20100112		
US 20100145056	A1	20100610	US 2009-624100	20091123
JP 2011084568	A	20110428	JP 2010-273586	20101208

PRIORITY APPLN. INFO.:

US 2002-409453P	P	20020910
US 2003-452231P	P	20030305
US 2003-491757P	P	20030801
JP 2004-571986	A3	20030910
US 2003-658959	A1	20030910
WO 2003-US28503	W	20030910
US 2006-447789	A3	20060606

OTHER SOURCE(S): MARPAT 140:287268

GI



AB Disclosed are Z-X-NHCH(R1)CH(OH)C(R2)(R3)N(R15)(Rc) (I; variables defined below; e.g. II). Compds. disclosed herein are inhibitors of the beta-secretase enzyme (no data) and are therefore useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal (no data). An unspecified method of preparation is claimed and >100 example preps. of intermediates and I are included. For example, II was prepared in 4 steps starting with preparation of (6-iodochroman-4-yl)amine from 6-iodo-4-chromanol followed by reaction with tert-Bu [(1S)-2-(3,5-difluorophenyl)-1-(2S)-oxiran-2-yl)ethyl]carbamate to give tert-Bu [(1S,2R)-1-(3,5-difluorobenzyl)-2-hydroxy-3-[(6-iodo-3,4-dihydro-2H-chromen-4-yl)amino]propyl]carbamate, followed by ethylation. For I: Z is H, (C3-C7 cycloalkyl)0-1(C1-C6 alkyl)-, (C3-C7 cycloalkyl)0-1(C2-C6 alkenyl)-, (C3-C7 cycloalkyl)0-1(C2-C6 alkynyl)- or (C3-C7 cycloalkyl)-; X = C(O), SO2; R1 is C1-C10 alkyl (un)substituted with 1, 2, or 3 halogen, -OH, -O-, -SH, -CN, -CF3, -OCF3, -C3-7 cycloalkyl, -C1-C4 alkoxy, amino, mono- or dialkylamino, aryl, heteroaryl, and heterocycloalkyl; R2 and R3 = H; F; -C1-C6 alkyl (un)substituted with -F, -OH, -CN, -CF3, C1-C3 alkoxy, or -NR5R6; -(CH2)0-2-R17; -(CH2)0-2-R18; -C2-C6 alkenyl or C2-C6 alkynyl;. R15 = H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 alkoxy C1-C6 alkyl, hydroxy C1-C6 alkyl, halo C1-C6 alkyl; R2, R3 and the C to which they are attached can form a C3-C7 carbocycle, wherein 1-3 C atoms are optionally replaced by -O-, -S-, -SO2-, -C(O)-, or -NR7-; Rc = -(CH2)0-3-(C3-C8) cycloalkyl, etc.; addnl. details are given in the claims.

IT 676137-42-1P 676137-48-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of ring-containing N-acetyl

2-hydroxy-1,3-diaminoalkanes as β -secretase inhibitors for treating Alzheimer's disease and other diseases characterized by deposition of A β -peptide)

RN 676137-42-1 CAPLUS

CN Acetamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-3-[[[2,3-dihydro-5-(2-methylpropyl)-1-(phenylmethyl)-1H-indol-7-yl]methyl]amino]-2-hydroxypropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 676137-48-7 CAPLUS

CN Acetamide, N-[(1S,2R)-1-[(3,5-difluorophenyl)methyl]-2-hydroxy-3-[[[5-(2-methylpropyl)-1-(phenylmethyl)-1H-indol-7-yl]methyl]amino]propyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 20 THERE ARE 20 CAPLUS RECORDS THAT CITE THIS RECORD (20 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1991:62458 CAPLUS

DOCUMENT NUMBER: 114:62458

ORIGINAL REFERENCE NO.: 114:10727a,10730a

TITLE: Attempted synthesis of olivacine isomers


AUTHOR(S): Kasturi, T. R.; Mathew, Lata; Sattigeri, J. A.

CORPORATE SOURCE: Dep. Org. Chem., Indian Inst. Sci., Bangalore, 560 012, India

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1990),


29B(11), 1004-6
CODEN: IJSBDB; ISSN: 0376-4699
Journal
English
CASREACT 114:62458

DOCUMENT TYPE:
LANGUAGE:
OTHER SOURCE(S):
GI



I


AB Attempted cyclization of tosyl lactone I with HCl/dioxane or P2O5/benzene gave, instead of olivacine isomers, only the cleaved product N-tosylaminoacetone.
IT 131713-52-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and N-tosylation of)
RN 131713-52-5 CAPLUS
CN 9H-Carbazole-3-methanamine, N-(2,2-dimethoxypropyl)-1-methyl-9-(phenylmethyl)- (CA INDEX NAME)




OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)

L8 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1990:572402 CAPLUS
DOCUMENT NUMBER: 113:172402
ORIGINAL REFERENCE NO.: 113:29249a,29252a
TITLE: Synthetic studies of indoles and related compounds.
Part 22. The Vilsmeier-Haack reaction of
N-benzyl-1,2,3,4-tetrahydrocarbazoles and its
synthetic application to olivacine and ellipticine
Yokoyama, Yuusaku; Okuyama, Naomi; Iwate, Shinji;
Momi, Tokuko; Murakami, Yasuoki
CORPORATE SOURCE: Sch. Pharm. Sci., Toho Univ., Funabashi, 274, Japan
SOURCE: Journal of the Chemical Society, Perkin Transactions
1: Organic and Bio-Organic Chemistry (1972-1999)
(1990), (5), 1319-29
CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 113:172402
GI




I



IV

AB Vilsmeier-Haack reaction of 9-benzyl-1,2,3,4-tetrahydrocarbazole at 120 °C gave 9-benzyl-1-methylcarbazole-3-carbaldehyde (I) and 9-benzyl-1-[N,N-(dimethylamino)methyl]carbazole-3-carbaldehyde in moderate yields, whereas, the same reaction at 0 °C gave 9-benzyl-1,2,3,4-tetrahydrocarbazole-1-carbaldehyde (II) in very good yield. II was converted into 9-benzyl-1-methylcarbazole by another Vilsmeier-Haack reaction. This carbazole unexpectedly underwent non-regioselective formylation under similar reaction conditions to give a mixture of compound I and 9-benzyl-8-methylcarbazole-3-carbaldehyde. On the basis of the above results, a mechanism of the formation of the aromatic aldehyde I was proposed, which involves 1,5-sigmatropic rearrangement of an N-methyldiene dimethylammonium cation from the 4a-position to the 3-position as a key step. Vilsmeier-Haack reaction of 9-benzyl-1,2,3,4-tetrahydro-4-methylcarbazole at 100 °C also gave 9-benzyl-1,4-dimethylcarbazole-3-carbaldehyde (III) in moderate yield. The total synthesis of two antitumor alkaloids, olivacine (IV) and ellipticine, were achieved by utilizing compds. I and III as key intermediates.

IT 129868-53-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and tosylation of)
 RN 129868-53-7 CAPLUS
 CN 9H-Carbazole-3-methanamine, N-(2,2-diethoxyethyl)-1,4-dimethyl-9-(phenylmethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (16 CITINGS)

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	54.16	453.87
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.83	-8.70

FILE 'REGISTRY' ENTERED AT 09:57:41 ON 25 MAY 2011

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAY 2011 HIGHEST RN 1299596-13-6
DICTIONARY FILE UPDATES: 24 MAY 2011 HIGHEST RN 1299596-13-6

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH January 14, 2011.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=> log hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.51	454.38

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-8.70

CA SUBSCRIBER PRICE

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 09:57:45 ON 25 MAY 2011

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACDR1614

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 10:01:54 ON 25 MAY 2011
FILE 'REGISTRY' ENTERED AT 10:01:54 ON 25 MAY 2011
COPYRIGHT (C) 2011 American Chemical Society (ACS)

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.51	454.38

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
0.00	-8.70

CA SUBSCRIBER PRICE

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	0.51	454.38
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	0.00	-8.70

FILE 'REGISTRY' ENTERED AT 10:02:11 ON 25 MAY 2011
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAY 2011 HIGHEST RN 1299596-13-6
 DICTIONARY FILE UPDATES: 24 MAY 2011 HIGHEST RN 1299596-13-6

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>


TSCA INFORMATION NOW CURRENT THROUGH January 14, 2011.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>
 Uploading C:\Program Files\STNEXP\Queries\10598281FOAM1b.str



chain nodes :
 10 19 20 21 22 23

```

ring nodes :
1  2  3  4  5  6  7  8  9  11 12 13 14 15 16
chain bonds :
9-10 10-12 19-20 19-21 21-22 21-23
ring bonds :
1-2 1-6 1-9 2-3 3-4 4-5 5-6 6-7 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16
exact/norm bonds :
1-9 6-7 7-8 8-9 19-20 19-21
exact bonds :
9-10 10-12 21-22 21-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 19:CLASS 20:CLASS 21:CLASS
22:CLASS 23:CLASS 24:Atom

```

L9 STRUCTURE UPLOADED

=> d l9

L9 HAS NO ANSWERS

L9 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l9 sss sam

SAMPLE SEARCH INITIATED 10:02:29 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 45563 TO ITERATE

100.0% PROCESSED 45563 ITERATIONS

24 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 898500 TO 924020

PROJECTED ANSWERS: 187 TO 773

L10 24 SEA SSS SAM L9

=> s l9 sss full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 196.35 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 10:02:34 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 914454 TO ITERATE

100.0% PROCESSED 914454 ITERATIONS

446 ANSWERS

SEARCH TIME: 00.00.02

L11 446 SEA SSS FUL L9

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST	196.86	651.24
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-8.70

FILE 'CAPLUS' ENTERED AT 10:02:39 ON 25 MAY 2011
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 May 2011 VOL 154 ISS 22
 FILE LAST UPDATED: 24 May 2011 (20110524/ED)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2011
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2011

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l11
 L12 55 L11

=> d ibib abs hitstr 55

L12 ANSWER 55 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1980:532369 CAPLUS
 DOCUMENT NUMBER: 93:132369
 ORIGINAL REFERENCE NO.: 93:21105a,21108a
 TITLE: Indole compounds and pharmaceutical compositions containing them
 INVENTOR(S): Webb, Colin Frederick
 PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
 SOURCE: Ger. Offen., 102 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2940687	A1	19800430	DE 1979-2940687	19791008
DE 2940687	C2	19910801		
ZA 7905239	A	19801126	ZA 1979-5239	19791002


FI 7903071	A	19800413	FI 1979-3071	19791004
DK 7904255	A	19800413	DK 1979-4255	19791009
AU 7951657	A	19800417	AU 1979-51657	19791010
AU 531783	B2	19830908		
GB 2035310	A	19800618	GB 1979-35208	19791010
GB 2035310	B	19821222		
US 4252803	A	19810224	US 1979-83343	19791010
AT 7906605	A	19840815	AT 1979-6605	19791010
AT 377511	B	19850325		
SE 7908443	A	19800413	SE 1979-8443	19791011
SE 448628	B	19870309		
SE 448628	C	19870618		
CH 646151	A5	19841115	CH 1979-9194	19791011
BE 879381	A1	19800201	BE 1979-197621	19791012
NL 7907583	A	19800415	NL 1979-7583	19791012
FR 2438651	A1	19800509	FR 1979-25446	19791012
FR 2438651	B1	19830304		
JP 55062063	A	19800510	JP 1979-130944	19791012
JP 63058817	B	19881117		
CA 1146550	A1	19830517	CA 1979-337443	19791012
			GB 1978-40279	A 19781012

PRIORITY APPLN. INFO.:


OTHER SOURCE(S):

MARPAT 93:132369

GI



I



II

AB The indole derivs. I [R, R1, R2, R3 = H, (substituted) alkyl, cycloalkyl, aryl, or aralkyl; RR1N, and R2R3N = ring; R4 = H, C1-3 alkyl, aryl; R5 = H, alkyl, aralkyl; Z = C1-4 alkylene; X = O, S] and their salts were prepared for use in treatment of hypertension and migraines (no data). Thus, II (R6 = CO2CH2Ph, R7 = OH) reacted with PhCH2NH2 in the presence of 2-chloro-1-methylpyridinium iodide to give II (R6 = CO2CH2Ph, R7 = NHCH2Ph), which was hydrogenated over Pd-C to give I (R6 = H, R7 = NHCH2Ph), isolated as compound with creatinine sulfate.

IT 74885-49-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 74885-49-7 CAPLUS

CN 1H-Indole-5-carboxamide, 3-(2-aminoethyl)-1-(phenylmethyl)-,
(2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 74885-48-6

CMF C18 H19 N3 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



OS.CITING REF COUNT: 29 THERE ARE 29 CAPLUS RECORDS THAT CITE THIS RECORD (30 CITINGS)

=> d ibib abs hitstr 1-55

L12 ANSWER 1 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2010:1609367 CAPLUS

DOCUMENT NUMBER: 154:173387

TITLE: The discovery of novel indole-2-carboxamides as cannabinoid CB1 receptor antagonists

AUTHOR(S): Cowley, Phillip M.; Baker, James; Barn, David R.; Buchanan, Kirsteen I.; Carlyle, Ian; Clark, John K.; Clarkson, Thomas R.; Deehan, Maureen; Edwards, Darren; Goodwin, Richard R.; Jaap, David; Kiyoi, Yasuko; Mort, Chris; Palin, Ronald; Prosser, Alan; Walker, Glenn; Ward, Nick; Wishart, Grant; Young, Trevor

CORPORATE SOURCE: Department of Chemistry, MSD, Newhouse, Lanarkshire, ML1 5SH, UK


SOURCE: Bioorganic & Medicinal Chemistry Letters (2011), 21(1), 497-501
CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I

AB The discovery and structure-activity relationship of a novel series of indole-2-carboxamide antagonists of the cannabinoid CB1 receptor is disclosed. Compound 26i (I) was found to be a high potency, selective cannabinoid CB1 antagonist.


IT 1262836-12-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(indolecarboxamides as cannabinoid CB1 receptor antagonists)

RN 1262836-12-3 CAPLUS

CN 1H-Indole-2,5-dicarboxamide, N2-(3-hydroxy-2,2-dimethylpropyl)-1-[[3-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2010:1342793 CAPLUS

DOCUMENT NUMBER: 153:554916

TITLE: A process for the preparation of frovatriptan and frovatriptan succinate and their intermediates

INVENTOR(S): Gore, Vinayak Govind; Gadkar, Maheshkumar; Tripathi, Anilkumar; Mankar, Viraj

PATENT ASSIGNEE(S): Generics UK Limited, UK; Mylan India Private Limited

SOURCE: PCT Int. Appl., 34pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2010122343	A1	20101028	WO 2010-GB50658	20100422
<p>W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW</p> <p>RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p>				
IN 2009K000657		A	20101029	IN 2009-KO657
PRIORITY APPLN. INFO.:		IN 2009-KO657		20090423
OTHER SOURCE(S):		CASREACT 153:554916		A 20090423


AB A process for preparation of 6-carboxamido-3-phthalimido-1,2,3,4-tetrahydrocarbazole comprises reaction of 4-aminobenzamide with nitrite in the presence of a mineral acid and a sulfonic acid, reduction of the resulting diazonium salt, and addition of (protected) 4-phthalimidocyclohexanone. Thus, 4-aminobenzamide in H₂O was treated sequentially with aqueous HCl, p-toluenesulfonic acid, aqueous NaNO₂, aqueous Na₂SO₃, MeOH, and 4-phthalimidocyclohexanone under cooling followed by heating at 75° for 8 h to give 70% 6-carboxamido-3-phthalimido-1,2,3,4-tetrahydrocarbazole.

IT 1253121-63-9P
 RL: IMF (Industrial manufacture); PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of frovatriptan and frovatriptan succinate and their intermediates)

RN 1253121-63-9 CAPLUS

CN 1H-Carbazole-6-carboxamide, 2,3,4,9-tetrahydro-3-(methylamino)-9-(phenylmethyl)-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 3 OF 55 CAPLUS COPYRIGHT 2011 ACS ON STN
 ACCESSION NUMBER: 2009:268662 CAPLUS
 DOCUMENT NUMBER: 150:298998
 TITLE: Use of secretory phospholipase A2 (SPLA2) inhibitors to decrease SPLA2 levels
 INVENTOR(S): Trias, Joaquim; Hislop, Colin

PATENT ASSIGNEE(S): Anthera Pharmaceuticals, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 48 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	US 20090062369	A1	20090305	US 2007-849243	20070831
PRIORITY APPLN. INFO.:				US 2007-849243	20070831


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Administration of sPLA2 inhibitors has been found to decrease sPLA2 levels in human serum. Provided herein are methods of decreasing serum sPLA2 levels in a subject in need thereof, as well as methods for accurately measuring sPLA2 levels in a serum sample.

IT 246513-34-8 246513-34-8D, salts and prodrug derivs.
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (use of secretory phospholipase A2 (sPLA2) inhibitors to decrease sPLA2 levels)

RN 246513-34-8 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 246513-34-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na

L12 ANSWER 4 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2009:86451 CAPLUS

DOCUMENT NUMBER: 150:160095

TITLE: Use of adenosine A2A receptor agonists and phosphodiesterase (PDE) inhibitors for the treatment of B-cell proliferative disorders, and combinations with other agents

INVENTOR(S): Rickles, Richard; Lee, Margaret S.

PATENT ASSIGNEE(S): CombinatoRx, Incorporated, USA

SOURCE: PCT Int. Appl., 70 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009011893	A2	20090122	WO 2008-US8758	20080717
WO 2009011893	A3	20090319		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
AU 2008276451	A1	20090122	AU 2008-276451	20080717
CA 2694983	A1	20090122	CA 2008-2694983	20080717
US 20090053168	A1	20090226	US 2008-175219	20080717
EP 2178369	A2	20100428	EP 2008-780231	20080717
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS			

PRIORITY APPLN. INFO.:

US 2007-950307P P 20070717

US 2007-965587P P 20070821


WO 2008-US8758 W 20080717

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention provides compns. and methods for the treatment of B-cell

proliferative disorders that employ an A2A receptor agonist or one or more PDE inhibitors. The methods and comps. may further include an antiproliferative compound

IT 184147-65-7
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (FR 181074; adenosine A2A receptor agonists and phosphodiesterase inhibitors for treatment of B-cell proliferative disorders, and combinations with other agents)
 RN 184147-65-7 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L12 ANSWER 5 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2009:83374 CAPLUS
 DOCUMENT NUMBER: 150:160094
 TITLE: Combinations for the treatment of B-cell proliferative disorders
 INVENTOR(S): Rickles, Richard; Pierce, Laura; Lee, Margaret S.
 PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA
 SOURCE: PCT Int. Appl., 79pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009011897	A1	20090122	WO 2008-US8764	20080717
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2008276455	A1	20090122	AU 2008-276455	20080717
CA 2694987	A1	20090122	CA 2008-2694987	20080717
US 20090047243	A1	20090219	US 2008-175121	20080717
EP 2178370	A1	20100428	EP 2008-780237	20080717

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI,
SK, TR, AL, BA, MK, RS

PRIORITY APPLN. INFO.:

US 2007-959877P P 20070717

US 2007-965595P P 20070821

WO 2008-US8764 W 20080717

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention features compns. and methods employing combinations of an A2A receptor agonist and a PDE (phosphodiesterase) inhibitor for the treatment of a B-cell proliferative disorder, e g, multiple myeloma. In at least one embodiment, the compns. of the invention comprise a PDE inhibitor active against at least two of PDE 2, 3, 4, and 7. In at least one embodiment, the compns. of the invention comprises further administering an antiproliferative compound


IT 184147-65-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(FR 181074; combinations for treatment of B-cell proliferative disorders using PDE inhibitors and A2A receptor agonists and antiproliferative compds.)

RN 184147-65-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 6 OF 55 CAPLUS COPYRIGHT 2011 ACS ON STN

ACCESSION NUMBER: 2007:1099326 CAPLUS

DOCUMENT NUMBER: 148:253384

TITLE: Design and bioassay of non-peptidic inhibitors of SARS coronavirus 3C-like proteinase

AUTHOR(S): Liu, Ying; Zheng, Teng-Fei; Jin, Feng; Zhou, Lu; Liu, Zhen-Ming; Wei, Ping; Lai, Lu-Hua

CORPORATE SOURCE: Beijing National Laboratory for Molecular Sciences, State Key Laboratory for Structural Chemistry of Unstable and Stable Species, College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871, Peop. Rep. China

SOURCE: Huaxue Xuebao (2007), 65(16), 1707-1712

CODEN: HHHHP4; ISSN: 0567-7351

PUBLISHER: Huaxue Xuebao Bianjibu

DOCUMENT TYPE: Journal

LANGUAGE: Chinese

OTHER SOURCE(S): CASREACT 148:253384

AB Severe acute respiratory syndrome (SARS) coronavirus 3C-like proteinase is the key enzyme for the maturation of the virus and has been proposed to be


a key target for structure based drug design against SARS. In this paper, based on the three-dimensional structure of SARS coronavirus 3C-like proteinase, the available chemical database (ACD) and clin. drug database were used for virtual screening, and the candidate non-peptidic compds. were purchased or synthesized. Several human rhinovirus (HRV) 3C protease inhibitors were also synthesized. All the compds. were tested against SARS 3C-like proteinase bioassay. Two types of compds. including hydroxyzine dihydrochloride, a well known antihistamine, were found to inhibit the enzyme and SARS virus in cell cultivating; one of the isatin compds. shows significant inhibition with an IC50 of (0.76±0.02) $\mu\text{mol}\cdot\text{L}^{-1}$. The primary result suggested that drugs in clin. usage can be developed for new purpose.

IT 184904-82-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(design and bioassay of non-peptidic inhibitors of SARS coronavirus 3C-like proteinase)

RN 184904-82-3 CAPLUS

CN 1H-Indole-5-carboxamide, 2,3-dihydro-1-(2-naphthalenylmethyl)-2,3-dioxo-
(CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L12 ANSWER 7 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2007:410811 CAPLUS

DOCUMENT NUMBER: 146:421837

TITLE: Preparation of fused pyrrole derivatives as GR modulators

INVENTOR(S): Sone, Toshihiko; Sawaki, Rieko; Nakajima, Tomoko

PATENT ASSIGNEE(S): Dainippon Sumitomo Pharma Co., Ltd., Japan

SOURCE: PCT Int. Appl., 403pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007040166	A1	20070412	WO 2006-JP319426	20060929
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,			

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

AU 2006298164	A1	20070412	AU 2006-298164	20060929
CA 2623154	A1	20070412	CA 2006-2623154	20060929
EP 1930320	A1	20080611	EP 2006-810832	20060929
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
KR 2008063288	A	20080703	KR 2008-7007427	20080327
IN 2008DN02633	A	20080704	IN 2008-DN2633	20080328
US 20100190768	A1	20100729	US 2008-88658	20080328
CN 101321726	A	20081210	CN 2006-80044619	20080528
PRIORITY APPLN. INFO.:			JP 2005-286576	A 20050930
			WO 2006-JP319426	W 20060929

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 146:421837
 GI



AB Title compds. I [R1 = H, (un)substituted alkyl, (un)substituted alkenyl, etc.; R2 = H, halo, carboxyl, etc.; -W4:W5-W6:W7- = -CR4:CR5-CR6:CR7-, -N:CR5-CR6:CR7-, -CR4:N-CR6:CR7-, etc.; R4-R7 = -E-A; E = single bond, -O-, -CO-, etc.; when E is a single bond, A is H, halo, cyano, etc.; when E is -O-, -CO-, etc., A is H, (un)substituted alkyl, (un)substituted cycloalkyl, etc.; R8 = -OR11, -SR11, -N(R11)R12; R11, R12 = H, (un)substituted alkyl; R9 = alkyl substituted with halo, cycloalkyl substituted with halo; R10 = -[C(R13)R14]n-R15; R13, R14 = H, alkyl, halo; R13 and R14 may combine to form a oxo group; or R13 and R14, together with the carbon atom to which they are attached, form a cycloalkane (one or two -CH2- in cycloalkane may be replaced with -NH-, -S-, -S(:O)-, etc.); n = 0-10; R15 = hydroxy, (un)substituted alkyl, (un)substituted alkenyl, etc.), prodrugs or pharmaceutically acceptable salts were prepared For example, reaction of 1-(1-benzyl-6-nitro-1H-indol-3-yl)-2,2,2-trifluoroethanone, e.g., prepared from 6-nitroindole in 2 steps, with trimethylphosphonium iodide followed by treatment with piperidine afforded

compound II. In glucocorticoid receptor (GR) binding assays, compound II exhibited the inhibitory activity of 92% at 100 nM. Compds. I are claimed useful for the treatment of inflammation and diabetes.


IT 934226-80-9P 934230-02-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fused pyrrole derivs. as GR modulators for treatment of inflammation and diabetes)


RN 934226-80-9 CAPLUS

CN Benzenepropanoic acid, 4-[[1-[2-[6-(aminocarbonyl)-1-(phenylmethyl)-1H-indol-3-yl]-3,3,3-trifluoro-2-hydroxypropyl]-4-piperidinyl]oxy]-3,5-dimethoxy-, ethyl ester (CA INDEX NAME)



RN 934230-02-1 CAPLUS

CN Benzenepropanoic acid, 4-[[1-[2-[6-(aminocarbonyl)-1-(phenylmethyl)-1H-indol-3-yl]-3,3,3-trifluoro-2-hydroxypropyl]-4-piperidinyl]oxy]-3,5-dimethoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 8 OF 55 CAPLUS COPYRIGHT 2011 ACS ON STN

ACCESSION NUMBER: 2007:11294 CAPLUS

DOCUMENT NUMBER: 146:142499

TITLE: Preparation of tetrahydrocarbazole derivatives useful as androgen receptor modulators

INVENTOR(S): Fales, Kevin Robert; Green, Jonathan Edward; Jadhav, Prabhakar Kondaji; Matthews, Donald Paul; Neel, David Andrew; Smith, Edward C R.

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 218 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007002181	A2	20070104	WO 2006-US24122	20060621
WO 2007002181	A3	20070301		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006262283	A1	20070104	AU 2006-262283	20060621
CA 2612723	A1	20070104	CA 2006-2612723	20060621
EP 1902026	A2	20080326	EP 2006-785258	20060621
EP 1902026	B1	20100217		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008546791	T	20081225	JP 2008-518350	20060621
AT 457979	T	20100315	AT 2006-785258	20060621
PT 1902026	E	20100317	PT 2006-785258	20060621
ES 2339480	T3	20100520	ES 2006-785258	20060621
IN 2007KN04710	A	20080627	IN 2007-KN4710	20071205
IN 244647	A1	20101224		
MX 2007015905	A	20080306	MX 2007-15905	20071213
US 20100022550	A1	20100128	US 2007-917398	20071213
US 7935722	B2	20110503		
CN 101203491	A	20080618	CN 2006-80022629	20071224
PRIORITY APPLN. INFO.:				
			US 2005-693604P	P 20050624
			WO 2006-US24122	W 20060621


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 146:142499; MARPAT 146:142499
GI



AB Title compds. I [$\text{R}_1 = \text{H, OH, CN, halo, etc.}$; $\text{R}_2 = \text{H, halo, alkyl or alkoxy, or R1 and R2 together form } -\text{OCH}_2- \text{ or } -\text{OCF}_2-$; $\text{R}_3 = \text{NHCOR}_5 \text{ or NHSO}_2\text{R}_6$; $\text{R}_4 = (\text{un})\text{substituted Ph or heteroaryl}$; $\text{R}_5 \text{ and R}_6 \text{ independently = alkyl, haloalkyl, alkoxy, etc.}$] and pharmaceutically acceptable salts were prepared as androgen receptor modulators. Thus, reacting p -bromophenylhydrazine hydrochloride with N -(4-oxocyclohexyl)isobutyramide (preparation given) in saturated ethanolic HCl at reflux for 18 h, followed by

alkylation with 3-fluorobenzyl bromide gave tetrahydrocarbazole II. II showed Ki of 2.6 nM in steroid hormone nuclear receptor binding assay and EC50 of 2.3 nM with 74.1% efficacy in C2C12 AR/ARE reporter assay. Tetrahydrocarbazoles I, and their pharmaceutical compns., are useful for treating physiol. disorders, particularly frailty, osteoporosis, osteopenia, and male and female sexual dysfunction.


IT 918791-04-5P, 9-(3-Fluorobenzyl)-6-(isobutanoylamino)-6,7,8,9-tetrahydro-5H-carbazole-3-carboxamide
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of tetrahydrocarbazoles as androgen receptor modulators)
 RN 918791-04-5 CAPLUS
 CN 1H-Carbazole-6-carboxamide, 9-[(3-fluorophenyl)methyl]-2,3,4,9-tetrahydro-3-[(2-methyl-1-oxopropyl)amino]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 9 OF 55 CAPLUS COPYRIGHT 2011 ACS ON STN

ACCESSION NUMBER: 2006:455326 CAPLUS
 DOCUMENT NUMBER: 145:145490
 TITLE: Isatin Compounds as Noncovalent SARS Coronavirus 3C-like Protease Inhibitors
 AUTHOR(S): Zhou, Lu; Liu, Ying; Zhang, Weilin; Wei, Ping; Huang, Changkang; Pei, Jianfeng; Yuan, Yaxia; Lai, Luhua
 CORPORATE SOURCE: State Key Laboratory for Structural Chemistry of Unstable and Stable Species, College of Chemistry and Molecular Engineering, Peking University, Beijing, 100871, Peop. Rep. China
 SOURCE: Journal of Medicinal Chemistry (2006), 49(12), 3440-3443
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 145:145490
 GI




AB A series of isatin derivs. were synthesized and tested against SARS CoV 3C-like protease. Substitutions at the N-1 and C-5 positions were examined to elucidate the differences in substrate binding sites of the rhinovirus 3C protease and SARS CoV 3C-like protease. Isatin I shows significant inhibition with an IC50 of 0.37 μ M. Further study showed that, unlike the irreversible covalent binding of isatin derivs. to human rhinovirus 3C protease, the compds. tested in this study are all noncovalent reversible inhibitors.

IT 184904-80-1P 184904-82-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of isatin derivs. as noncovalent SARS coronavirus 3C-like protease inhibitors)


RN 184904-80-1 CAPLUS

CN 1H-Indole-5-carboxamide, 2,3-dihydro-2,3-dioxo-1-(phenylmethyl)- (CA INDEX NAME)



RN 184904-82-3 CAPLUS

CN 1H-Indole-5-carboxamide, 2,3-dihydro-1-(2-naphthalenylmethyl)-2,3-dioxo- (CA INDEX NAME)



OS.CITING REF COUNT: 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 10 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2006:167023 CAPLUS

DOCUMENT NUMBER: 144:247226
 TITLE: Use of a phosphodiesterase 5 (PDE5) inhibitor for treating and preventing hypopigmentary disorders
 INVENTOR(S): Peuker, Heidemarie
 PATENT ASSIGNEE(S): Switch Biotech A.-G., Germany
 SOURCE: PCT Int. Appl., 48 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018088	A1	20060223	WO 2005-EP7747	20050715
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1759700	A1	20070307	EP 2004-19695	20040819
EP 1759700	B1	20090805		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, HR, LT, LV, MK				
AT 438403	T	20090815	AT 2004-19695	20040819
ES 2330934	T3	20091217	ES 2004-19695	20040819
AU 2005274546	A1	20060223	AU 2005-274546	20050715
AU 2005274546	B2	20110203		
CA 2619779	A1	20060223	CA 2005-2619779	20050715
JP 2008509944	T	20080403	JP 2007-526325	20050715
US 20080051408	A1	20080228	US 2007-660351	20070705
PRIORITY APPLN. INFO.:				
			EP 2004-19695	A 20040819
			US 2004-603069P	P 20040819
			WO 2005-EP7747	W 20050715


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention discloses the use of PDE5 inhibitors, preferably sildenafil or tadalafil, optionally in combination with a further active ingredient, for treating and/or preventing hypopigmentary disorders.

IT 184147-65-7, FR 181074
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (phosphodiesterase 5 inhibitor for treatment and prevention of hypopigmentary disorder)

RN 184147-65-7 CAPLUS

CN 1H-indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 11 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2006:81629 CAPLUS

DOCUMENT NUMBER: 144:311874

TITLE: An efficient synthesis of carbazole-based secretory phospholipase A2 (sPLA2) inhibitors LSN433771 and LSN426891

AUTHOR(S): May, Scott A.; Wilson, Thomas M.; Fields, Allison L.
 CORPORATE SOURCE: Chemical Product Research and Development, Eli Lilly and Company, Indianapolis, IN, 46285-4813, USA

SOURCE: Tetrahedron Letters (2006), 47(8), 1351-1353
 CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 144:311874


AB The flexible and efficient synthesis of two structurally similar carbazole derivs. is described. This general strategy features an intramol. palladium-mediated biaryl coupling reaction to join two aromatic domains of the target mols. Formation of the carbazole core is accomplished via nitrene insertion. The synthesis of secretory phospholipase A2 (sPLA2) inhibitors LSN433771 and LSN426891 is detailed.

IT 220862-61-3P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of carbazole-based secretory phospholipase A2 inhibitors via intramol. palladium-mediated biaryl coupling reaction and nitrene insertion)

RN 220862-61-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)





REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 12 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2005:1042216 CAPLUS
 DOCUMENT NUMBER: 143:347050
 TITLE: Preparation of
 4-(5-(aminomethyl)indole-1-ylmethyl)benzamide
 derivatives as opioid receptor antagonists for the
 treatment of obesity
 INVENTOR(S): Benesh, Dana Rae; Blanco-Pillado, Maria-Jesus
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090303	A1	20050929	WO 2005-US7702	20050309
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2558030	A1	20050929	CA 2005-2558030	20050309
EP 1751103	A1	20070214	EP 2005-725070	20050309
EP 1751103	B1	20090114		
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
JP 2007529523	T	20071025	JP 2007-503959	20050309
AT 420858	T	20090115	AT 2005-725070	20050309
ES 2318472	T3	20090501	ES 2005-725070	20050309
US 20070155793	A1	20070705	US 2006-598281	20060823
PRIORITY APPLN. INFO.:			US 2004-553176P	P 20040315
			WO 2005-US7702	W 20050309
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): CASREACT 143:347050; MARPAT 143:347050				
GI				




AB Title compds. represented by the formula I [wherein X1 = CH2, CH or N; X2 = CH or N; R1, R2 = independently H, alkyl(aryl), alkenyl, etc.; R3, R3' = independently H, alkyl, alkynyl, etc.; R4, R5 = independently H, (halo)alkyl, aryl, etc.; m = 0-2; n = 0-2; p = 0-2; and pharmaceutically acceptable salts, solvates, prodrugs, enantiomers, racemates, diastereomers and diastereomeric mixture thereof] were prepared as opioid receptor antagonists. For example, II was provided in a multi-step synthesis starting from the reaction of 5-formylindole with 4-bromomethylbenzonitrile. I were tested for antagonistic activity of mu-, gamma- and delta-opioid receptor in SPA-based GTPyS binding assay, and their pharmaceutical formulations were also presented. Thus, I and their pharmaceutical compns. are useful as opioid receptor antagonists for the treatment of obesity (no data).

IT 865543-00-6P 865543-03-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 4-(5-(aminomethyl)indole-1-ylmethyl)benzamide derivs. as opioid receptor antagonists for treatment of obesity)


RN 865543-00-6 CAPLUS

CN 1H-Indole-5-carboxamide, 1-[[4-[[[(3-methylbutyl)amino]methyl]phenyl]methyl]- (CA INDEX NAME)




RN 865543-03-9 CAPLUS

CN 1H-Indole-5-carboxamide, 2,3-dihydro-1-[[4-[[[(3-methylbutyl)amino]methyl]phenyl]methyl]- (CA INDEX NAME)




IT 865543-02-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of 4-(5-(aminomethyl)indole-1-ylmethyl)benzamide derivs. as
 opioid receptor antagonists for treatment of obesity)
 RN 865543-02-8 CAPLUS
 CN 1H-Indole-5-carboxamide, 1-[(4-formylphenyl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 13 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2005:348093 CAPLUS
 DOCUMENT NUMBER: 143:43840
 TITLE: Regioselective cyclization of unsymmetrical
 dicyanoanilines to novel 2,3-bifunctionalized indole
 regioisomers and their use in the synthesis of
 4,5-dihydro[1,3]oxazino[5,4-b]indole-6-carbonitriles
 AUTHOR(S): Maitraie, D.; Reddy, G. Venkat; Rao, V. V. V. N. S.
 Rama; Ravikanth, S.; Narsaiah, B.; Rao, P. Shanthan;
 Ravikumar, K.; Sridhar, B.
 CORPORATE SOURCE: Fluoroorganic Division, Indian Institute of Chemical
 Technology, Hyderabad, 500007, India
 SOURCE: Tetrahedron (2005), 61(16), 3999-4008
 CODEN: TETRAB; ISSN: 0040-4020
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:43840
 GI




AB Synthesis of 2,3-bifunctionalized indole regioisomers from unsym.
dicyanoanilines by regioselective cyclization in two independent ways.
One of the regioisomers were further utilized in synthesis of
4,5-dihydro[1,3]-oxazino[5,4-b] indole-6-carbonitriles, e.g., I.

IT 853053-03-9P 853053-06-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of dihydrooxazinoindolecarbonitriles via hydrolysis of
indolecarboxylate followed by cyclization)


RN 853053-03-9 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-amino-7-(aminocarbonyl)-6-methyl-1-
(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



RN 853053-06-2 CAPLUS

CN 1H-Indole-2-carboxylic acid, 3-amino-7-(aminocarbonyl)-6-phenyl-1-
(phenylmethyl)-4-(trifluoromethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
(8 CITINGS)

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 14 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2004:1124642 CAPLUS

DOCUMENT NUMBER: 142:79915

TITLE: Composition comprising a pulmonary surfactant and a
pde5 inhibitor for the treatment of lung diseases

INVENTOR(S): Wollin, Stefan-Lutz

PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 32 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110450	A1	20041223	WO 2004-EP51120	20040615
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2529007	A1	20041223	CA 2004-2529007	20040615
EP 1638567	A1	20060329	EP 2004-741805	20040615
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006527737	T	20061207	JP 2006-516154	20040615
US 20060148693	A1	20060706	US 2005-560116	20051209
US 7238664	B2	20070703		

PRIORITY APPLN. INFO.:

EP 2003-13615 A 20030616
 WO 2004-EP51120 W 20040615


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention relates to the combined administration of a pulmonary surfactant and a PDE5 inhibitor for the treatment of a disease in which pulmonary surfactant malfunction and/or phosphodiesterase 5 (PDE5) activity is detrimental. For example, a suspension for intrabronchial instillation contained Sildenafil 0.79mg and Luspultide 15.34g.

IT 184147-65-7
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical composition comprising pulmonary surfactants in combination with phosphodiesterase 5 inhibitors for the treatment of lung diseases)

RN 184147-65-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 15 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2004:1036929 CAPLUS

DOCUMENT NUMBER: 142:16825


TITLE: Composition comprising a PDE4 inhibitor and a PDE5 inhibitor

INVENTOR(S): Dunkern, Thorsten; Hatzelmann, Armin; Schudt, Christian; Grimminger, Friedrich; Ghofrani, Hossein

Ardeschir
 PATENT ASSIGNEE(S): Altana Pharma A.-G., Germany
 SOURCE: PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103407	A2	20041202	WO 2004-EP50869	20040519
WO 2004103407	A3	20050217		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004241749	A1	20041202	AU 2004-241749	20040519
AU 2004241749	B2	20100325		
CA 2525946	A1	20041202	CA 2004-2525946	20040519
EP 1628682	A2	20060301	EP 2004-766017	20040519
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
BR 2004010326	A	20060523	BR 2004-10326	20040519
CN 1791429	A	20060621	CN 2004-80013349	20040519
JP 2006528229	T	20061214	JP 2006-530210	20040519
NZ 544040	A	20090331	NZ 2004-544040	20040519
ZA 2005008116	A	20070131	ZA 2005-8116	20051007
MX 2005012302	A	20060130	MX 2005-12302	20051115
US 20060094723	A1	20060504	US 2005-556888	20051115
IN 2005MN01393	A	20070706	IN 2005-MN1393	20051213
IN 234325	A1	20090710		
NO 2005005941	A	20051214	NO 2005-5941	20051214
US 20100234382	A1	20100916	US 2010-785973	20100524
PRIORITY APPLN. INFO.:			EP 2003-11609	A 20030522
			WO 2004-EP50869	W 20040519
			US 2005-556888	A1 20051115

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 GI




I

AB The invention relates to the combined administration of a PDE4 inhibitor and a PDE5 inhibitor for the treatment of a disease in which phosphodiesterase 4 (PDE4) and/or phosphodiesterase 5 (PDE5) activity is detrimental. Patients were administered orally one tablet of Roflumilase and once daily a tablet of Viagra. An example of another selected PDE4 inhibitor is I.

IT 184147-65-7, FR 181074
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (composition comprising a PDE4 inhibitor and a PDE5 inhibitor)

RN 184147-65-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 16 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2004:927166 CAPLUS

DOCUMENT NUMBER: 141:395428



TITLE: Biaryl methyl indolines, indoles, and tetrahydroquinolines, useful as serine protease inhibitors, and particularly as anticoagulants, and their preparation, pharmaceutical compositions, and use.

INVENTOR(S): Smallheer, Joanne M.; Quan, Mimi L.; Wang, Shuaige; Bisacchi, Gregory S.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 153 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094372	A2	20041104	WO 2004-US11856	20040415
WO 2004094372	A3	20050602		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040220206	A1	20041104	US 2004-824025	20040414
US 7129264	B2	20061031		
EP 1633716	A2	20060315	EP 2004-750251	20040415
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006523716	T	20061019	JP 2006-513080	20040415
PRIORITY APPLN. INFO.:				
			US 2003-463452P	P 20030416
			US 2004-824025	A 20040414
			WO 2004-US11856	W 20040415
OTHER SOURCE(S): MARPAT 141:395428				
GI				



AB The invention provides compds. I or stereoisomers, pharmaceutically


acceptable salts or hydrates, or prodrugs thereof [wherein: W = (un)substituted CH₂CH₂, CH:CH, CH:N, or CH₂CH₂CH₂; L₁ = CH₂, CH₂CH₂, CH₂S(O)0-2, or CH₂C(O); L₂ = bond, (un)substituted CH₂, CH₂CH₂, O, NH, C(O), S(O)0-2, CH₂C(O), C(O)CH₂, CH₂O, OCH₂, CH₂NH, NHCH₂, CH₂S(O)0-2, S(O)0-2CH₂, C(O)O, OC(O), C(O)NH, NHC(O), S(O)NH, S(O)NHNH, NHS(O), or NHS(O)2; A = (un)substituted C₃-10 carbocycle or 5- to 12-membered heterocycle with 1-4 N/O/S(O)0-2 heteroatoms; B = (un)substituted alk(en/yn)yl, C₃-10 carbocycle, or 5- to 12-membered heterocycle with 1-4 N/O/S(O)0-2 heteroatoms; X = (independently) (un)substituted CH or N]. I are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, the invention relates to compds. that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compns. comprising I, and methods of treating thromboembolic and/or inflammatory disorders using I. I had Ki values of ≤ 15 μM in assays for Factor XIa and plasma kallikrein, thereby confirming their utility as effective inhibitors of these entities. Approx. 115 compds. I and various intermediates were prepared. For instance, 5-cyanoindole was reduced to 5-cyanoindoline with NaBH₃CN (40%) or with Et₃SiH (77%). Then, Suzuki coupling of 2-IC₆H₄CO₂Me with 2-OCHC₆H₄B(OH)₂ gave 83% 2-OCHC₆H₄-C₆H₄CO₂Me-2, which underwent reductive alkylation with 5-cyanoindoline (86%). The obtained 1-substituted 5-cyanoindoline was converted to the corresponding 5-amidoxime, which was reduced by Zn in AcOH to give the 5-amidine (18.5%). Alkaline saponification of the ester moiety gave

invention compound II, isolated as the bis(trifluoroacetate) salt.
 IT 787631-36-1P, 2'-((5-Carbamoyl-2,3-dihydroindol-1-ylmethyl)-5'-[[3-chlorophenethyl]carbamoyl]-4-methoxybiphenyl-2-carboxylic acid
 787631-37-2P, 5'-((Benzylcarbamoyl)-2'-((5-carbamoyl-2,3-dihydroindol-1-ylmethyl)-4-methoxybiphenyl-2-carboxylic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of biaryl methyl indolines, indoles, and tetrahydroquinolines as serine protease inhibitors and anticoagulants)


RN 787631-36-1 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid,
 2'-[[5-(aminocarbonyl)-2,3-dihydro-1H-indol-1-yl]methyl]-5'-[[2-(3-chlorophenyl)ethyl]amino]carbonyl]-4-methoxy- (CA INDEX NAME)



RN 787631-37-2 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid,
 2'-[[5-(aminocarbonyl)-2,3-dihydro-1H-indol-1-yl]methyl]-4-methoxy-5'-[[1-(phenylmethyl)amino]carbonyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 17 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2004:412918 CAPLUS

DOCUMENT NUMBER: 140:423584

TITLE: A preparation of indole derivatives useful in the
treatment of androgen-receptor related diseases
INVENTOR(S): Hermkens, Pedro Harold Han; Stock, Herman Thijs;
Teerhuis, Neeltje Miranda; Lommerse, Johannes Petrus
Maria; Van der Louw, Jaap

PATENT ASSIGNEE(S): Akzo Nobel N.V., Neth.
SOURCE: PCT Int. Appl., 75 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004041782	A1	20040521	WO 2003-EP50783	20031103
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
TW 310032	B	20050521	TW 2003-130277	20031030
CA 2504907	A1	20040521	CA 2003-2504907	20031103
AU 2003301853	A1	20040607	AU 2003-301853	20031103
AU 2003301853	B2	20100218		
BR 2003016020	A	20050920	BR 2003-16020	20031103
EP 1585727	A1	20051019	EP 2003-810458	20031103
EP 1585727	B1	20100526		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1714078	A	20051228	CN 2003-80103950	20031103
CN 100391944	C	20080604		
JP 2006507293	T	20060302	JP 2004-549180	20031103

JP 4643989	B2	20110302		
NZ 539657	A	20080430	NZ 2003-539657	20031103
RU 2328484	C2	20080710	RU 2005-117374	20031103
AT 469128	T	20100615	AT 2003-810458	20031103
ES 2344836	T3	20100908	ES 2003-810458	20031103
NO 2005002012	A	20050526	NO 2005-2012	20050425
NO 329778	B1	20101213		
HR 2005000396	A2	20050630	HR 2005-396	20050503
ZA 2005003559	A	20060830	ZA 2005-3559	20050504
IN 2005CN00826	A	20070817	IN 2005-CN826	20050504
IN 225099	A1	20081226		
MX 2005004929	A	20050818	MX 2005-4929	20050506
US 20060128722	A1	20060615	US 2005-534945	20050506
US 7795280	B2	20100914		
LV 13359	B	20060320	LV 2005-68	20050607
HK 1078875	A1	20100903	HK 2006-101557	20060206
US 20110065768	A1	20110317	US 2010-875295	20100903
PRIORITY APPLN. INFO.:			EP 2002-79648	A 20021107
			US 2002-424579P	P 20021107
			WO 2003-EP50783	W 20031103
			US 2005-534945	A3 20050506

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:423584

GI



AB The invention relates to a preparation of indole derivs. of formula I [wherein: X = S, S(O), SO₂; R₁ is (un)substituted 5- or 6-membered monocyclic, (hetero/homo)cyclic ring; R₂ is 2-O₂NC₆H₄, 2-cyanophenyl, 2-hydroxymethylphenyl, pyridin-2-yl, pyridin-2-yl-N-oxide, etc.; R₃ is H, halogen or Cl-4alkyl; R₄ is H, OH, Cl-4alkoxy, or halogen; R₅ is H, OH, Cl-4alkoxy, NH₂, CN, halogen, Cl-4fluoroalkyl, or NO₂, etc.], useful for the treatment of androgen-receptor related diseases. Anti-androgenic activity of the invented compds. was determined in an in vitro bioassay of Chinese hamster ovary (CHO) cells stably transfected with the human androgen receptor expression plasmid and a reporter plasmid in which the MMTV-promoter was linked to the luciferase reporter gene. For instance, indole derivs. II (EC₅₀ < 5 nM; efficacy > 0.8) was prepared via N-benzoylation of 6-methoxyindole by 3,5-difluorobenzyl bromide, and subsequent addition of the obtained 1-(3,5-difluorobenzyl)-6-methoxy-1H-indole to 2-nitrobenzenesulfenyl chloride (example 1).


IT 691399-73-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of indole derivs. useful in the treatment of androgen-receptor
related diseases)

RN 691399-73-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(3,5-difluorophenyl)methyl]-3-[(2-nitrophenyl)thio]- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD
(8 CITINGS)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 18 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:770917 CAPLUS

DOCUMENT NUMBER: 140:228430

TITLE: Discovery of Inhibitors that Elucidate the Role of
UCH-L1 Activity in the H1299 Lung Cancer Cell Line
AUTHOR(S): Liu, Yichin; Lashuel, Hilal A.; Choi, Sungwoon; Xing,
Xuechao; Case, April; Ni, Jake; Yeh, Li-An; Cuny,
Gregory D.; Stein, Ross L.; Lansbury, Peter T.
CORPORATE SOURCE: Center for Neurologic Diseases, Brigham and Women's
Hospital, Cambridge, MA, 02139, USA

SOURCE: Chemistry & Biology (2003), 10(9), 837-846

CODEN: CBOLE2; ISSN: 1074-5521

PUBLISHER: Cell Press

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Neuronal ubiquitin C-terminal hydrolase (UCH-L1) has been linked to
Parkinson's disease (PD), the progression of certain nonneuronal tumors,
and neuropathic pain. Certain lung tumor-derived cell lines express
UCH-L1 but it is not expressed in normal lung tissue, suggesting that this
enzyme plays a role in tumor progression, either as a trigger or as a
response. Small-mol. inhibitors of UCH-L1 would be helpful in
distinguishing between these scenarios. By utilizing high-throughput
screening (HTS) to find inhibitors and traditional medicinal chemical to
optimize their affinity and specificity, we have identified a class of
isatin O-acyl oximes that selectively inhibit UCH-L1 as compared to its
systemic isoform, UCH-L3. Three representatives of this class (30, 50,
51) have IC50 values of 0.80-0.94 μ M for UCH-L1 and 17-25 μ M for
UCH-L3. The Ki of 30 toward UCH-L1 is 0.40 μ M and inhibition is
reversible, competitive, and active site directed. Two isatin oxime
inhibitors increased proliferation of the H1299 lung tumor cell line but
had no effect on a lung tumor line that does not express UCH-L1.
Inhibition of UCH-L1 expression in the H1299 cell line using RNAi had a
similar proproliferative effect, suggesting that the UCH-L1 enzymic
activity is antiproliferative and that UCH-L1 expression may be a response

to tumor growth. The mol. mechanism of this response remains to be determined

IT 668468-14-2
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (discovery of inhibitors that elucidate role of UCH-L1 activity in H1299 lung cancer)

RN 668468-14-2 CAPLUS

CN 1H-Indole-5-carboxamide, 3-[(acetyloxy)imino]-1-[(3,4-dichlorophenyl)methyl]-2,3-dihydro-2-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 76 THERE ARE 76 CAPLUS RECORDS THAT CITE THIS RECORD (78 CITINGS)

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 19 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:491029 CAPLUS

DOCUMENT NUMBER: 139:63337

TITLE: Use of selective phosphodiesterase 5 (PDE5) inhibitors in the treatment of pulmonary diseases having a ventilation-perfusion mismatch

INVENTOR(S): Ghofrani, Ardeschir; Grimminger, Friedrich Josef; Schudt, Christian

PATENT ASSIGNEE(S): Altana Pharma AG, Germany

SOURCE: PCT Int. Appl., 32 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051346	A2	20030626	WO 2002-EPI4279	20021214
WO 2003051346	A3	20040212		
W: AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, HU, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, RO, SG, TN, UA, US, VN, YU, ZA, ZW				
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR				
CA 2470210	A1	20030626	CA 2002-2470210	20021214
AU 2002361417	A1	20030630	AU 2002-361417	20021214
EP 1461022	A2	20040929	EP 2002-796635	20021214
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005513060	T	20050512	JP 2003-552279	20021214
US 20050107394	A1	20050519	US 2005-499215	20050104
PRIORITY APPLN. INFO.:			EP 2001-129951	A 20011217
			EP 2002-9555	A 20020426
			EP 2002-23936	A 20021025
			WO 2002-EPI4279	W 20021214


AB The invention discloses the use of PDE5 inhibitors for the treatment of patients having a pulmonary disorder in which in which a pulmonary

ventilation-pulmonary perfusion mismatch is present.

IT 184150-13-8
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (phosphodiesterase 5 inhibitors for treatment of pulmonary disease with
 ventilation-perfusion mismatch)

RN 184150-13-8 CAPLUS

CN 1H-Indole-5-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-
 oxopropyl)-2-propyl- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 20 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2002:777892 CAPLUS

DOCUMENT NUMBER: 137:279090

TITLE: Substituted carbazoles as inhibitors of sPLA2

INVENTOR(S): Harper, Richard Waltz; Lin, Ho-Shen; Richett, Michael
 Enrico

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCI Int. Appl., 92 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002079154	A1	20021010	WO 2002-US6636	20020315
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2441077	A1	20021010	CA 2002-2441077	20020315
AU 2002244246	A1	20021015	AU 2002-244246	20020315
EP 1395554	A1	20040310	EP 2002-709779	20020315
EP 1395554	B1	20070214		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004525154	T	20040819	JP 2002-577781	20020315
AT 353876	T	20070315	AT 2002-709779	20020315

US 20040087796 A1 20040506 US 2003-467965 20030814
 PRIORITY APPLN. INFO.: US 2001-279300P P 20010328
 WO 2002-US6636 W 20020315

OTHER SOURCE(S): CASREACT 137:279090; MARPAT 137:279090


AB Carbazoles with hydroxy-functional amide (hydroxamic or esters) are disclosed together with using such compds. for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock. Seven carbazoles, N-alkoxy-N-(5-carbamoyl-9-benzyl-4-carbazolyloxy)acetamides (alkoxy = MeO, EtO, PhCH₂O), their derivs. and analogs, were prepared by amidation of 9-benzyl-5-carbamoyl-4-carbazolylacetic acid sodium salt with O-alkoxy hydroxylamine hydrochlorides in 50-88% yields. The carbazoles gave IC₅₀ (nM) values of 12.0-29.0 against sPLA2.

IT 466635-42-7P 466635-47-2P 466635-49-4P
 466635-50-7P 466635-51-8P 466635-53-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of carbazolyloxyacetamide sPLA2 inhibitors)


RN 466635-42-7 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-[2-(hydroxyamino)-2-oxoethoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 466635-47-2 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-[2-(methoxyamino)-2-oxoethoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 466635-49-4 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-[2-(ethoxyamino)-2-oxoethoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 466635-50-7 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-[2-oxo-2-[(phenylmethoxy)amino]ethoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 466635-51-8 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-[2-(methoxymethylamino)-2-oxoethoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 466635-53-0 CAPLUS


CN 9H-Carbazole-4-carboxamide, 5-[2-oxo-2-[(phenylmethoxy)amino]ethoxy]-9-(phenylmethyl)-7-(2-thienyl)- (CA INDEX NAME)




IT 207340-86-1
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of carbazolyloxyacetamide sPLA2 inhibitors)
 RN 207340-86-1 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-
 (CA INDEX NAME)



IT 220862-30-6P 246513-34-8P 246513-45-1P
 246513-46-2P 247902-84-7P 247902-85-8P
 247904-05-8P 247904-15-0P 247904-16-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of carbazolyloxyacetamide sPLA2 inhibitors)
 RN 220862-30-6 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-pentyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-
 (CA INDEX NAME)




RN 246513-34-8 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-
 , sodium salt (1:1) (CA INDEX NAME)



● Na


RN 246513-45-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 246513-46-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247902-84-7 CAPLUS


CN 9H-Carbazole-4-carboxamide, 5-hydroxy-7-pentyl-9-(phenylmethyl)- (CA INDEX NAME)




RN 247902-85-8 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-pentyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247904-05-8 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-(2-thienyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 247904-15-0 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-(phenylmethyl)-7-(2-thienyl)- (CA INDEX NAME)



RN 247904-16-1 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-(2-thienyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)



IT 466635-52-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of carbazolyloxyacetamide sPLA2 inhibitors)
 RN 466635-52-9 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 5-[2-oxo-2-(phenoxyamino)ethoxy]-9-(phenylmethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)
 REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 21 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2002:736140 CAPLUS
 DOCUMENT NUMBER: 137:242179
 TITLE: Remedies for arteriosclerosis
 INVENTOR(S): Saiga, Akihiko; Ono, Takashi; Yamada, Katsutoshi;
 Hanasaki, Kohji
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan

SOURCE: PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002074342	A1	20020926	WO 2002-JP2585	20020319
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
TW 314457	B	20090911	TW 2002-105096	20020318
CA 2441110	A1	20020926	CA 2002-2441110	20020319
CA 2441110	C	20101012		
AU 2002238962	A1	20021003	AU 2002-238962	20020319
EP 1378246	A1	20040107	EP 2002-705327	20020319
EP 1378246	B1	20090415		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2002008275	A	20040413	BR 2002-8275	20020319
CN 1553814	A	20041208	CN 2002-809552	20020319
CN 1553814	B	20100526		
EP 2044958	A2	20090408	EP 2008-21793	20020319
EP 2044958	A3	20090708		
R:	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR			
AT 428425	T	20090515	AT 2002-705327	20020319
PT 1378246	E	20090522	PT 2002-705327	20020319
KR 908968	B1	20090722	KR 2003-7012268	20020319
ES 2324766	T3	20090814	ES 2002-705327	20020319
JP 4499361	B2	20100707	JP 2002-573049	20020319
MX 2003008440	A	20040129	MX 2003-8440	20030918
US 20040248898	A1	20041209	US 2003-472234	20030922
PRIORITY APPLN. INFO.:			JP 2001-78569	A 20010319
			JP 2001-401289	A 20011228
			EP 2002-705327	A3 20020319
			WO 2002-JP2585	W 20020319


OTHER SOURCE(S): MARPAT 137:242179

AB Novel remedies and preventives for arteriosclerosis which are characterized by treating or preventing arteriosclerosis with the use of V type and/or X type sPLA2 inhibitors.


IT 207340-86-1 220862-34-0 220862-37-3
 220862-61-3
 RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (remedies for arteriosclerosis)

RN 207340-86-1 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-
 (CA INDEX NAME)




RN 220862-34-0 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(2-furanyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-37-3 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-phenoxyphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-61-3 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 22 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2002:487530 CAPLUS

DOCUMENT NUMBER: 137:47114

TITLE: Novel sPLA2 inhibitors

INVENTOR(S): Beight, Douglas Wade; Kinnick, Michael Dean; Lin, Ho-Shen; Morin, John Michael, Jr.; Richett, Michael Enrico; Sall, Daniel Jon; Sawyer, Jason Scott

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 140 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002050034	A2	20020627	WO 2001-US43185	20011206
WO 2002050034	A3	20030116		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2431028	A1	20020627	CA 2001-2431028	20011206
AU 2002039263	A	20020701	AU 2002-39263	20011206
EP 1345898	A2	20030924	EP 2001-987004	20011206
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004518659	T	20040624	JP 2002-551531	20011206
US 20040063941	A1	20040401	US 2003-450633	20030616
US 6872743	B2	20050329		


PRIORITY APPLN. INFO.: US 2000-256396P P 20001218
WO 2001-US43185 W 20011206

OTHER SOURCE(S): MARPAT 137:47114


AB A novel class of tetracyclic compds. is disclosed together using such compds. for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock. Several carbazole derivs. were prepared in several steps by standard methods and tested as sPLA2 inhibitors. E.g., Me (11-benzyl-7-carbamoyl-11H-benzo[a]carbazol-6-

xyloxy)acetate, prepared in 59% yield, had an IC50 0.0094 μ M against sPLA2.


IT 438588-86-4P 438588-88-6P 438589-51-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of carbazole derivs. as sPLA2 inhibitors)
 RN 438588-86-4 CAPLUS
 CN Acetic acid, 2-[[6-(aminocarbonyl)-1,2,3,10-tetrahydro-10-(phenylmethyl)cyclopenta[a]carbazol-5-yl]oxy]- (CA INDEX NAME)



RN 438588-88-6 CAPLUS
 CN Acetic acid, 2-[[7-(aminocarbonyl)-2,3,4,11-tetrahydro-11-(phenylmethyl)-1H-benzo[a]carbazol-6-yl]oxy]- (CA INDEX NAME)



RN 438589-51-6 CAPLUS
 CN Acetic acid, 2-[[7-(aminocarbonyl)-11-(phenylmethyl)-11H-benzo[a]carbazol-6-yl]oxy]-, methyl ester (CA INDEX NAME)




IT 438588-85-3P 438588-87-5P 438589-53-8P
 438589-54-9P 438589-55-0P 438589-61-8P
 438589-66-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of carbazole derivs. as sPLA2 inhibitors)


RN 438588-85-3 CAPLUS

CN Acetic acid, 2-[[6-(aminocarbonyl)-1,2,3,10-tetrahydro-10-(phenylmethyl)cyclopenta[a]carbazol-5-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 438588-87-5 CAPLUS

CN Acetic acid, 2-[[7-(aminocarbonyl)-2,3,4,11-tetrahydro-11-(phenylmethyl)-1H-benzo[a]carbazol-6-yl]oxy]-, methyl ester (CA INDEX NAME)



RN 438589-53-8 CAPLUS


CN Acetic acid, 2-[[7-(aminocarbonyl)-2,3,4,11-tetrahydro-11-(phenylmethyl)-1H-benzo[a]carbazol-6-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 438589-54-9 CAPLUS


CN Acetic acid, 2-[[6-(aminocarbonyl)-1,2,3,10-tetrahydro-10-(phenylmethyl)cyclopenta[a]carbazol-5-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 438589-55-0 CAPLUS


CN Acetic acid, 2-[[7-(aminocarbonyl)-11-(phenylmethyl)-11H-benzo[a]carbazol-6-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 438589-61-8 CAPLUS

CN 1H-Benzo[a]carbazole-7-carboxamide, 2,3,4,11-tetrahydro-6-hydroxy-11-(phenylmethyl)- (CA INDEX NAME)



RN 438589-66-3 CAPLUS

CN Cyclopenta[a]carbazole-6-carboxamide, 1,2,3,10-tetrahydro-5-hydroxy-10-(phenylmethyl)- (CA INDEX NAME)




IT 438589-52-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of carbazole derivs. as sPLA2 inhibitors)

RN 438589-52-7 CAPLUS

CN Acetic acid, 2-[[7-(aminocarbonyl)-11-(phenylmethyl)-11H-benzo[a]carbazol-6-yl]oxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 23 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2002:487525 CAPLUS

DOCUMENT NUMBER: 137:47111

TITLE: Novel sPLA2 inhibitors

INVENTOR(S): Beight, Douglas Wade; Jandzinski, John David; Kinnick, Michael Dean; Lin, Ho-Shen; Morin, John Michael, Jr.; Richett, Michael Enrico; Sall, Daniel Jon; Sawyer, Jason Scott

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 161 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002050029	A2	20020627	WO 2001-US43186	20011206
WO 2002050029	A3	20020906		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL,

PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG,
 US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
 GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
 GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2431721	A1	20020627	CA 2001-2431721	20011206
AU 2002039264	A	20020701	AU 2002-39264	20011206
EP 1349836	A2	20031008	EP 2001-987005	20011206
EP 1349836	B1	20060614		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004523504	T	20040805	JP 2002-551526	20011206
AT 329905	T	20060715	AT 2001-987005	20011206
ES 2264708	T3	20070116	ES 2001-987005	20011206
US 20040092543	A1	20040513	US 2003-450745	20030616
US 6992100	B2	20060131		

PRIORITY APPLN. INFO.:	US 2000-256395P	P	20001218
	WO 2001-US43186	W	20011206

OTHER SOURCE(S): MARPAT 137:47111
 GI




AB A novel class of tetracyclic compds. is disclosed together using such compds. for inhibiting sPLA2 mediated release of fatty acids for treatment of Inflammatory Diseases such as septic shock. Benzocarbazole I, prepared in several steps by standard methods, exhibited an inhibition value IC50 38.6 µM against sPLA2.

IT 438588-82-0P 438588-83-1P 438588-85-3P
 438588-86-4P 438588-87-5P 438588-88-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation of benzocarbazoles for inhibition of sPLA2)

RN 438588-82-0 CAPLUS


CN Acetic acid, 2-[[1-(aminocarbonyl)-5-(phenylmethyl)-5H-benzo[b]carbazol-11-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 438588-83-1 CAPLUS


CN Acetic acid, 2-[[1-(aminocarbonyl)-7,8,9,10-tetrahydro-5-(phenylmethyl)-5H-benzo[b]carbazol-11-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 438588-85-3 CAPLUS

CN Acetic acid, 2-[[6-(aminocarbonyl)-1,2,3,10-tetrahydro-10-(phenylmethyl)cyclopenta[a]carbazol-5-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 438588-86-4 CAPLUS

CN Acetic acid, 2-[[6-(aminocarbonyl)-1,2,3,10-tetrahydro-10-(phenylmethyl)cyclopenta[a]carbazol-5-yl]oxy]- (CA INDEX NAME)




RN 438588-87-5 CAPLUS

CN Acetic acid, 2-[[7-(aminocarbonyl)-2,3,4,11-tetrahydro-11-(phenylmethyl)-1H-benzo[a]carbazol-6-yl]oxy]-, methyl ester (CA INDEX NAME)



RN 438588-88-6 CAPLUS

CN Acetic acid, 2-[[7-(aminocarbonyl)-2,3,4,11-tetrahydro-11-(phenylmethyl)-1H-benzo[a]carbazol-6-yl]oxy]- (CA INDEX NAME)



IT 438588-93-3P 438588-94-4P 438589-01-6P


438589-02-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzocarbazoles for inhibition of sPLA2)


RN 438588-93-3 CAPLUS

CN 5H-Benzo[b]carbazole-1-carboxamide, 11-hydroxy-5-(phenylmethyl)- (CA INDEX NAME)




RN 438588-94-4 CAPLUS

CN Acetic acid, 2-[[1-(aminocarbonyl)-5-(phenylmethyl)-5H-benzo[b]carbazol-11-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 438589-01-6 CAPLUS

CN 5H-Benzo[b]carbazole-1-carboxamide, 7,8,9,10-tetrahydro-11-hydroxy-5-(phenylmethyl)- (CA INDEX NAME)



RN 438589-02-7 CAPLUS

CN Acetic acid, 2-[[1-(aminocarbonyl)-7,8,9,10-tetrahydro-5-(phenylmethyl)-5H-benzo[b]carbazol-11-yl]oxy]-, methyl ester (CA INDEX NAME)




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 24 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2002:213824 CAPLUS
 DOCUMENT NUMBER: 136:247492
 TITLE: Preparation of indolecarboxylates as neoplasm inhibitors.
 INVENTOR(S): Pamukcu, Rifat; Piazza, Gary A.
 PATENT ASSIGNEE(S): Cell Pathways, Inc., USA
 SOURCE: U.S., 45 pp., Cont. of U.S. Ser. No. 200,139, abandoned.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6358992	B1	20020319	US 1999-443395	19991119
PRIORITY APPLN. INFO.:			US 1998-200139	B1 19981125
OTHER SOURCE(S):	MARPAT	136:247492		

GI



AB Claimed is a method of treating a mammal having precancerous lesions comprising administration of title compds. [I; R1 = H, halo, NO2, (protected) carboxy, acyl, cyano, hydroxyiminoalkyl, alkenyl optionally substituted with oxo, alkyl optionally substituted with protected carboxy, carboxy, OH ; R2 = H, halo, alkenyl, acyl, alkyl optionally substituted with protected carboxy, carboxy, alkoxy, OH; R1R2 = atoms to form a 4-7 membered (oxo)carbocyclic ring; R3 = (substituted) alkenyl, alkyl; R4 = (protected) carboxy, acyl, cyano, halo, heterocyclyl, amino optionally substituted with acyl or protected carboxy, alkyl optionally substituted with (protected) carboxy, acyl] (no data). Thus, Me 3-acetyl-2-propylindole-6-carboxylate in DMF was treated with NaH then with 2-chlorobenzyl bromide followed by stirring for 1 h to give Me 3-acetyl-1-(2-chlorobenzyl)-2-propylindole-6-carboxylate.

IT 184147-86-2P 184148-12-7P 184148-20-7P


184148-72-9P 184148-77-4P 184149-11-9P

184150-27-4P 184150-38-7P 184150-41-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of indolecarboxylates as neoplasm inhibitors)


RN 184147-86-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-(1-oxopropyl)- (CA INDEX NAME)




RN 184148-12-7 CAPLUS

CN Benzoic acid, 2-[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 184148-20-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184148-72-9 CAPLUS


CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-[(2-nitrophenyl)methyl]-2-propyl- (CA INDEX NAME)



RN 184148-77-4 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184149-11-9 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-aminophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, hydrochloride (1:?) (CA INDEX NAME)




● x HCl


RN 184150-27-4 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-formyl-2-propyl-, hydrochloride (1:?) (CA INDEX NAME)



RN 184150-38-7 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-(1-hydroxypropyl)-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 184150-41-2 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-bromophenyl)methyl]-2-propyl- (CA INDEX NAME)



IT	184147-58-8P	184147-65-7P	184147-72-6P
	184147-80-6P	184147-92-0P	184147-98-6P
	184148-11-6P	184148-13-8P	184148-14-9P
	184148-15-0P	184148-16-1P	184148-17-2P
	184148-19-4P	184148-21-8P	184148-66-1P
	184148-67-2P	184148-68-3P	184148-69-4P
	184148-70-7P	184148-71-8P	184148-73-0P
	184148-74-1P	184148-75-2P	184148-76-3P
	184148-78-5P	184148-79-6P	184148-80-9P
	184148-82-1P	184148-83-2P	184148-84-3P
	184148-85-4P	184148-86-5P	184148-87-6P
	184148-89-8P	184148-90-1P	184149-00-6P
	184149-12-0P	184149-15-3P	184149-16-4P
	184149-17-5P	184149-18-6P	184149-22-2P
	184149-23-3P	184149-24-4P	184149-35-7P
	184149-56-2P	184149-57-3P	184149-58-4P
	184149-59-5P	184149-60-8P	184149-61-9P
	184149-62-0P	184149-63-1P	184149-64-2P
	184149-65-3P	184149-66-4P	184149-67-5P
	184150-10-5P	184150-11-6P,	
	4-(2-Chlorobenzyl)-1-oxo-1,2,3,4-tetrahydrocyclopent[b]indole-6-		

carboxamide	184150-12-7P	184150-13-8P
184150-14-9P	184150-15-0P	184150-16-1P
184150-17-2P	184150-18-3P	184150-19-4P
184150-22-9P	184150-23-0P	184150-24-1P
184150-25-2P	184150-28-5P	184150-31-0P
184150-32-1P	184150-34-3P	184150-35-4P
184150-37-6P	184150-39-8P	184150-40-1P
184150-42-3P	184150-43-4P	184150-44-5P
184150-45-6P	184150-46-7P	184150-47-8P
184150-48-9P	184150-49-0P	184150-50-3P
184150-53-6P	184150-54-7P	184150-55-8P
184150-56-9P	184150-57-0P	184150-58-1P
184150-59-2P	184150-66-1P	184151-83-5P,


9-(2-Chlorobenzyl)-5-oxo-5,6,7,8-tetrahydrocarbazole-2-carboxamide
184151-84-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indolecarboxylates as neoplasm inhibitors)


RN 184147-58-8 CAPLUS

CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-propyl-
(CA INDEX NAME)




RN 184147-65-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184147-72-6 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184147-80-6 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 184147-92-0 CAPLUS
 CN 1H-Indole-6-carboxamide, 2-acetyl-1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184147-98-6 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-ethyl-2-(1-oxopropyl)- (CA INDEX NAME)




RN 184148-11-6 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(4-chloro-2-fluorophenyl)methyl]-3-(2-methyl-1-

oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-13-8 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-14-9 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(phenylmethyl)-2-propyl- (CA INDEX NAME)




RN 184148-15-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(3-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-16-1 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-2-propyl-1-[(2-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 184148-17-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-([1,1'-biphenyl]-2-ylmethyl)-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-19-4 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(2-phenylethyl)-2-propyl- (CA INDEX NAME)




RN 184148-21-8 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184148-66-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-67-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-bromophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-68-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-iodophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-69-4 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-[(2-methylphenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184148-70-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-methoxyphenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-71-8 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-cyanophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-73-0 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2,6-dichlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-74-1 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chloro-4-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-75-2 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(4-bromo-2-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-76-3 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-cyano-2-propyl- (CA INDEX NAME)



RN 184148-78-5 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-methyl-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-79-6 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-(methoxymethyl)-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-80-9 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-82-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2,3-diethyl- (CA INDEX NAME)




RN 184148-83-2 CAPLUS

CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-ethyl- (CA INDEX NAME)




RN 184148-84-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-formyl-2-propyl- (CA INDEX NAME)




RN 184148-85-4 CAPLUS

CN 1H-Indole-6-carboxamide, 3-benzoyl-1-[(2-chlorophenyl)methyl]-2-propyl-
(CA INDEX NAME)




RN 184148-86-5 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-phenylacetyl)-2-propyl-
(CA INDEX NAME)




RN 184148-87-6 CAPLUS

CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-2-propyl-
(CA INDEX NAME)




RN 184148-89-8 CAPLUS


CN Benzoic acid, 2-[[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]-
(CA INDEX NAME)




RN 184148-90-1 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-(aminocarbonyl)phenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 184149-00-6 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(1-oxo-2-buten-1-yl)-2-propyl- (CA INDEX NAME)




RN 184149-12-0 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-hydroxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184149-15-3 CAPLUS

CN 1H-Indole-3-carboxylic acid, 6-(aminocarbonyl)-1-[(2-chlorophenyl)methyl]-
(CA INDEX NAME)




RN 184149-16-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-(1-oxopropyl)-
(CA INDEX NAME)



RN 184149-17-5 CAPLUS


CN 1H-Indole-6-carboxamide, 3-chloro-1-[(2-chlorophenyl)methyl]-2-propyl-
(CA INDEX NAME)



RN 184149-18-6 CAPLUS


CN 1H-Indole-6-carboxamide, 3-bromo-1-[(2-bromophenyl)methyl]-2-propyl- (CA INDEX NAME)

INDEX NAME)




RN 184149-22-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-(1-hydroxy-2-methylpropyl)- (CA INDEX NAME)




RN 184149-23-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-[1-(hydroxyimino)ethyl]-2-propyl- (CA INDEX NAME)




RN 184149-24-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[[2-[[[(methylamino)carbonyl]amino]phenyl]methyl]-3-(2-methyl-1-oxopropyl)-2-propyl]- (CA INDEX NAME)




RN 184149-35-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-(acetamino)phenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184149-56-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclopropylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-57-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclopropylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-58-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclobutylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-59-5 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclobutylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-60-8 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclopentylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-61-9 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclopentylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-62-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclohexylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-63-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclohexylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-64-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3-methyl-1-oxo-2-buten-1-yl)-2-propyl- (CA INDEX NAME)




RN 184149-65-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(3-methyl-1-oxo-2-buten-1-yl)-2-propyl- (CA INDEX NAME)




RN 184149-66-4 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3-methoxy-1-oxobutyl)-2-propyl- (CA INDEX NAME)




RN 184149-67-5 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(3-methoxy-1-oxobutyl)-2-propyl- (CA INDEX NAME)



RN 184150-10-5 CAPLUS
 CN Benzoic acid, 4-[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]-3-chloro- (CA INDEX NAME)




RN 184150-11-6 CAPLUS
 CN Cyclopent[b]indole-6-carboxamide, 4-[(2-chlorophenyl)methyl]-1,2,3,4-tetrahydro-1-oxo- (CA INDEX NAME)




RN 184150-12-7 CAPLUS

CN 1H-Indole-7-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-13-8 CAPLUS

CN 1H-Indole-5-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-14-9 CAPLUS


CN 1H-Indole-3-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-15-0 CAPLUS
 CN 1H-Indole-4-carboxamide, 1-[(2-chlorophenyl)methyl]-2-propyl- (CA INDEX NAME)



RN 184150-16-1 CAPLUS
 CN 1H-Carbazole-7-carboxamide, 9-[(2-chlorophenyl)methyl]-2,3,4,9-tetrahydro-1-oxo- (CA INDEX NAME)




RN 184150-17-2 CAPLUS
 CN 1H-Carbazole-7-carboxamide, 9-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-2,3,4,9-tetrahydro-1-oxo- (CA INDEX NAME)




RN 184150-18-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-bromo-2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184150-19-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-[2-(4-morpholinyl)acetyl]-2-propyl- (CA INDEX NAME)




RN 184150-22-9 CAPLUS

CN 1H-Indole-3,6-dicarboxamide, 1-[(2-chlorophenyl)methyl]-N3,N3-dimethyl-2-propyl- (CA INDEX NAME)




RN 184150-23-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(4-morpholinylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184150-24-1 CAPLUS

CN 1H-Indole-3,6-dicarboxamide, 1-[(2-chlorophenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184150-25-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-formyl- (CA INDEX NAME)




RN 184150-28-5 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-methyl-3-(1-oxopropyl)- (CA INDEX NAME)




RN 184150-31-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-(benzo[b]thien-5-ylmethyl)-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-32-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2,4-dichlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-34-3 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(1-naphthalenylmethyl)-2-propyl- (CA INDEX NAME)




RN 184150-35-4 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(2-naphthalenylmethyl)-2-propyl- (CA INDEX NAME)




RN 184150-37-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-(1-propen-1-yl)- (CA INDEX NAME)




RN 184150-39-8 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3,3-dimethyl-1-oxobutyl)- (CA INDEX NAME)




RN 184150-40-1 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184150-42-3 CAPLUS
CN 1H-Indole-6-carboxamide, 2-acetyl-1-[(2-chlorophenyl)methyl]-3-methyl- (CA INDEX NAME)



RN 184150-43-4 CAPLUS
CN 1H-Indole-6-carboxamide, 2-chloro-1-[(2-chlorophenyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 184150-44-5 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-(1-oxopropyl)-3-propyl- (CA INDEX NAME)




RN 184150-45-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-(2-methyl-1-oxopropyl)-3-propyl- (CA INDEX NAME)




RN 184150-46-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3-oxo-1-buten-1-yl)- (CA INDEX NAME)




RN 184150-47-8 CAPLUS

CN Cyclopent[b]indole-6-carboxamide, 4-[(2-chlorophenyl)methyl]-1,2,3,4-tetrahydro-3-oxo- (CA INDEX NAME)




RN 184150-48-9 CAPLUS

CN Cyclopent[b]indole-6-carboxamide, 4-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-1,2,3,4-tetrahydro-3-oxo- (CA INDEX NAME)




RN 184150-49-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[[2-chloro-4-[[(phenylsulfonyl)amino]carbonyl]phenyl]methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-50-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-ethoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-53-6 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-nitro-2-propyl- (CA INDEX NAME)




RN 184150-54-7 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(4-chloro-2-fluorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)



RN 184150-55-8 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2,4-dichlorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-56-9 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(4-bromo-2-chlorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-57-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-bromo-2-fluorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-58-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chloro-4-fluorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-59-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-(benzo[b]thien-5-ylmethyl)-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-66-1 CAPLUS


CN Benzoic acid, 4-[[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]-3-chloro-, methyl ester (CA INDEX NAME)



RN 184151-83-5 CAPLUS
 CN 1H-Carbazole-7-carboxamide, 9-[(2-chlorophenyl)methyl]-2,3,4,9-tetrahydro-4-oxo- (CA INDEX NAME)



RN 184151-84-6 CAPLUS
 CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
 REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 25 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2002:122770 CAPLUS
 DOCUMENT NUMBER: 136:178015
 TITLE: Drugs for incontinence - salified and nonsalified nitric oxide-donors and phosphodiesterase inhibitors
 INVENTOR(S): Del Soldato, Piero; Benedini, Francesca
 PATENT ASSIGNEE(S): Nicox S.A., Fr.
 SOURCE: PCT Int. Appl., 59 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002011707	A2	20020214	WO 2001-EP8734	20010727
WO 2002011707	A3	20021205		
W: AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG IT 2000MI1848 A1 20020208 IT 2000-MI1848 20000808 IT 1318674 B1 20030827 AU 2001091691 A 20020218 AU 2001-91691 20010727 EP 1307184 A2 20030507 EP 2001-971798 20010727 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR JP 2004511436 T 20040415 JP 2002-517044 20010727 US 20030203899 A1 20031030 US 2003-343330 20030206 PRIORITY APPLN. INFO.: IT 2000-MI1848 A 20000808 WO 2001-EP8734 W 20010727				

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OTHER SOURCE(S): MARPAT 136:178015

AB Use in the incontinence of one or more of the following classes of drugs selected from the following: (B) salified and nonsalified nitric oxide-donor drugs, of formula: A - X1 - N(O)z, (B') nitrate salts of drugs used for the incontinence, and which do not contain in the mol. a nitric oxide donor group; (C) organic or inorg. salts of compds. inhibiting phosphodiesterases.

IT 184147-65-7
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (salified and nonsalified nitric oxide-donors and phosphodiesterase inhibitors for treatment of incontinence)

RN 184147-65-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2002:122769 CAPLUS
 DOCUMENT NUMBER: 136:189342
 TITLE: Drugs for treatment of sexual dysfunction
 INVENTOR(S): Del Soldato, Piero
 PATENT ASSIGNEE(S): Nicox S.A., Fr.
 SOURCE: PCT Int. Appl., 40 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002011706	A2	20020214	WO 2001-EP8733	20010727
WO 2002011706	A3	20030918		
W:	AE, AG, AL, AU, BA, BB, BG, BR, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ZA			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
IT 2000MI1847	A1	20020208	IT 2000-MI1847	20000808
IT 1318673	B1	20030827		
AU 2001091690	A	20020218	AU 2001-91690	20010727
EP 1363628	A2	20031126	EP 2001-971797	20010727
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR			
JP 2004506619	T	20040304	JP 2002-517043	20010727
US 20030171393	A1	20030911	US 2003-333927	20030204
PRIORITY APPLN. INFO.:			IT 2000-MI1847	A 20000808
			WO 2001-EP8733	W 20010727

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:189342

AB Pharmaceuticals containing nitric oxide-donor drugs or inorg. salts of compds. inhibiting phosphodiesterases are useful for the treatment of sexual dysfunction. Thus, a formulation contained 2-(acetyloxy)benzoic acid 6-(nitroxy-methyl)-2-methylpyridyl ester-HCl (NCX 4050) 4.2, white petrolatum 24, Polysorbate-60 4.8, glycerin 9.5, and water 48 g. NCX 4050 showed vasorelaxing activity on the aortas.

IT 398460-36-1
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (drugs for treatment of sexual dysfunction)


RN 398460-36-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, nitrate (1:1) (CA INDEX NAME)

CM 1

CRN 184147-65-7

CMF C23 H25 Cl N2 O2



CM 2

CRN 7697-37-2
CMF H N O3




OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 27 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2002:71855 CAPLUS
DOCUMENT NUMBER: 136:134669
TITLE: Indoleoxoacetamides and tetrahydrocarbazoles as sPLA2
inhibitors in treating sepsis
INVENTOR(S): Loh, Andrew; Macias, William Louis; Skerjanec, Simona
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 152 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002005796	A2	20020124	WO 2001-US16509	20010629
WO 2002005796	A3	20020906		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2413582	A1	20020124	CA 2001-2413582	20010629
EP 1303262	A2	20030423	EP 2001-952123	20010629
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001012460	A	20030722	BR 2001-12460	20010629

JP 2004503586	T	20040205	JP 2002-511729	20010629
US 20040110825	A1	20040610	US 2003-332178	20030103
PRIORITY APPLN. INFO.:			US 2000-218928P	P 20000714
			US 2000-256398P	P 20001218
			WO 2001-US16509	W 20010629

OTHER SOURCE(S): MARPAT 136:134669
GI




AB Indoleoxoacetamides and tetrahydrocarbazoles were prepared for use as sPLA2 inhibitors in treating sepsis. Thus, 3-methoxy-2-methylaniline was N-tert.-butoxycarbonylated, lithiated at the Me group with sec-butyllithium and then treated with N-methoxy-N-methylacetamide, and cyclized with CF3CO2H to give 4-methoxy-2-methylindole. The latter compound was N-benzylated, demethylated, treated with BrCH2CO2Me, followed by ester hydrolysis and esterification with 4-(2-chloroethyl)morpholine hydrochloride to give the indole I. The results of clin. trials are reported.

IT	207340-74-7P	207340-75-8P	207340-86-1P
	220862-21-5P	220862-22-6P	220862-23-7P
	220862-24-8P	220862-26-0P	220862-27-1P
	220862-30-6P	220862-31-7P	220862-32-8P
	220862-33-9P	220862-34-0P	220862-35-1P
	220862-36-2P	220862-37-3P	220862-38-4P
	220862-39-5P	220862-40-8P	220862-41-9P
	220862-42-0P	220862-43-1P	220862-44-2P
	220862-45-3P	220862-46-4P	220862-47-5P
	220862-48-6P	220862-49-7P	220862-50-0P
	220862-51-1P	220862-53-3P	220862-54-4P
	220862-55-5P	220862-59-9P	220862-61-3P
	220862-63-5P	220862-66-8P	220862-68-0P
	220862-72-6P	220862-74-8P	220862-76-0P
	220862-84-0P	246513-34-8P	246513-46-2P
	321858-11-1P	391936-29-1P	391936-30-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indoleoxoacetamides and tetrahydrocarbazoles as sPLA2 inhibitors in treating sepsis)


RN 207340-74-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methoxy-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 207340-75-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methoxy-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 207340-86-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-21-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-22-6 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-2-methyl-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-23-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-24-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[4-(trifluoromethyl)phenyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-26-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-5-[2-[(methylsulfonyl)amino]ethoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-27-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-[2-[(trifluoromethyl)sulfonyl]amino]ethoxy]- (CA INDEX NAME)




RN 220862-30-6 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-pentyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-31-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(1-methylethyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-32-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-33-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-phenyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-34-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(2-furanyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-35-1 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]-, lithium salt (1:1)
(CA INDEX NAME)



● Li


RN 220862-36-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-37-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-phenoxyphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-38-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-39-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-40-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(phenylmethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-41-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-42-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(1-naphthalenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-43-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-44-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-45-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-46-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-47-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3,5-dimethylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-48-6 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-iodophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-49-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-chlorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-50-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,3-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-51-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,6-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-53-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,6-dichlorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-54-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethoxy)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-55-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-([1,1'-biphenyl]-2-ylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-59-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-61-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-63-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-chloro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-66-8 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[(2-propen-1-yloxy)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-68-0 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-(propoxymethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-72-6 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 5-(cyanomethoxy)-7-methoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-74-8 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-(2H-tetrazol-5-ylmethoxy)- (CA INDEX NAME)




RN 220862-76-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-(2-amino-2-oxoethoxy)-7-methoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-84-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(4-chlorophenyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 246513-34-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(4-chlorophenyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)




RN 246513-46-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 321858-11-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-[2-[(methylsulfonyl)amino]-2-oxoethoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 391936-29-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, ethyl ester (CA INDEX NAME)



RN 391936-30-4 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-
 , 2-(4-morpholinyl)ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
 (6 CITINGS)
 REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 28 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2002:10308 CAPLUS


DOCUMENT NUMBER: 136:64151
 TITLE: Secretory PLA2 inhibitors as remedies for Alzheimer's disease
 INVENTOR(S): Hanasaki, Kohji; Ikeda, Minoru; Ono, Takashi
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 45 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000257	A1	20020103	WO 2001-JP5482	20010627
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG AU 2001067826 A 20020108 AU 2001-67826 20010627 US 20040102442 A1 20040527 US 2002-312615 20021227 PRIORITY APPLN. INFO.: JP 2000-195445 A 20000629 WO 2001-JP5482 W 20010627				


OTHER SOURCE(S): MARPAT 136:64151
 AB It is found out that type X sPLA2 inhibitors are useful in preventing or treating Alzheimer's disease.
 IT 207340-86-1 220862-34-0 220862-37-3
 220862-61-3
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (secretory PLA2 inhibitors as remedies for Alzheimer's disease)
 RN 207340-86-1 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-
 (CA INDEX NAME)




RN 220862-34-0 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-37-3 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-phenoxyphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-61-3 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 29 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2002:10307 CAPLUS
 DOCUMENT NUMBER: 136:64164
 TITLE: Remedies for cirrhosis
 INVENTOR(S): Hanasaki, Kohji; Ikeda, Minoru; Ono, Takashi
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 45 pp.

DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 1 Japanese
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000256	A1	20020103	WO 2001-JP5481	20010627
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG AU 2001067825 A 20020108 AU 2001-67825 20010627 US 20040106669 A1 20040603 US 2002-312366 20021226 US 6967200 B2 20051122				

PRIORITY APPLN. INFO.: JP 2000-195436 A 20000629
 WO 2001-JP5481 W 20010627

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:64164


AB It is found out that type X sPLA2 inhibitors are useful in preventing or treating cirrhosis.

IT 207340-86-1 220862-34-0 220862-37-3
 220862-61-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (secretory PLA2 inhibitors as remedies for cirrhosis)


RN 207340-86-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-34-0 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(2-furanyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-37-3 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-phenoxyphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-61-3 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 30 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2002:10306 CAPLUS
 DOCUMENT NUMBER: 136:64112
 TITLE: Remedies for cancer
 INVENTOR(S): Hanasaki, Kohji; Ikeda, Minoru; Ono, Takashi
 PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 56 pp.

DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 1 Japanese
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000255	A1	20020103	WO 2001-JP5480	20010627
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001067824	A	20020108	AU 2001-67824	20010627
EP 1300159	A1	20030409	EP 2001-945613	20010627
EP 1300159	B1	20071010		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
TW 583000	B	20040411	TW 2001-115543	20010627
AT 375171	T	20071015	AT 2001-945613	20010627
ES 2294003	T3	20080401	ES 2001-945613	20010627
US 20040077651	A1	20040422	US 2002-312451	20021227
JP 2000-195434 A 20000629 WO 2001-JP5480 W 20010627				

PRIORITY APPLN. INFO.:

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 136:64112


AB It is found out that type X secretory PLA2 inhibitors are useful in preventing or treating cancer.

IT 207340-86-1 220862-34-0 220862-37-3
 220862-61-3

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (type X secretory PLA2 inhibitors as remedies for cancer)


RN 207340-86-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-34-0 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(2-furanyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-37-3 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-phenoxyphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-61-3 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethoxy)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 31 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2001:676601 CAPLUS
 DOCUMENT NUMBER: 135:236446
 TITLE: Compositions containing potential secretory
 phospholipase A2 (sPLA2) inhibitors for the treatment

of pain
 INVENTOR(S): Macias, William Louis
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 196 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066111	A1	20010913	WO 2001-US9	20010116
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: MARPAT 135:236446 US 2000-188135P P 20000309

OTHER SOURCE(S): MARPAT 135:236446

AB A method is disclosed for the treatment of pain by administering to an animal in need thereof a therapeutically effective amount of a sPLA2 inhibitor, e.g. a 1H-indole-3-glyoxylamide or sPLA2 inhibitor in combination with propoxyphene. Preparation of [(3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy]acetic acid is described.


IT 207340-73-6 359841-74-0 359841-74-0D, derives.

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(secretory phospholipase A2 inhibitors for treatment of pain)


RN 207340-73-6 CAPLUS

CN Butanoic acid, 4-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-3-yl]oxy]- (CA INDEX NAME)




RN 359841-74-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-(carboxyoxo)-9-(phenylmethyl)- (CA INDEX NAME)



RN 359841-74-0 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 5-(carboxyoxymethyl)-9-(phenylmethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 32 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2001:676600 CAPLUS
 DOCUMENT NUMBER: 135:236432
 TITLE: Methods and formulations containing secretory phospholipase A2 (sPLA2) inhibitors for the treatment of renal dysfunction
 INVENTOR(S): Macias, William Louis; Meador, Vincent Phillip
 PATENT ASSIGNEE(S): Eli Lilly and Co., USA
 SOURCE: PCT Int. Appl., 161 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001066110	A2	20010913	WO 2001-US7	20010116
WO 2001066110	A3	20020425		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, SZ, BE, CY, FR, GR, IE, IT, MC, NL, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,

DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1265607 A2 20021218 EP 2001-956186 20010116
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2003525901 T 20030902 JP 2001-564763 20010116
 US 20030087944 A1 20030508 US 2002-203436 20020805
 PRIORITY APPLN. INFO.: US 2000-188039P P 20000309
 WO 2001-US7 W 20010116

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 135:236432

AB A method is disclosed for the treatment of symptoms associated with renal dysfunction by administering to an animal in need thereof a therapeutically effective amount of a sPLA2 inhibitor, e.g. a 1H-indole-3-glyoxylamide. Preparation of [(3-(2-Amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy]acetic acid is described.


IT 207340-73-6 359841-74-0 359841-74-0D, derivs.

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(secretory phospholipase A2 inhibitors for treatment of renal dysfunction)


RN 207340-73-6 CAPLUS

CN Butanoic acid, 4-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-3-yl]oxy]- (CA INDEX NAME)




RN 359841-74-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-(carboxyoxy)-9-(phenylmethyl)- (CA INDEX NAME)



RN 359841-74-0 CAPLUS


CN 9H-Carbazole-4-carboxamide, 5-(carboxyoxy)-9-(phenylmethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 33 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2001:565004 CAPLUS
DOCUMENT NUMBER: 135:152715
TITLE: Secretory phospholipase A2 inhibitors for the
treatment of inflammation
INVENTOR(S): Fleisch, Jerome Herbert; Macias, William Louis
PATENT ASSIGNEE(S): Eli Lilly and Company, USA
SOURCE: PCT Int. Appl., 200 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001055108	A2	20010802	WO 2001-US11	20010116
WO 2001055108	A3	20011220		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001036440	A	20010807	AU 2001-36440	20010116
PRIORITY APPLN. INFO.:			US 2000-177907P	P 20000125
			WO 2001-US11	W 20010116
OTHER SOURCE(S): MARPAT 135:152715				
AB Title inhibitors for the treatment of inflammation (no data) comprise indoleglyoxamides, carbazoles, etc.				
IT 207340-73-6				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (secretory phospholipase A2 inhibitors for the treatment of inflammation)				
RN	207340-73-6 CAPLUS			
CN	Butanoic acid, 4-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-3- yl]oxy]- (CA INDEX NAME)			





REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 34 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2001:507675 CAPLUS
 DOCUMENT NUMBER: 135:77102
 TITLE: Preparation of carbazole amino acid derivatives as secretory phospholipase A2 (sPLA2) inhibitors
 INVENTOR(S): Lin, Ho-Shen; Richett, Michael Enrico
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 147 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049662	A2	20010712	WO 2001-US10850	20010105
WO 2001049662	A3	20020627		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1248769	A2	20021016	EP 2001-918984	20010105
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 20030096854	A1	20030522	US 2002-168152	20020612
US 20040204473	A1	20041014	US 2004-830380	20040422
PRIORITY APPLN. INFO.:			US 2000-175028P	P 20000107
			WO 2001-US10850	W 20010105
			US 2002-168152	A3 20020612

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 135:77102
 GI



II

AB Carbazole amino acid derivs. I [Z indicates a cyclohexenyl or Ph ring; R is a non-interfering substituent and f = 1-3; R1 is NHNH2, NH2, or CONH2; R2 is -O(CH2)tR5, where R5 is a carbamoyl group or -(Lh)-(acyl amino acid) (Lh is a linker of length 1-7) and t = 1-5; R3 is a non-interfering substituent or a carbocyclic or heterocyclic radical which may be substituted with non-interfering substituents; R4 is (a) (C5-C20)-alkyl, -alkenyl, or -alkynyl or a carbocyclic or heterocyclic radical, which may be substituted or (b) -(L)-R80, where (L)- is a divalent linking group of 1 to 12 atoms selected from carbon, hydrogen, oxygen, nitrogen, and sulfur (with provisos) and R80 is a group selected from (a) or a pharmaceutically acceptable racemate, solvate, tautomer, optical isomer, prodrug or salt were prepared for inhibiting sPLA2 mediated release of fatty acids for treatment of inflammatory diseases such as septic shock. Thus, carbazole amino acids II (R is an amino acid side chain) were prepared via coupling of amino acid Me esters and saponification and showed IC50 = 16.1-324

nM

for inhibition of sPLA2.


IT 346712-90-1P 346712-91-2P 346712-92-3P
346712-93-4P 346712-94-5P 346712-96-7P
346712-98-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of carbazole amino acid derivs. as secretory phospholipase A2 (sPLA2) inhibitors)

RN 346712-90-1 CAPLUS


CN Glycine, N-[[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]acetyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 346712-91-2 CAPLUS

CN L-Alanine, N-[[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346712-92-3 CAPLUS

CN L-Leucine, N-[[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346712-93-4 CAPLUS

CN L-Aspartic acid, N-[[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]acetyl]-, dimethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346712-94-5 CAPLUS

CN L-Glutamic acid, N-[[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]acetyl]-, dimethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346712-96-7 CAPLUS

CN L-Methionine, N-[[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]acetyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346712-98-9 CAPLUS

CN L-Phenylalanine, N-[[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]acetyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 346712-88-7P 346712-89-8P 346713-00-6P

346713-02-8P 346713-03-9P 346713-04-0P


346713-05-1P 346713-06-2P 346713-07-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);

BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of carbazole amino acid derivs. as secretory phospholipase A2
 (sPLA2) inhibitors)


RN 346712-88-7 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-(2-amino-2-oxoethoxy)-9-(phenylmethyl)- (CA
 INDEX NAME)




RN 346712-89-8 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-[2-(ethylamino)-2-oxoethoxy]-9-(
 phenylmethyl)- (CA INDEX NAME)



RN 346713-00-6 CAPLUS


CN Glycine, N-[[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-
 yl]oxy]acetyl]- (9CI) (CA INDEX NAME)



RN 346713-02-8 CAPLUS

CN L-Alanine, N-[[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-
 yl]oxy]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346713-03-9 CAPLUS

CN L-Leucine, N-[[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346713-04-0 CAPLUS

CN L-Aspartic acid, N-[[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346713-05-1 CAPLUS

CN L-Glutamic acid, N-[[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346713-06-2 CAPLUS

CN L-Methionine, N-[[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 346713-07-3 CAPLUS

CN L-Phenylalanine, N-[[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]acetyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 207340-86-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of carbazole amino acid derivs. as secretory phospholipase A2
(sPLA2) inhibitors)

RN 207340-86-1 CAPLUS

CN Acetic acid, 2-[[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-
(CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 35 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2001:507563 CAPLUS

DOCUMENT NUMBER: 135:87174

TITLE: Combination therapy using a neutrophil elastase inhibitor and an secretory phospholipase A2 inhibitor for the treatment of inflammatory and respiratory diseases

INVENTOR(S): Macias, William Louis

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 263 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001049323	A1	20010712	WO 2000-US34262	20001222
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1259260	A1	20021127	EP 2000-990230	20001222
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003519198	T	20030617	JP 2001-549689	20001222
US 20030092767	A1	20030515	US 2002-149365	20020607
PRIORITY APPLN. INFO.:			US 2000-174723P	P 20000106
			WO 2000-US34262	W 20001222

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 135:87174

AB A pharmaceutical composition for the treatment of an inflammatory disease or a respiratory disease in mammals comprises, as active ingredients, a neutrophil elastase inhibitor and an sPLA2 inhibitor. Preparation of [(3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indole-4-yl)oxy]acetic acid is described.

IT 207340-74-7 207340-74-7D, isomers and prodrug


derivs. 207340-75-8 207340-75-8D, isomers and
 prodrug derivs. 207340-86-1 207340-86-1D, isomers
 and prodrug derivs. 220862-21-5 220862-21-5D,
 isomers and prodrug derivs. 220862-22-6 220862-22-6D
 , isomers and prodrug derivs. 220862-23-7
 220862-23-7D, isomers and prodrug derivs. 220862-24-8
 220862-24-8D, isomers and prodrug derivs. 220862-26-0
 220862-26-0D, isomers and prodrug derivs. 220862-27-1
 220862-27-1D, isomers and prodrug derivs. 220862-30-6
 220862-30-6D, isomers and prodrug derivs. 220862-31-7
 220862-31-7D, isomers and prodrug derivs. 220862-32-8
 220862-32-8D, isomers and prodrug derivs. 220862-33-9
 220862-33-9D, isomers and prodrug derivs. 220862-34-0
 220862-34-0D, isomers and prodrug derivs. 220862-35-1
 220862-35-1D, isomers and prodrug derivs. 220862-36-2
 220862-36-2D, isomers and prodrug derivs. 220862-37-3
 220862-37-3D, isomers and prodrug derivs. 220862-38-4
 220862-38-4D, isomers and prodrug derivs. 220862-39-5
 220862-39-5D, isomers and prodrug derivs. 220862-40-8
 220862-40-8D, isomers and prodrug derivs. 220862-41-9
 220862-41-9D, isomers and prodrug derivs. 220862-42-0
 220862-42-0D, isomers and prodrug derivs. 220862-43-1
 220862-43-1D, isomers and prodrug derivs. 220862-44-2
 220862-44-2D, isomers and prodrug derivs. 220862-45-3
 220862-45-3D, isomers and prodrug derivs. 220862-46-4
 220862-46-4D, isomers and prodrug derivs. 220862-47-5
 220862-47-5D, isomers and prodrug derivs. 220862-48-6
 220862-48-6D, isomers and prodrug derivs. 220862-49-7
 220862-49-7D, isomers and prodrug derivs. 220862-50-0
 220862-50-0D, isomers and prodrug derivs. 220862-51-1
 220862-51-1D, isomers and prodrug derivs. 220862-54-4
 220862-54-4D, isomers and prodrug derivs. 220862-55-5
 220862-55-5D, isomers and prodrug derivs. 220862-59-9
 220862-59-9D, isomers and prodrug derivs. 220862-61-3
 220862-61-3D, isomers and prodrug derivs. 220862-63-5
 220862-63-5D, isomers and prodrug derivs. 220862-66-8
 220862-66-8D, isomers and prodrug derivs. 220862-68-0
 220862-68-0D, isomers and prodrug derivs. 220862-72-6
 220862-74-8 220862-74-8D, isomers and prodrug derivs.
 220862-76-0 220862-76-0D, isomers and prodrug derivs.
 220862-84-0 225653-40-7 225653-40-7D,
 isomers and prodrug derivs.

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES
 (Uses)

(neutrophil elastase inhibitor-secretory phospholipase A2 inhibitor
 combination therapy for inflammatory and respiratory diseases)


RN 207340-74-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methoxy-9-(phenylmethyl)-9H-carbazol-
 4-yl]oxy]- (CA INDEX NAME)




RN 207340-74-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methoxy-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 207340-75-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methoxy-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 207340-75-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methoxy-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 207340-86-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-
(CA INDEX NAME)




RN 207340-86-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-
(CA INDEX NAME)




RN 220862-21-5 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-
(CA INDEX NAME)




RN 220862-21-5 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-22-6 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-2-methyl-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-22-6 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-2-methyl-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-23-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-23-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-24-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[4-(trifluoromethyl)phenyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-24-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[4-(trifluoromethyl)phenyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-26-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-5-[2-[(methylsulfonyl)amino]ethoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-26-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-5-[2-[(methylsulfonyl)amino]ethoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-27-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-[2-[[trifluoromethyl)sulfonyl]amino]ethoxy]- (CA INDEX NAME)




RN 220862-27-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-[2-[[trifluoromethyl)sulfonyl]amino]ethoxy]- (CA INDEX NAME)




RN 220862-30-6 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-2-pentyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-30-6 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-pentyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-31-7 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(1-methylethyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-31-7 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(1-methylethyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-32-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-32-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-33-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-phenyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-33-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-phenyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-34-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(2-furanyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-34-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(2-furanyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-35-1 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]-, lithium salt (1:1)
(CA INDEX NAME)



● Li

RN 220862-35-1 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]-, lithium salt (1:1)
(CA INDEX NAME)



● Li


RN 220862-36-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-36-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-37-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-phenoxyphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-37-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-phenoxyphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-38-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-38-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-39-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-39-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-40-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(phenylmethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-40-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(phenylmethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-41-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-41-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-42-0 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(1-naphthalenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-42-0 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(1-naphthalenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-43-1 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-43-1 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-44-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-44-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-45-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-45-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-46-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-46-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-47-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3,5-dimethylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-47-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3,5-dimethylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-48-6 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-iodophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-48-6 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-iodophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-49-7 CAPLUS

CN Acetic acid, 2-[(5-(aminocarbonyl)-9-[(2-chlorophenyl)methyl]-9H-carbazol-4-yl)oxy]- (CA INDEX NAME)




RN 220862-49-7 CAPLUS


CN Acetic acid, 2-[(5-(aminocarbonyl)-9-[(2-chlorophenyl)methyl]-9H-carbazol-4-yl)oxy]- (CA INDEX NAME)




RN 220862-50-0 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,3-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-50-0 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,3-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-51-1 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,6-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-51-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,6-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-54-4 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethoxy)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-54-4 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethoxy)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-55-5 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-([1,1'-biphenyl]-2-ylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-55-5 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-([1,1'-biphenyl]-2-ylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-59-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-59-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-61-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-61-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-63-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-chloro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-63-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-chloro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-66-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[(2-propen-1-yloxy)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-66-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[(2-propen-1-yloxy)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-68-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-(propoxymethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-68-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-(propoxymethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-72-6 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-(cyanomethoxy)-7-methoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-74-8 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-(2H-tetrazol-5-ylmethoxy)- (CA INDEX NAME)




RN 220862-74-8 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-(2H-tetrazol-5-ylmethoxy)- (CA INDEX NAME)




RN 220862-76-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-(2-amino-2-oxoethoxy)-7-methoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-76-0 CAPLUS


CN 9H-Carbazole-4-carboxamide, 5-(2-amino-2-oxoethoxy)-7-methoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-84-0 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(4-chlorophenyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 225653-40-7 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 7-methoxy-5-[[[(methylsulfonyl)amino]methoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 225653-40-7 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 7-methoxy-5-[[[(methylsulfonyl)amino]methoxy]-9-(phenylmethyl)- (CA INDEX NAME)




OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(2 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 36 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2001:478039 CAPLUS
DOCUMENT NUMBER: 135:242095
TITLE: Efficient synthesis of 3-substituted 2-arylindoles via
Suzuki coupling reactions on a solid phase
AUTHOR(S): Zhang, H.-C.; Ye, H.; White, K. B.; Maryanoff, B. E.
CORPORATE SOURCE: Drug Discovery, The R. W. Johnson Pharmaceutical
Research Institute, Spring House, PA, 19477-0776, USA
SOURCE: Tetrahedron Letters (2001), 42(29), 4751-4754
CODEN: TELEAY, ISSN: 0040-4039
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 135:242095

AB 2-Aryl-3-alkylindoles were prepared on solid phase via palladium-mediated
heteroannulation of 1-alkyl-2-(trimethylsilyl)acetylenes with amide
resin-bound o-iodoaniline, followed by transformation of trimethylsilyl to
iodide and then Suzuki coupling reactions. Traceless synthesis of sym.
and unsym. 2,3-diarylindoles was achieved via palladium-mediated one-pot
coupling/intramol. indole cyclization of aryl-substituted terminal alkynes
with sulfonyl resin-bound o-iodoaniline, followed by regioselective
bromination and Suzuki coupling reactions.
IT 361161-30-0DP, resin-bound 361161-31-1DP,
resin-bound
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(efficient synthesis of 3-substituted 2-arylindoles via Suzuki coupling
reactions on a solid phase)
RN 361161-30-0 CAPLUS
CN 1H-Indole-5-carboxamide, 2-iodo-3-methyl-1-(phenylmethyl)- (CA INDEX
NAME)



RN 361161-31-1 CAPLUS
CN 1H-Indole-5-carboxamide, 1-[(4-fluorophenyl)methyl]-2-iodo-3-methyl- (CA
INDEX NAME)




IT 361161-35-5P 361161-36-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(efficient synthesis of 3-substituted 2-arylindoles via Suzuki coupling
reactions on a solid phase)


RN 361161-35-5 CAPLUS

CN 1H-Indole-5-carboxamide, 1-[(4-fluorophenyl)methyl]-3-methyl-2-(4-methylphenyl)- (CA INDEX NAME)



RN 361161-36-6 CAPLUS

CN 1H-Indole-5-carboxamide, 1-[(4-fluorophenyl)methyl]-2-(4-methoxyphenyl)-3-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 47 THERE ARE 47 CAPLUS RECORDS THAT CITE THIS
RECORD (51 CITINGS)
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 37 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2001:283786 CAPLUS

DOCUMENT NUMBER: 134:290409

TITLE: Preparation of V type and/or X type sPLA2 inhibitors

INVENTOR(S): Ono, Takashi; Ueno, Masahiko; Hanasaki, Kohji

PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	----	-----	-----

WO 2001026653 A1 20010419 WO 2000-JP7024 20001010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,
SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG


PRIORITY APPLN. INFO.: JP 1999-293273 A 19991015
OTHER SOURCE(S): MARPAT 134:290409
GI



AB V type and/or X type sPLA2 inhibitors which contain as the active ingredient compds. represented by general formulas [I; X = CHR2, N; X1 = C, N; X2 = C, N; Y = R6; Z = R7; YZ = C(CONH2):CHCH:CH; R1 = OH, NHSO2C6H5; R2, R3, R4 independently = H, CH3, C6H5, F; ; R5 = 4-C6H5C6H4CH2, C6H5CH2, cyclohexylmethyl, 2-cyclopentylphenyl; R6 = H, C1-3 alkyl; R7 = COCONH2, CH2CONH2; dotted bond = single, double], prodrugs thereof, and pharmaceutically acceptable salts of the same or solvates of the same are prepared as V type and/or X type sPLA2 inhibitors. Thus, the title compound II was prepared and tested for X type sPLA2 inhibition with an IC50 of 3 nM.


IT 207340-86-1P 220862-34-0P 220862-37-3P
220862-61-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of V type and/or X type sPLA2 inhibitors)

RN 207340-86-1 CAPLUS
CN Acetic acid, 2-[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-
(CA INDEX NAME)




RN 220862-34-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(2-furanyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-37-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-phenoxyphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-61-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 38 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2001:57225 CAPLUS

DOCUMENT NUMBER: 134:131518

TITLE: Preparation of substituted carbazoles and analogous
tricyclics as secretory phospholipase A2 (sPLA2)
inhibitors

INVENTOR(S): Bach, Nicholas James; Draheim, Susan Elizabeth;
Dillard, Robert Delane; Mihelich, Edward David;
Sawyer, Jason Scott; Beight, Douglas Wade; Phillips,
Michael Leroy; Suarez, Tulio; Sall, Daniel Jon;
Bastian, Jolie Anne; Denney, Michael Lyle; Hite, Gary
Alan; Kinnick, Michael Dean; Vasileff, Robert
Theodore; Morin, John Michael, Jr.; Lin, Ho-Shen;
Richett, Michael Enrico; Harper, Richard Waltz;
McGill, John McNeill, III; Anderson, Benjamin Alan;
Harn, Nancy Kay; Loncharich, Richard James; Schevitz,
Richard Walter

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: U.S., 174 pp., Cont.-in-part of U.S. Ser. No. 959,477.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6177440	B1	20010123	US 1998-63066	19980421
HU 9903545	A2	20000228	HU 1999-3545	19971023
HU 9903545	A3	20010528		
US 6713645	B1	20040330	US 2000-688106	20001013
PRIORITY APPLN. INFO.:				
			US 1996-29849P	P 19961030
			US 1997-959477	A2 19971028
			US 1998-63066	A3 19980421
			US 2000-688106	A 20001013


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 134:131518

GI




I




II

- AB Carbazole, thiocarbazonol, pyridoindole, azacarbazonol, (thio)pyranoindole, and carboline derivs. I are disclosed [wherein: A = Ph or pyridyl; B or D = N and the other is C; Z = cyclohexenyl, Ph, pyridyl, or a heterocyclic ring with one S, O, or N atom; R20 = (un)substituted alkyl, alkenyl, alkynyl, carbo- or heterocyclic radical, or L-R80; L = linking group of 1-12 C, H, O, N, and/or S atoms; R80 = (un)substituted alkyl, alkenyl, alkynyl, carbo- or heterocyclic radical; R21 = non-interfering substituent; R1 = NHH2, NH2, or CONH2; R2 = OH or (un)substituted alkoxy; R3 = non-interfering substituent, (un)substituted carbo- or heterocyclic radical; with provisos]. I are inhibitors of human non-pancreatic secretory phospholipase A2 (sPLA2). I suppress sPLA2-mediated release of fatty acids, thereby inhibiting the arachidonic acid cascade, and are useful in the treatment of septic shock and a variety of other sPLA2 related diseases, such as arthritis. Over 70 examples were synthesized. For instance, the thiocarbazonol II was prepared in a nine-step synthesis. 4-Methoxyindole was N-benzylated and then acylated in the 3-position with Me oxalyl chloride. The resulting ketone was reduced to the alc. with NaBH4, to form Me (1-benzyl-4-methoxyindol-3-yl)hydroxyacetate. The alc. was mesylated and displaced by mercaptoacetic acid, and the thio ether cyclized to afford the 3-thia-1,2,3,4-tetrahydrocarbazole nucleus. The ester was hydrolyzed and converted to the carboxamide. Finally, the Me ether was cleaved to give the alc., followed by etherification with Et bromoacetate, and hydrolysis to yield II. I were effective inhibitors of recombinant human sPLA2 at concns. of < 100 μM in a chromogenic assay. I also suppressed contractile response of guinea pig dorsal pleural strips to sPLA2 at concns. < 20 μM. I reduced sPLA2 catalytic activity in the serum of transgenic mice (no data).
- IT 207340-75-8P, Methyl [(9-benzyl-4-carbamoyl-7-methoxycarbazol-5-yl)oxy]acetate 207340-86-1P, [[9-[(Phenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid 220862-55-5P, [[9-[(2-Biphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid 220862-72-6P, 9-Benzyl-7-methoxy-5-(cyanomethyloxy)carbazole-4-carboxamide
- RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
- (drug candidate; preparation of substituted carbazoles and analogous tricyclics as secretory phospholipase A2 (sPLA2) inhibitors)
- RN 207340-75-8 CAPLUS
- CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methoxy-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 207340-86-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-
(CA INDEX NAME)




RN 220862-55-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-([1,1'-biphenyl]-2-ylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-72-6 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-(cyanomethoxy)-7-methoxy-9-(phenylmethyl)-
(CA INDEX NAME)




IT 207340-74-7P, [(9-Benzyl-4-carbamoyl-7-methoxycarbazol-5-yl)oxy]acetic acid 207340-76-9P, [(9-Benzyl-4-carbamoyl-7-methoxycarbazol-5-yl)oxy]acetic acid sodium salt 220862-21-5P, [(9-(Phenylmethyl)-5-carbamoyl-2-methylcarbazol-4-yl)oxy]acetic acid 220862-22-6P, [[9-[(3-Fluorophenyl)methyl]-5-carbamoyl-2-methylcarbazol-4-yl]oxy]acetic acid 220862-23-7P, [[9-[(3-Methylphenyl)methyl]-5-carbamoyl-2-methylcarbazol-4-yl]oxy]acetic acid 220862-24-8P, [[9-[(Phenyl)methyl]-5-carbamoyl-2-(4-trifluoromethylphenyl)carbazol-4-yl]oxy]acetic acid 220862-26-0P, 9-Benzyl-4-[[2-(methanesulfonamido)ethyl]oxy]-2-methoxycarbazole-5-carboxamide 220862-27-1P, 9-Benzyl-4-[[2-(trifluoromethanesulfonamido)ethyl]oxy]-2-methoxycarbazole-5-carboxamide 220862-30-6P, [[5-Carbamoyl-2-pentyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetic acid 220862-31-7P, [[5-Carbamoyl-2-(1-methylethyl)-9-(phenylmethyl)carbazol-4-yl]oxy]acetic acid 220862-32-8P, [[5-Carbamoyl-9-(phenylmethyl)-2-[[[tris(1-methylethyl)silyl]oxy]methyl]carbazol-4-yl]oxy]acetic acid 220862-33-9P, [[5-Carbamoyl-2-phenyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetic acid 220862-34-0P, [[5-Carbamoyl-2-(2-furyl)-9-(phenylmethyl)carbazol-4-yl]oxy]acetic acid 220862-35-1P, [[5-Carbamoyl-9-(phenylmethyl)-2-[[[tris(1-methylethyl)silyl]oxy]methyl]carbazol-4-yl]oxy]acetic acid lithium salt 220862-36-2P, [[9-[(3-Fluorophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid 220862-37-3P, [[9-[(3-Phenoxyphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid 220862-38-4P, [[9-[(2-Fluorophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid 220862-39-5P, [[9-[(2-Trifluoromethylphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid 220862-40-8P, [[9-[(2-Benzylphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid 220862-41-9P, [[9-[(3-Trifluoromethylphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid 220862-42-0P, [[9-[(1-Naphthyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid 220862-43-1P, [[9-[(2-Cyanophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid 220862-44-2P, [[9-[(3-Cyanophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid 220862-45-3P, [[9-[(2-Methylphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid 220862-46-4P, [[9-[(3-Methylphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid 220862-47-5P, [[9-[(3,5-Dimethylphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid 220862-48-6P, [[9-[(3-Iodophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid 220862-49-7P, [[9-[(2-Chlorophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid 220862-50-0P, [[9-[(2,3-Difluorophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid 220862-51-1P, [[9-[(2,6-Difluorophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid 220862-53-3P, [[9-[(2,6-Dichlorophenyl)methyl]-5-carbamoylcarbazol-

4-yl]oxy]acetic acid 220862-54-4P,
 [[9-[(3-Trifluoromethoxyphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic
 acid 220862-59-9P, [[9-Benzyl-5-carbamoyl-1-methylcarbazol-4-
 yl]oxy]acetic acid 220862-61-3P,
 [(9-Benzyl-5-carbamoyl-1-fluorocarbazol-4-yl)oxy]acetic acid
 220862-63-5P, [(9-Benzyl-5-carbamoyl-1-chlorocarbazol-4-
 yl)oxy]acetic acid 220862-66-8P,
 [[5-Carbamoyl-9-(phenylmethyl)-2-[(prop-1-en-3-yl)oxy]methyl]carbazol-4-
 yl]oxy]acetic acid 220862-68-0P,
 [[5-Carbamoyl-9-(phenylmethyl)-2-[(propyloxy)methyl]carbazol-4-
 yl]oxy]acetic acid 220862-74-8P,
 9-Benzyl-7-methoxy-5-[(1H-tetrazol-5-ylmethyl)oxy]carbazole-4-carboxamide
 220862-76-0P, 9-Benzyl-7-methoxy-5-[(carbamoylmethyl)oxy]carbazole-
 4-carboxamide 220862-84-0P,
 [[5-Carbamoyl-2-(4-chlorophenyl)-9-(phenylmethyl)carbazol-4-yl]oxy]acetic
 acid 246513-34-8P, [[9-(Phenylmethyl)-5-carbamoylcarbazol-4-
 yl]oxy]acetic acid sodium salt 246513-35-9P,
 [[9-[(3-Chlorophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid
 246513-36-0P, [[9-[(3-Trifluoromethylphenyl)methyl]-5-
 carbamoylcarbazol-4-yl]oxy]acetic acid sodium salt 246513-37-1P
 , [[9-[(2-Methylphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid
 sodium salt 246513-39-3P,
 [[9-[(3-Methylphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid
 sodium salt 246513-40-6P,
 [[9-[(3-Trifluoromethoxyphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic
 acid sodium salt 246868-00-8P,
 2-[(5-Carbamoyl-9-benzyl-9H-pyrido[3,4-b]indol-4-yl)oxy]acetic acid
 hydrochloride 247903-77-1P,
 [[9-[(2-Biphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl
 ester 247904-05-8P,
 [[5-Carbamoyl-9-(phenylmethyl)-2-(2-thienyl)carbazol-4-yl]oxy]acetic acid
 247904-07-0P, [[9-[(3-Fluorophenyl)methyl]-2-methyl-5-
 carbamoylcarbazol-4-yl]oxy]acetic acid sodium salt 321858-11-1P
 , 9-Benzyl-4-(methanesulfonamidomethyloxy)carbazole-5-carboxamide
 321858-12-2P, [[5-Carbamoyl-9-(phenylmethyl)-2-
 (hydroxymethyl)carbazol-4-yl]oxy]acetic acid 321858-13-3P,
 [[9-[(2-Benzylphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid
 sodium salt 321858-14-4P,
 [[9-[(1-Naphthyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid sodium
 salt 321858-15-5P, [[9-[(2-Cyanophenyl)methyl]-5-
 carbamoylcarbazol-4-yl]oxy]acetic acid sodium salt 321858-16-6P
 , [[9-[(3,5-Dimethylphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic
 acid sodium salt 321858-17-7P,
 [[9-[(3-Iodophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid sodium
 salt 321858-18-8P, [[9-[(2,3-Difluorophenyl)methyl]-5-
 carbamoylcarbazol-4-yl]oxy]acetic acid sodium salt 321858-19-9P
 , [[9-[(2,6-Difluorophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic
 acid sodium salt 321858-20-2P,
 [[9-[(2,6-Dichlorophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid
 sodium salt 321858-27-9P,
 [[9-[(Phenyl)methyl]-2-methyl-5-carbamoylcarbazol-4-yl]oxy]acetic acid
 sodium salt

RL: BAC (Biological activity or effector, except adverse); BSU (Biological
 study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; preparation of substituted carbazoles and analogous
 tricyclics as secretory phospholipase A2 (sPLA2) inhibitors)


RN 207340-74-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methoxy-9-(phenylmethyl)-9H-carbazol-
 4-yl]oxy]- (CA INDEX NAME)



RN 207340-76-9 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methoxy-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 220862-21-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-22-6 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-2-methyl-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-23-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-24-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[4-(trifluoromethyl)phenyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-26-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-5-[2-[(methylsulfonyl)amino]ethoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-27-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-[[2-[(trifluoromethyl)sulfonyl]amino]ethoxy]- (CA INDEX NAME)




RN 220862-30-6 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-pentyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-31-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(1-methylethyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-32-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-33-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-phenyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-34-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(2-furanyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-35-1 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]-, lithium salt (1:1) (CA INDEX NAME)



● Li


RN 220862-36-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-37-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-phenoxyphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-38-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-39-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-40-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(phenylmethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-41-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-42-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(1-naphthalenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-43-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-44-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-45-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-46-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-47-5 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3,5-dimethylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-48-6 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-iodophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-49-7 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-chlorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-50-0 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,3-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-51-1 CAPLUS

CN Acetic acid, 2-[(5-(aminocarbonyl)-9-[(2,6-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-53-3 CAPLUS


CN Acetic acid, 2-[(5-(aminocarbonyl)-9-[(2,6-dichlorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-54-4 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethoxy)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-59-9 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-1-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-61-3 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-63-5 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-1-chloro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-66-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[(2-propen-1-yloxy)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-68-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-(propoxymethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-74-8 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-(2H-tetrazol-5-ylmethoxy)- (CA INDEX NAME)




RN 220862-76-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-(2-amino-2-oxoethoxy)-7-methoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-84-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(4-chlorophenyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 246513-34-8 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(4-chlorophenyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 246513-35-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-chlorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 246513-36-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 246513-37-1 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 246513-39-3 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 246513-40-6 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethoxy)phenyl]methyl]-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 246868-00-8 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-pyrido[3,4-b]indol-4-yl]oxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 247903-77-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-([1,1'-biphenyl]-2-ylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247904-05-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-(2-thienyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 247904-07-0 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-2-methyl-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 321858-11-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-[2-[(methylsulfonyl)amino]-2-oxoethoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 321858-12-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(hydroxymethyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 321858-13-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(phenylmethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 321858-14-4 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(1-naphthalenylmethyl)-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 321858-15-5 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 321858-16-6 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3,5-dimethylphenyl)methyl]-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 321858-17-7 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-iodophenyl)methyl]-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 321858-18-8 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,3-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 321858-19-9 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,6-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 321858-20-2 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,6-dichlorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 321858-27-9 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na

IT 207341-24-0P, 9-Benzyl-4-carbamoyl-5,7-dimethoxycarbazole
 207341-25-1P, 9-Benzyl-4-carbamoyl-5-hydroxy-7-methoxycarbazole
 246513-45-1P, 9-[(Phenyl)methyl]-4-hydroxy-5-carbamoylcarbazole
 246513-46-2P, [[9-[(Phenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 246513-52-0P,
 9-Benzyl-5-carbamoyl-4-methoxy-1-fluorocarbazole 246513-53-1P,
 [(9-Benzyl-5-carbamoyl-1-fluorocarbazol-4-yl)oxy]acetic acid methyl ester
 246513-56-4P, 9-[(3-Fluorophenyl)methyl]-4-hydroxy-5-carbamoylcarbazole 246513-57-5P,
 [[9-[(3-Fluorophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid tert-butyl ester 246513-60-0P,
 9-[(3-Chlorophenyl)methyl]-4-hydroxy-5-carbamoylcarbazole 246513-61-1P, [[9-[(3-Chlorophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid tert-butyl ester 246513-64-4P,
 9-[(3-Trifluoromethylphenyl)methyl]-4-hydroxy-5-carbamoylcarbazole 246513-65-5P, [[9-[(3-Trifluoromethylphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 246513-68-8P,
 9-[(2-Methylphenyl)methyl]-4-hydroxy-5-carbamoylcarbazole 246513-69-9P, [[9-[(2-Methylphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 246513-72-4P,
 9-[(3-Methylphenyl)methyl]-4-hydroxy-5-carbamoylcarbazole 246513-73-5P, [[9-[(3-Methylphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 246513-76-8P,
 9-[(3-Trifluoromethoxyphenyl)methyl]-4-hydroxy-5-carbamoylcarbazole 246513-77-9P, [[9-[(3-Trifluoromethoxyphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 246513-79-1P,
 9-Benzyl-5-carbamoyl-4-methoxy-1-methylcarbazole 246513-80-4P,
 [(9-Benzyl-5-carbamoyl-1-methylcarbazol-4-yl)oxy]acetic acid methyl ester 246513-84-8P, [(9-Benzyl-5-carbamoyl-1-chlorocarbazol-4-yl)oxy]acetic acid methyl ester 246868-15-5P,
 4-Hydroxy-5-carbamoyl-9-benzyl-9H-pyrido[3,4-b]indole 247902-64-3P, 9-[(Phenyl)methyl]-2-methyl-4-hydroxy-5-carbamoylcarbazole 247902-65-4P,
 [[9-[(Phenyl)methyl]-2-methyl-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 247902-68-7P,
 9-[(3-Fluorophenyl)methyl]-2-methyl-4-hydroxy-5-carbamoylcarbazole 247902-69-8P, [[9-[(3-Fluorophenyl)methyl]-2-methyl-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 247902-72-3P,
 9-[(3-Methylphenyl)methyl]-2-methyl-4-hydroxy-5-carbamoylcarbazole 247902-73-4P, [[9-[(3-Methylphenyl)methyl]-2-methyl-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 247902-78-9P,
 9-[(Phenyl)methyl]-2-(4-trifluoromethylphenyl)-4-hydroxy-5-carbamoylcarbazole 247902-79-0P,
 [[9-[(Phenyl)methyl]-2-(4-trifluoromethylphenyl)-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 247902-84-7P,


5-Carbamoyl-4-hydroxy-2-pentyl-9-(phenylmethyl)carbazole
 247902-85-8P, [[5-Carbamoyl-2-pentyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetic acid methyl ester 247902-90-5P,
 5-Carbamoyl-4-hydroxy-2-(1-methylethyl)-9-(phenylmethyl)carbazole
 247902-91-6P, [[5-Carbamoyl-2-(1-methylethyl)-9-(phenylmethyl)carbazol-4-yl]oxy]acetic acid methyl ester
 247902-95-0P, [[5-Carbamoyl-9-(phenylmethyl)-2-[[tris(1-methylethyl)silyl]oxy]methyl]carbazol-4-yl]oxy]acetic acid methyl ester
 247903-00-0P, 5-Carbamoyl-4-hydroxy-2-phenyl-9-(phenylmethyl)carbazole 247903-01-1P,
 [[5-Carbamoyl-2-phenyl-9-(phenylmethyl)carbazol-4-yl]oxy]acetic acid methyl ester 247903-06-6P,
 5-Carbamoyl-2-(4-chlorophenyl)-4-hydroxy-9-(phenylmethyl)carbazole
 247903-07-7P, [[5-Carbamoyl-2-(4-chlorophenyl)-9-(phenylmethyl)carbazol-4-yl]oxy]acetic acid methyl ester
 247903-12-4P, 5-Carbamoyl-2-(2-furyl)-4-hydroxy-9-(phenylmethyl)carbazole 247903-13-5P,
 [[5-Carbamoyl-2-(2-furyl)-9-(phenylmethyl)carbazol-4-yl]oxy]acetic acid methyl ester 247903-16-8P,
 5-Carbamoyl-4-hydroxy-9-(phenylmethyl)-2-[[tris(1-methylethyl)silyl]oxymethyl]carbazole 247903-20-4P,
 9-[[3-Phenoxyphenyl)methyl]-4-hydroxy-5-carbamoylcarbazole
 247903-21-5P, [[9-[[3-Phenoxyphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid tert-butyl ester 247903-25-9P,
 9-[[2-Fluorophenyl)methyl]-4-hydroxy-5-carbamoylcarbazole
 247903-26-0P, [[9-[[2-Fluorophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 247903-29-3P,
 9-[[2-Trifluoromethylphenyl)methyl]-4-hydroxy-5-carbamoylcarbazole
 247903-30-6P, [[9-[[2-Trifluoromethylphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 247903-33-9P,
 9-[[2-Benzylphenyl)methyl]-4-hydroxy-5-carbamoylcarbazole
 247903-34-0P, [[9-[[2-Benzylphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 247903-37-3P,
 9-[[1-Naphthyl)methyl]-4-hydroxy-5-carbamoylcarbazole
 247903-38-4P, [[9-[[1-Naphthyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 247903-41-9P,
 9-[[2-Cyanophenyl)methyl]-4-hydroxy-5-carbamoylcarbazole
 247903-42-0P, [[9-[[2-Cyanophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 247903-45-3P,
 9-[[3-Cyanophenyl)methyl]-4-hydroxy-5-carbamoylcarbazole
 247903-46-4P, [[9-[[3-Cyanophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid tert-butyl ester 247903-49-7P,
 9-[[3,5-Dimethylphenyl)methyl]-4-hydroxy-5-carbamoylcarbazole
 247903-50-0P, [[9-[[3,5-Dimethylphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 247903-53-3P,
 9-[[3-Iodophenyl)methyl]-4-hydroxy-5-carbamoylcarbazole
 247903-54-4P, [[9-[[3-Iodophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 247903-57-7P,
 9-[[2-Chlorophenyl)methyl]-4-hydroxy-5-carbamoylcarbazole
 247903-58-8P, [[9-[[2-Chlorophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid tert-butyl ester 247903-61-3P,
 9-[[2,3-Difluorophenyl)methyl]-4-hydroxy-5-carbamoylcarbazole
 247903-62-4P, [[9-[[2,3-Difluorophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 247903-65-7P,
 9-[[2,6-Difluorophenyl)methyl]-4-hydroxy-5-carbamoylcarbazole
 247903-66-8P, [[9-[[2,6-Difluorophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 247903-69-1P,
 9-[[2,6-Dichlorophenyl)methyl]-4-hydroxy-5-carbamoylcarbazole
 247903-70-4P, [[9-[[2,6-Dichlorophenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 247903-75-9P,
 9-[[2-Biphenyl)methyl]-4-hydroxy-5-carbamoylcarbazole
 247903-76-0P, [[9-[[2-Biphenyl)methyl]-5-carbamoylcarbazol-4-yl]oxy]acetic acid methyl ester 247903-79-3P,
 9-[[2,6-Dichlorophenyl)methyl]-4-hydroxy-5-carbamoylcarbazole

yl]oxy]acetic acid tert-butyl ester 247903-95-3P,
 9-Benzyl-5-carbamoyl-4-hydroxy-1-methylcarbazole 247903-97-5P,
 9-Benzyl-5-carbamoyl-4-hydroxy-1-fluorocarbazole 247904-02-5P,
 9-Benzyl-5-carbamoyl-4-methoxy-1-chlorocarbazole 247904-09-2P,
 4-[(2-Aminoethyl)oxy]-9-benzyl-2-methoxycarbazole-5-carboxamide
 247904-15-0P, 5-Carbamoyl-4-hydroxy-9-(phenylmethyl)-2-(2-
 thienyl)carbazole 247904-16-1P,
 [[5-Carbamoyl-9-(phenylmethyl)-2-(2-thienyl)carbazol-4-yl]oxy]acetic acid
 methyl ester 247904-19-4P,
 5-Carbamoyl-4-hydroxy-9-(phenylmethyl)-2-[[prop-1-en-3-
 yl]oxy]methyl]carbazole 247904-20-7P,
 [[5-Carbamoyl-9-(phenylmethyl)-2-[(propyloxy)methyl]carbazol-4-
 yl]oxy]acetic acid methyl ester 321858-61-1P,
 [[5-Carbamoyl-9-(phenylmethyl)-2-(hydroxymethyl)carbazol-4-yl]oxy]acetic
 acid methyl ester 321859-15-8P,
 [[5-Carbamoyl-9-(phenylmethyl)-2-[[prop-1-en-3-yl]oxy]methyl]carbazol-4-
 yl]oxy]acetic acid methyl ester
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(intermediate; preparation of substituted carbazoles and analogous
 tricyclics as secretory phospholipase A2 (sPLA2) inhibitors)


RN 207341-24-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5,7-dimethoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 207341-25-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-7-methoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 246513-45-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 246513-46-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246513-52-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 8-fluoro-5-methoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 246513-53-1 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246513-56-4 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 9-[(3-fluorophenyl)methyl]-5-hydroxy- (CA INDEX NAME)



RN 246513-57-5 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 246513-60-0 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 9-[(3-chlorophenyl)methyl]-5-hydroxy- (CA INDEX NAME)




RN 246513-61-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-chlorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 246513-64-4 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[[3-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 246513-65-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246513-68-8 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 246513-69-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246513-72-4 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[(3-methylphenyl)methyl]- (CA INDEX NAME)




RN 246513-73-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246513-76-8 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[[3-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 246513-77-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethoxy)phenyl]methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246513-79-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-methoxy-8-methyl-9-(phenylmethyl)- (CA INDEX NAME)




RN 246513-80-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246513-84-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-chloro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246868-15-5 CAPLUS

CN 9H-Pyrido[3,4-b]indole-5-carboxamide, 4-hydroxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 247902-64-3 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-7-methyl-9-(phenylmethyl)- (CA INDEX NAME)




RN 247902-65-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247902-68-7 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(3-fluorophenyl)methyl]-5-hydroxy-7-methyl- (CA INDEX NAME)




RN 247902-69-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-2-methyl-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247902-72-3 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-7-methyl-9-[(3-methylphenyl)methyl]-
(CA INDEX NAME)




RN 247902-73-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-[(3-methylphenyl)methyl]-9H-
carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247902-78-9 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-(phenylmethyl)-7-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 247902-79-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[4-(trifluoromethyl)phenyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247902-84-7 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-7-pentyl-9-(phenylmethyl)- (CA INDEX NAME)




RN 247902-85-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-pentyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247902-90-5 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-7-(1-methylethyl)-9-(phenylmethyl)-
(CA INDEX NAME)




RN 247902-91-6 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(1-methylethyl)-9-(phenylmethyl)-9H-
carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247902-95-0 CAPLUS


CN Acetic acid, 2-[[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[[tris(1-
methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA
INDEX NAME)




RN 247903-00-0 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 5-hydroxy-7-phenyl-9-(phenylmethyl)- (CA INDEX NAME)



RN 247903-01-1 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-phenyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-06-6 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 7-(4-chlorophenyl)-5-hydroxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 247903-07-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(4-chlorophenyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-12-4 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-(2-furanyl)-5-hydroxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 247903-13-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(2-furanyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-16-8 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-(phenylmethyl)-7-[[[tris(1-methylethyl)silyl]oxy]methyl]- (CA INDEX NAME)




RN 247903-20-4 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[(3-phenoxyphenyl)methyl]- (CA INDEX NAME)




RN 247903-21-5 CAPLUS

CN Acetic acid, 2-[[[5-(aminocarbonyl)-9-[(3-phenoxyphenyl)methyl]-9H-carbazol-4-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 247903-25-9 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(2-fluorophenyl)methyl]-5-hydroxy- (CA INDEX NAME)




RN 247903-26-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-29-3 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 247903-30-6 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-33-9 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[[2-(phenylmethyl)phenyl]methyl]- (CA INDEX NAME)




RN 247903-34-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(phenylmethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-37-3 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-(1-naphthalenylmethyl)- (CA INDEX NAME)




RN 247903-38-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(1-naphthalenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-41-9 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(2-cyanophenyl)methyl]-5-hydroxy- (CA INDEX NAME)




RN 247903-42-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-45-3 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(3-cyanophenyl)methyl]-5-hydroxy- (CA INDEX NAME)




RN 247903-46-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 247903-49-7 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(3,5-dimethylphenyl)methyl]-5-hydroxy- (CA INDEX NAME)




RN 247903-50-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3,5-dimethylphenyl)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-53-3 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[(3-iodophenyl)methyl]- (CA INDEX NAME)




RN 247903-54-4 CAPLUS

CN Acetic acid, 2-[5-(aminocarbonyl)-9-[(3-iodophenyl)methyl]-9H-carbazol-4-yl]oxy-, methyl ester (CA INDEX NAME)




RN 247903-57-7 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(2-chlorophenyl)methyl]-5-hydroxy- (CA INDEX NAME)




RN 247903-58-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-chlorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 247903-61-3 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(2,3-difluorophenyl)methyl]-5-hydroxy- (CA INDEX NAME)




RN 247903-62-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,3-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-65-7 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(2,6-difluorophenyl)methyl]-5-hydroxy- (CA INDEX NAME)




RN 247903-66-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,6-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-69-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(2,6-dichlorophenyl)methyl]-5-hydroxy- (CA INDEX NAME)




RN 247903-70-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,6-dichlorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-75-9 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-([1,1'-biphenyl]-2-ylmethyl)-5-hydroxy- (CA INDEX NAME)




RN 247903-76-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-([1,1'-biphenyl]-2-ylmethyl)-9H-carbazol-4-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 247903-95-3 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-8-methyl-9-(phenylmethyl)- (CA INDEX NAME)




RN 247903-97-5 CAPLUS

CN 9H-Carbazole-4-carboxamide, 8-fluoro-5-hydroxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 247904-02-5 CAPLUS

CN 9H-Carbazole-4-carboxamide, 8-chloro-5-methoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 247904-09-2 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-(2-aminoethoxy)-7-methoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 247904-15-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-(phenylmethyl)-7-(2-thienyl)- (CA INDEX NAME)




RN 247904-16-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-(2-thienyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247904-19-4 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-(phenylmethyl)-7-[(2-propen-1-yloxy)methyl]- (CA INDEX NAME)




RN 247904-20-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-(propoxymethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 321858-61-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(hydroxymethyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)



RN 321859-15-8 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[(2-propen-1-yloxy)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
 REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 39 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2000:441578 CAPLUS
 DOCUMENT NUMBER: 133:53700
 TITLE: Combination therapy for the treatment of sepsis with activated protein C and a secretory phospholipase A2 (sPLA2) inhibitor
 INVENTOR(S): Maciak, Ronald Steven
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 279 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000037022	A2	20000629	WO 1999-US30433	19991220
WO 2000037022	A3	20020613		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2358492	A1	20000629	CA 1999-2358492	19991220
AU 2000019408	A	20000712	AU 2000-19408	19991220
EP 1214041	A2	20020619	EP 1999-963109	19991220

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, FI, CY

JP 2002542148 T 20021210 JP 2000-589136 19991220
 PRIORITY APPLN. INFO.: US 1998-113124P P 19981221
 WO 1999-US30433 W 19991220

OTHER SOURCE(S): MARPAT 133:53700

AB The invention provides a method of prevention and treatment for sepsis for mammals. The treatment is a combination therapy of activated protein C and an sPLA2 inhibitor.


IT 207340-86-1D, prodrug derivs. 220862-21-5
 220862-21-5D, prodrug derivs. 220862-22-6
 220862-22-6D, prodrug derivs. 220862-23-7
 220862-23-7D, prodrug derivs. 220862-24-8
 220862-24-8D, prodrug derivs. 220862-26-0
 220862-26-0D, prodrug derivs. 220862-27-1
 220862-27-1D, prodrug derivs. 220862-30-6
 220862-30-6D, prodrug derivs. 220862-31-7
 220862-31-7D, prodrug derivs. 220862-32-8
 220862-32-8D, prodrug derivs. 220862-33-9
 220862-33-9D, prodrug derivs. 220862-34-0
 220862-34-0D, prodrug derivs. 220862-35-1
 220862-35-1D, prodrug derivs. 220862-37-3
 220862-37-3D, prodrug derivs. 220862-38-4
 220862-38-4D, prodrug derivs. 220862-39-5
 220862-39-5D, prodrug derivs. 220862-40-8
 220862-40-8D, prodrug derivs. 220862-41-9
 220862-41-9D, prodrug derivs. 220862-42-0
 220862-42-0D, prodrug derivs. 220862-43-1
 220862-43-1D, prodrug derivs. 220862-44-2
 220862-44-2D, prodrug derivs. 220862-45-3
 220862-45-3D, prodrug derivs. 220862-46-4
 220862-46-4D, prodrug derivs. 220862-47-5
 220862-47-5D, prodrug derivs. 220862-48-6
 220862-48-6D, prodrug derivs. 220862-49-7
 220862-49-7D, prodrug derivs. 220862-50-0
 220862-50-0D, prodrug derivs. 220862-51-1
 220862-51-1D, prodrug derivs. 220862-53-3
 220862-53-3D, prodrug derivs. 220862-54-4
 220862-54-4D, prodrug derivs. 220862-55-5
 220862-55-5D, prodrug derivs. 220862-59-9
 220862-59-9D, prodrug derivs. 220862-61-3
 220862-61-3D, prodrug derivs. 220862-63-5
 220862-63-5D, prodrug derivs. 220862-66-8
 220862-66-8D, prodrug derivs. 220862-68-0
 220862-68-0D, prodrug derivs. 220862-72-6
 220862-72-6D, prodrug derivs. 220862-74-8
 220862-74-8D, prodrug derivs. 220862-76-0
 220862-76-0D, prodrug derivs. 220862-84-0
 220862-84-0D, prodrug derivs. 225653-40-7
 225653-40-7D, prodrug derivs. 278171-82-7
 278171-82-7D, prodrug derivs.

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(activated protein C-secretory phospholipase A2 inhibitor combination for sepsis treatment)

RN 207340-86-1 CAPLUS


CN Acetic acid, 2-[(5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl)oxy]-
 (CA INDEX NAME)




RN 220862-21-5 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-21-5 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-22-6 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-2-methyl-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-22-6 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-2-methyl-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-23-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-methylphenyl)methyl]-2-methyl-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-23-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-24-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[4-(trifluoromethyl)phenyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-24-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[4-(trifluoromethyl)phenyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-26-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-5-[2-[(methylsulfonyl)amino]ethoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-26-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-5-[2-[(methylsulfonyl)amino]ethoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-27-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-[2-[(trifluoromethyl)sulfonyl]amino]ethoxy]- (CA INDEX NAME)




RN 220862-27-1 CAPLUS


CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-[2-[(trifluoromethyl)sulfonyl]amino]ethoxy]- (CA INDEX NAME)




RN 220862-30-6 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-pentyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-30-6 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-pentyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-31-7 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(1-methylethyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-31-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(1-methylethyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-32-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-32-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-33-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-phenyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-33-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-phenyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-34-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(2-furanyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-34-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-35-1 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]-, lithium salt (1:1) (CA INDEX NAME)



● Li

RN 220862-35-1 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]-, lithium salt (1:1) (CA INDEX NAME)



● Li


RN 220862-37-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-phenoxymethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-37-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-phenoxymethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-38-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-38-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-39-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-39-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-40-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(phenylmethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-40-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(phenylmethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-41-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-41-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-42-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(1-naphthalenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-42-0 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(1-naphthalenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-43-1 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-43-1 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-44-2 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-44-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-45-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-45-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-46-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-46-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-47-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3,5-dimethylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-47-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3,5-dimethylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-48-6 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-iodophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-48-6 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-iodophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-49-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-chlorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-49-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-chlorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-50-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,3-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-50-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,3-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-51-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,6-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-51-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,6-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-53-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,6-dichlorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-53-3 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,6-dichlorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-54-4 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethoxy)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-54-4 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethoxy)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-55-5 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-([1,1'-biphenyl]-2-ylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-55-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-([1,1'-biphenyl]-2-ylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-59-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-59-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-61-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-61-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-63-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-chloro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-63-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-chloro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-66-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[(2-propen-1-yloxy)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-66-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[(2-propen-1-yloxy)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-68-0 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-(propoxymethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-68-0 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-(propoxymethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-72-6 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 5-(cyanomethoxy)-7-methoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-72-6 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 5-(cyanomethoxy)-7-methoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-74-8 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-(2H-tetrazol-5-ylmethoxy)- (CA INDEX NAME)




RN 220862-74-8 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-(2H-tetrazol-5-ylmethoxy)- (CA INDEX NAME)




RN 220862-76-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-(2-amino-2-oxoethoxy)-7-methoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-76-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-(2-amino-2-oxoethoxy)-7-methoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-84-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(4-chlorophenyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-84-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(4-chlorophenyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 225653-40-7 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-5-[[(methylsulfonyl)amino]methoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 225653-40-7 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-5-[[(methylsulfonyl)amino]methoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 278171-82-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-[(3-fluorophenyl)methyl]-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 278171-82-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-[(3-fluorophenyl)methyl]-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



IT 207340-86-1
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (phospholipase A2 inhibitor combination for sepsis treatment)
 RN 207340-86-1 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-
 (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
 (1 CITINGS)
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L12 ANSWER 40 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1999:690826 CAPLUS
 DOCUMENT NUMBER: 131:310547
 TITLE: Preparation of substituted carbazoles for use as
 secretory phospholipase A2 (sPLA2) inhibitors
 INVENTOR(S): Anderson, Benjamin Alan; Bach, Nicholas James;
 Bastian, Jolie Anne; Harn, Nancy Kay; Harper, Richard
 Waltz; Hite, Gary Alan; Kinnick, Michael Dean; Lin,
 Ho-shen; Loncharich, Richard James; McGill, John
 Mcneill; Mihelich, Edward David; Morin, John Michael,
 Jr.; Phillips, Michael Leroy; Richett, Michael Enrico;
 Sall, Daniel Jon; Sawyer, Jason Scott; Schevitz,
 Richard Walter; Vasileff, Robert Theodore
 PATENT ASSIGNEE(S): Eli Lilly and Co., USA
 SOURCE: Eur. Pat. Appl., 244 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

EP 952149	A2	19991027	EP 1999-302941	19990416
EP 952149	A3	20010816		
EP 952149	B1	20040609		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2269246	A1	19991017	CA 1999-2269246	19990416
CA 2269246	C	20090825		
CA 2269262	A1	19991017	CA 1999-2269262	19990416
NO 9901821	A	19991018	NO 1999-1821	19990416
NO 314400	B1	20030317		
NO 9901822	A	19991018	NO 1999-1822	19990416
NO 312240	B1	20020415		
AU 9923817	A	19991028	AU 1999-23817	19990416
AU 753436	B2	20021017		
AU 9923819	A	19991028	AU 1999-23819	19990416
AU 753547	B2	20021024		
TR 9900853	A3	19991122	TR 1999-853	19990416
JP 11322713	A	19991124	JP 1999-109629	19990416
CN 1240210	A	20000105	CN 1999-107687	19990416
JP 2000026416	A	20000125	JP 1999-152400	19990416
JP 4435330	B2	20100317		
TR 9900843	A2	20000221	TR 1999-843	19990416
BR 9901279	A	20000502	BR 1999-1279	19990416
CN 1253948	A	20000524	CN 1999-107957	19990416
CN 1149193	C	20040512		
MX 9903587	A	20000731	MX 1999-3587	19990416
MX 9903589	A	20000731	MX 1999-3589	19990416
NZ 335251	A	20001124	NZ 1999-335251	19990416
NZ 335253	A	20001124	NZ 1999-335253	19990416
BR 9902365	A	20010424	BR 1999-2365	19990416
SG 81976	A1	20010724	SG 1999-1681	19990416
SG 81977	A1	20010724	SG 1999-1869	19990416
HU 9901220	A3	20011128	HU 1999-1220	19990416
HU 9901221	A3	20011128	HU 1999-1221	19990416
ZA 9902771	A	20020418	ZA 1999-2771	19990416
ZA 9902772	A	20020716	ZA 1999-2772	19990416
NZ 507564	A	20021025	NZ 1999-507564	19990416
NZ 518027	A	20030429	NZ 1999-518027	19990416
AT 268756	T	20040615	AT 1999-302941	19990416
AT 271037	T	20040715	AT 1999-302967	19990416
PT 950657	E	20041130	PT 1999-302967	19990416
ES 2222663	T3	20050201	ES 1999-302941	19990416
ES 2226286	T3	20050316	ES 1999-302967	19990416
TW 238160	B	20050821	TW 1999-106130	19990416
IN 1999CA00346	A	20051202	IN 1999-CA346	19990416
IN 240478	A1	20100514	IN 1999-CA347	19990416

PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 131:310547
GI




AB Substituted carbazoles (I) [where Z = cyclohexenyl or Ph; R1 = NHNH2, NH2, or CONH2; R2 = OH or (un)substituted alkoxy; R3 = non-interfering substituent or (un)substituted carbocyclic or heterocyclic; R21 = non-interfering substituent; n = 1-3] were prepared as inhibitors of human non-pancreatic secretory phospholipase A2 (sPLA2) for treatment of septic shock and other sPLA2 related diseases. For instance, a solution of 3,5-dimethoxyaniline and benzaldehyde in MeOH was cooled and treated with Na cyanoborohydride to form N-benzyl-3,5-dimethoxyaniline. The aniline was coupled with 2-carbethoxy-6-bromocyclohexanone in benzene and the residue treated with ZnCl2, followed by refluxing with hydrazine hydrate for 5 days to yield the carbazole (II). The claimed tricyclics suppress sPLA2 mediated release of fatty acids, thereby inhibiting the arachidonic acid cascade. Compds. of the invention were found to be effective inhibitors at concns. of < 100μM in an sPLA2 chromogenic assay, to suppress contractile response in dorsal pleural strips from male guinea pigs at concns. of < 20μM, and to be effective in reducing PLA2 catalytic activity in the serum of transgenic mice (no data).

IT 247904-06-9P 247904-07-0P 247904-09-2P
 247904-15-0P 247904-16-1P 247904-19-4P
 247904-20-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of substituted carbazoles for use as sPLA2 inhibitors)

RN 247904-06-9 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 247904-07-0 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-2-methyl-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 247904-09-2 CAPLUS


CN 9H-Carbazole-4-carboxamide, 5-(2-aminoethoxy)-7-methoxy-9-(phenylmethyl)- (CA INDEX NAME)



RN 247904-15-0 CAPLUS


CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-(phenylmethyl)-7-(2-thienyl)- (CA

INDEX NAME)




RN 247904-16-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-(2-thienyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247904-19-4 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-(phenylmethyl)-7-[(2-propen-1-yloxy)methyl]- (CA INDEX NAME)




RN 247904-20-7 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-(propoxymethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)



IT 220862-24-8P 220862-29-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of substituted carbazoles for use as sPLA2 inhibitors)
 RN 220862-24-8 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[4-(trifluoromethyl)phenyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-29-3 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 5-[[[(methylsulfonyl)amino]methoxy]-9-(phenylmethyl)- (CA INDEX NAME)




IT	207340-86-1P	207341-25-1P	220862-72-6P
	246513-45-1P	246513-46-2P	246513-56-4P
	246513-57-5P	246513-60-0P	246513-61-1P
	246513-64-4P	246513-65-5P	246513-68-8P
	246513-69-9P	246513-72-4P	246513-73-5P
	246513-76-8P	246513-77-9P	246513-80-4P
	247902-64-3P	247902-65-4P	247902-68-7P
	247902-69-8P	247902-72-3P	247902-73-4P
	247902-78-9P	247903-20-4P	247903-21-5P
	247903-25-9P	247903-26-0P	247903-29-3P

247903-30-6P	247903-33-9P	247903-34-0P
247903-37-3P	247903-38-4P	247903-41-9P
247903-42-0P	247903-45-3P	247903-46-4P
247903-49-7P	247903-50-0P	247903-53-3P
247903-54-4P	247903-57-7P	247903-58-8P
247903-61-3P	247903-62-4P	247903-65-7P
247903-66-8P	247903-69-1P	247903-70-4P
247903-75-9P	247903-76-0P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(target compound; preparation of substituted carbazoles for use as sPLA2 inhibitors)


RN 207340-86-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-
(CA INDEX NAME)




RN 207341-25-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-7-methoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-72-6 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-(cyanomethoxy)-7-methoxy-9-(phenylmethyl)-
(CA INDEX NAME)




RN 246513-45-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 246513-46-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246513-56-4 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(3-fluorophenyl)methyl]-5-hydroxy- (CA INDEX NAME)




RN 246513-57-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 246513-60-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(3-chlorophenyl)methyl]-5-hydroxy- (CA INDEX NAME)




RN 246513-61-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-chlorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 246513-64-4 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 246513-65-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246513-68-8 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 246513-69-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246513-72-4 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[(3-methylphenyl)methyl]- (CA INDEX NAME)




RN 246513-73-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246513-76-8 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[[3-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 246513-77-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethoxy)phenyl]methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246513-80-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247902-64-3 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-7-methyl-9-(phenylmethyl)- (CA INDEX NAME)




RN 247902-65-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247902-68-7 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(3-fluorophenyl)methyl]-5-hydroxy-7-methyl- (CA INDEX NAME)




RN 247902-69-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-2-methyl-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247902-72-3 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-7-methyl-9-[(3-methylphenyl)methyl]-
(CA INDEX NAME)




RN 247902-73-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-[(3-methylphenyl)methyl]-9H-
carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247902-78-9 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-(phenylmethyl)-7-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 247903-20-4 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[(3-phenoxyphenyl)methyl]- (CA INDEX NAME)




RN 247903-21-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-phenoxyphenyl)methyl]-9H-carbazol-4-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 247903-25-9 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(2-fluorophenyl)methyl]-5-hydroxy- (CA INDEX NAME)




RN 247903-26-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-29-3 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 247903-30-6 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-33-9 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[[2-(phenylmethyl)phenyl]methyl]- (CA INDEX NAME)




RN 247903-34-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(phenylmethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-37-3 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-(1-naphthalenylmethyl)- (CA INDEX NAME)




RN 247903-38-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(1-naphthalenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-41-9 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(2-cyanophenyl)methyl]-5-hydroxy- (CA INDEX NAME)




RN 247903-42-0 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-45-3 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 9-[(3-cyanophenyl)methyl]-5-hydroxy- (CA
 INDEX NAME)



RN 247903-46-4 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 247903-49-7 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 9-[(3,5-dimethylphenyl)methyl]-5-hydroxy- (CA
 INDEX NAME)




RN 247903-50-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3,5-dimethylphenyl)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-53-3 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[(3-iodophenyl)methyl]- (CA INDEX NAME)




RN 247903-54-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-iodophenyl)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-57-7 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(2-chlorophenyl)methyl]-5-hydroxy- (CA INDEX NAME)




RN 247903-58-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-chlorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 247903-61-3 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(2,3-difluorophenyl)methyl]-5-hydroxy- (CA INDEX NAME)




RN 247903-62-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,3-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-65-7 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(2,6-difluorophenyl)methyl]-5-hydroxy- (CA INDEX NAME)




RN 247903-66-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,6-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-69-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(2,6-dichlorophenyl)methyl]-5-hydroxy- (CA INDEX NAME)




RN 247903-70-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,6-dichlorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-75-9 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-([1,1'-biphenyl]-2-ylmethyl)-5-hydroxy- (CA INDEX NAME)




RN 247903-76-0 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-([1,1'-biphenyl]-2-ylmethyl)-9H-carbazol-4-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




IT	207340-74-7P	207340-75-8P	207340-76-9P
	207341-24-0P	220862-21-5P	220862-22-6P
	220862-23-7P	220862-26-0P	220862-27-1P
	220862-30-6P	220862-31-7P	220862-32-8P
	220862-33-9P	220862-34-0P	220862-35-1P
	220862-36-2P	220862-37-3P	220862-38-4P
	220862-39-5P	220862-40-8P	220862-41-9P
	220862-42-0P	220862-43-1P	220862-44-2P
	220862-45-3P	220862-46-4P	220862-47-5P
	220862-48-6P	220862-49-7P	220862-50-0P
	220862-51-1P	220862-53-3P	220862-54-4P
	220862-55-5P	220862-59-9P	220862-61-3P
	220862-63-5P	220862-66-8P	220862-68-0P
	220862-74-8P	220862-76-0P	220862-84-0P
	246513-34-8P	246513-52-0P	246513-53-1P
	246513-79-1P	246513-84-8P	247902-79-0P
	247902-84-7P	247902-85-8P	247902-90-5P
	247902-91-6P	247902-95-0P	247903-00-0P
	247903-01-1P	247903-06-6P	247903-07-7P
	247903-12-4P	247903-13-5P	247903-16-8P
	247903-77-1P	247903-95-3P	247903-97-5P
	247904-02-5P	247904-05-8P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compound; preparation of substituted carbazoles for use as sPLA2 inhibitors)


RN 207340-74-7 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methoxy-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 207340-75-8 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methoxy-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 207340-76-9 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methoxy-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 207341-24-0 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 5,7-dimethoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-21-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-22-6 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-2-methyl-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-23-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-methylphenyl)methyl]-2-methyl-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-26-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-5-[2-[(methylsulfonyl)amino]ethoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-27-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-[2-[[trifluoromethyl)sulfonyl]amino]ethoxy]- (CA INDEX NAME)




RN 220862-30-6 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-2-pentyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-31-7 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(1-methylethyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-32-8 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-33-9 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-phenyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-34-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(2-furanyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-35-1 CAPLUS


CN Acetic acid, 2-[[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]-, lithium salt (1:1) (CA INDEX NAME)



● Li


RN 220862-36-2 CAPLUS

CN Acetic acid, 2-[[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-37-3 CAPLUS

CN Acetic acid, 2-[(5-(aminocarbonyl)-9-[(3-phenoxyphenyl)methyl]-9H-carbazol-4-yl)oxy]- (CA INDEX NAME)




RN 220862-38-4 CAPLUS


CN Acetic acid, 2-[(5-(aminocarbonyl)-9-[(2-fluorophenyl)methyl]-9H-carbazol-4-yl)oxy]- (CA INDEX NAME)




RN 220862-39-5 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-40-8 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(phenylmethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-41-9 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-42-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(1-naphthalenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-43-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-44-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-45-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-46-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-47-5 CAPLUS

CN Acetic acid, 2-[(5-(aminocarbonyl)-9-[(3,5-dimethylphenyl)methyl]-9H-carbazol-4-yl)oxy]- (CA INDEX NAME)




RN 220862-48-6 CAPLUS

CN Acetic acid, 2-[(5-(aminocarbonyl)-9-[(3-iodophenyl)methyl]-9H-carbazol-4-yl)oxy]- (CA INDEX NAME)




RN 220862-49-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-chlorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-50-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,3-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-51-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,6-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-53-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,6-dichlorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-54-4 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethoxy)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-55-5 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-([1,1'-biphenyl]-2-ylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-59-9 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-1-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-61-3 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-63-5 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-1-chloro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-66-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[(2-propen-1-yloxy)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-68-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-(propoxymethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-74-8 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-(2H-tetrazol-5-ylmethoxy)- (CA INDEX NAME)




RN 220862-76-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-(2-amino-2-oxoethoxy)-7-methoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-84-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(4-chlorophenyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 246513-34-8 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(4-chlorophenyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 246513-52-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 8-fluoro-5-methoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 246513-53-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246513-79-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-methoxy-8-methyl-9-(phenylmethyl)- (CA INDEX NAME)




RN 246513-84-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-chloro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247902-79-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[4-(trifluoromethyl)phenyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247902-84-7 CAPLUS


CN 9H-Carbazole-4-carboxamide, 5-hydroxy-7-pentyl-9-(phenylmethyl)- (CA INDEX NAME)




RN 247902-85-8 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-pentyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247902-90-5 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 5-hydroxy-7-(1-methylethyl)-9-(phenylmethyl)- (CA INDEX NAME)




RN 247902-91-6 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(1-methylethyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247902-95-0 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)



RN 247903-00-0 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 5-hydroxy-7-phenyl-9-(phenylmethyl)- (CA INDEX NAME)




RN 247903-01-1 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-phenyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-06-6 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-(4-chlorophenyl)-5-hydroxy-9-(phenylmethyl)-
(CA INDEX NAME)




RN 247903-07-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(4-chlorophenyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-12-4 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-(2-furanyl)-5-hydroxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 247903-13-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(2-furanyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-16-8 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-(phenylmethyl)-7-[[[tris(1-methylethyl)silyl]oxy]methyl]- (CA INDEX NAME)




RN 247903-77-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-([1,1'-biphenyl]-2-ylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 247903-95-3 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-8-methyl-9-(phenylmethyl)- (CA INDEX NAME)




RN 247903-97-5 CAPLUS

CN 9H-Carbazole-4-carboxamide, 8-fluoro-5-hydroxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 247904-02-5 CAPLUS

CN 9H-Carbazole-4-carboxamide, 8-chloro-5-methoxy-9-(phenylmethyl)- (CA INDEX NAME)



RN 247904-05-8 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-(2-thienyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L12 ANSWER 41 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1999:672368 CAPLUS

DOCUMENT NUMBER: 131:286503

TITLE: Preparation of substituted tricyclics as secretory phospholipase A2 (sPLA2) inhibitors

INVENTOR(S): Bach, Nicholas James; Bastian, Jolie Anne; Beight, Douglas Wade; Kinnick, Michael Dean; Martinelli, Michael John; Mihelich, Edward David; Morin, John Michael, Jr.; Sall, Daniel Jon; Sawyer, Jason Scott; Smith, Edward C. R.; Suarez, Tulio; Wang, Qiuping; Wilson, Thomas Michael

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: Eur. Pat. Appl., 74 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 950661	A1	19991020	EP 1999-302969	19990416
EP 950661	B1	20031112		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2269256	A1	19991017	CA 1999-2269256	19990416
NO 9901823	A	19991018	NO 1999-1823	19990416
AU 9923818	A	19991028	AU 1999-23818	19990416
AU 757454	B2	20030220		

CN 1235968	A	19991124	CN 1999-108097	19990416
JP 11322745	A	19991124	JP 1999-109656	19990416
JP 4435325	B2	20100317		
BR 9901275	A	20000502	BR 1999-1275	19990416
MX 9903588	A	20000731	MX 1999-3588	19990416
HU 9901219	A1	20000828	HU 1999-1219	19990416
TR 9900842	A2	20000921	TR 1999-842	19990416
NZ 335252	A	20001124	NZ 1999-335252	19990416
EP 1156050	A2	20011121	EP 2001-203116	19990416
EP 1156050	A3	20011128		
EP 1156050	B1	20040218		


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO

ZA 9902773	A	20020716	ZA 1999-2773	19990416
TW 555760	B	20031001	TW 1999-106131	19990416
AT 254128	T	20031115	AT 1999-302969	19990416
AT 259818	T	20040315	AT 2001-203116	19990416
ES 2210979	T3	20040701	ES 1999-302969	19990416
ES 2213668	T3	20040901	ES 2001-203116	19990416
SG 106035	A1	20040930	SG 1999-1844	19990416
IN 1999CA00348	A	20050311	IN 1999-CA348	19990416
			US 1998-62165	A 19980417
			EP 1999-302969	A3 19990416


PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 131:286503

GI



I




II


AB Thiocarbazole, pyridoindole, azacarbazole, (thio)pyranoindole, and carboline derivs. (I) [where A = Ph or pyridyl; B or D = N and the other is C; Z = cyclohexenyl, Ph, pyridyl, or a heterocyclic ring with one S or O; R20 = (un)substituted alkyl, alkenyl, alkynyl, carbo- or heterocyclic radical, or L-R80; L = linking group of 1-12 C, H, O, N, and/or S atoms; R80 = (un)substituted alkyl, alkenyl, alkynyl, carbo- or heterocyclic radical; R21 = non-interfering substituent; R1 = NHNH2, NH2, or CONH2; R2 = OH or (un)substituted alkoxy; R3 = non-interfering substituent, (un)substituted carbo- or heterocyclic radical] were prepared as inhibitors of human non-pancreatic secretory phospholipase A2 (sPLA2). For instance, the thiocarbazole (II) was prepared in a nine step synthesis. 4-Methoxyindole was N-benzylated and then acylated with Me oxalyl chloride. The ketone was reduced to the alc. with NaBH4 to form Me (1-benzyl-4-methoxyindol-3-yl)hydroxyacetate. The alc. was displaced by mercaptoacetic acid and the thio ether cyclized to afford the 3-thia-1,2,3,4-tetrahydrocarbazol-5-ylcarboxylate. The ester was converted to the carboxamide. Finally, the Me ether was cleaved to give the alc., followed by O-acetylation with Et bromoacetate and deesterification to yield II. Compds. of the invention were found to be effective inhibitors at concns. of < 100 μ M in an sPLA2 chromogenic assay, to suppress contractile response in dorsal pleural strips from male guinea pigs at concns. < 20 μ M, and to be effective in reducing PLA2 catalytic activity in the serum of transgenic mice (no data). The claimed

tricyclics suppress sPLA2 mediated release of fatty acids, thereby inhibiting the arachidonic acid cascade, and are useful in the treatment of septic shock and other sPLA2 related diseases.

IT 246868-15-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of substituted tricyclics as secretory phospholipase A2 (sPLA2) inhibitors)
 RN 246868-15-5 CAPLUS
 CN 9H-Pyrido[3,4-b]indole-5-carboxamide, 4-hydroxy-9-(phenylmethyl)- (CA INDEX NAME)



IT 246868-00-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (target compound; preparation of substituted tricyclics as secretory phospholipase A2 (sPLA2) inhibitors)
 RN 246868-00-8 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-pyrido[3,4-b]indol-4-yl]oxy]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
 REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 42 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1999:672362 CAPLUS
 DOCUMENT NUMBER: 131:286402
 TITLE: Preparation of carbazolecarboxamides as sPLA2 inhibitors

INVENTOR(S): Bach, Nicholas James; Bastian, Jolie Anne; Hite, Gary Alan; Kinnick, Michael Dean; Mihelich, Edward David; Morin, John Michael, Jr.; Sall, Daniel Jon; Vasileff, Robert Theodore

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: Eur. Pat. Appl., 54 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 950657	A2	19991020	EP 1999-302967	19990416
EP 950657	A3	20010816		
EP 950657	B1	20040714		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2269246	A1	19991017	CA 1999-2269246	19990416
CA 2269246	C	20090825		
CA 2269262	A1	19991017	CA 1999-2269262	19990416
NO 9901821	A	19991018	NO 1999-1821	19990416
NO 314400	B1	20030317		
NO 9901822	A	19991018	NO 1999-1822	19990416
NO 312240	B1	20020415		
AU 9923817	A	19991028	AU 1999-23817	19990416
AU 753436	B2	20021017		
AU 9923819	A	19991028	AU 1999-23819	19990416
AU 753547	B2	20021024		
TR 9900853	A3	19991122	TR 1999-853	19990416
JP 11322713	A	19991124	JP 1999-109629	19990416
CN 1240210	A	20000105	CN 1999-107687	19990416
JP 2000026416	A	20000125	JP 1999-152400	19990416
JP 4435330	B2	20100317		
TR 9900843	A2	20000221	TR 1999-843	19990416
BR 9901279	A	20000502	BR 1999-1279	19990416
CN 1253948	A	20000524	CN 1999-107957	19990416
CN 1149193	C	20040512		
MX 9903587	A	20000731	MX 1999-3587	19990416
MX 9903589	A	20000731	MX 1999-3589	19990416
NZ 335251	A	20001124	NZ 1999-335251	19990416
NZ 335253	A	20001124	NZ 1999-335253	19990416
BR 9902365	A	20010424	BR 1999-2365	19990416
SG 81976	A1	20010724	SG 1999-1681	19990416
SG 81977	A1	20010724	SG 1999-1869	19990416
HU 9901220	A3	20011128	HU 1999-1220	19990416
HU 9901221	A3	20011128	HU 1999-1221	19990416
ZA 9902771	A	20020418	ZA 1999-2771	19990416
ZA 9902772	A	20020716	ZA 1999-2772	19990416
NZ 507564	A	20021025	NZ 1999-507564	19990416
NZ 518027	A	20030429	NZ 1999-518027	19990416
AT 268756	T	20040615	AT 1999-302941	19990416
AT 271037	T	20040715	AT 1999-302967	19990416
PT 950657	E	20041130	PT 1999-302967	19990416
ES 2222663	T3	20050201	ES 1999-302941	19990416
ES 2226286	T3	20050316	ES 1999-302967	19990416
TW 238160	B	20050821	TW 1999-106130	19990416
IN 1999CA00346	A	20051202	IN 1999-CA346	19990416
IN 240478	A1	20100514	IN 1999-CA347	19990416
PRIORITY APPLN. INFO.:			US 1998-62328	A 19980417
			NZ 1999-507564	A1 19990416

OTHER SOURCE(S):
GI

MARPAT 131:286402



I



II


AB Title compds. [I; R = alk(en)yl, carbocyclic or heterocyclic radical (sic), etc.; R1 = OH or O(CH2)nR6; R3 = non-interfering substituent (sic), carbocyclic or heterocyclic radical (sic), etc.; R4R5 = (un)substituted CH(COR1)(CH2)3 or -C(COR1):CHCH:CH; R1 = NHNH2, NH2, CONH2; R6 = H, cyano, NH2, Ph, etc.; n = 1-5] were prepared. Thus, Me 3-amino-2-bromobenzoate (preparation given) was condensed with 1,3-cyclohexanedione and the product cyclized to give Me 1,2-dihydro-4(3H)-oxo-9H-carbazol-5-carboxylate which was converted in 5 steps to the Na salt of title compound II. Data for biol. activity of I were given.

IT	207340-86-1P	220862-36-2P	220862-59-9P
	220862-61-3P	220862-63-5P	246513-34-8P
	246513-35-9P	246513-36-0P	246513-37-1P
	246513-39-3P	246513-40-6P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carbazolecarboxamides as sPLA2 inhibitors)


RN 207340-86-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-36-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-59-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-61-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-63-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-chloro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 246513-34-8 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 246513-35-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-chlorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)




RN 246513-36-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 246513-37-1 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)




● Na

RN 246513-39-3 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 246513-40-6 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethoxy)phenyl]methyl]-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)




● Na

IT	246513-45-1P	246513-46-2P	246513-52-0P
	246513-53-1P	246513-56-4P	246513-57-5P
	246513-60-0P	246513-61-1P	246513-64-4P
	246513-65-5P	246513-68-8P	246513-69-9P
	246513-72-4P	246513-73-5P	246513-76-8P
	246513-77-9P	246513-79-1P	246513-80-4P
	246513-84-8P		


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of carbazolecarboxamides as sPLA2 inhibitors)

RN 246513-45-1 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 246513-46-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246513-52-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 8-fluoro-5-methoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 246513-53-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246513-56-4 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(3-fluorophenyl)methyl]-5-hydroxy- (CA INDEX NAME)




RN 246513-57-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 246513-60-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 9-[(3-chlorophenyl)methyl]-5-hydroxy- (CA INDEX NAME)




RN 246513-61-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-chlorophenyl)methyl]-9H-carbazol-4-yl]oxy]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 246513-64-4 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 246513-65-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246513-68-8 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[(2-methylphenyl)methyl]- (CA INDEX NAME)




RN 246513-69-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246513-72-4 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[(3-methylphenyl)methyl]- (CA INDEX NAME)




RN 246513-73-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246513-76-8 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-hydroxy-9-[[3-(trifluoromethoxy)phenyl]methyl]- (CA INDEX NAME)




RN 246513-77-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethoxy)phenyl]methyl]-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 246513-79-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-methoxy-8-methyl-9-(phenylmethyl)- (CA INDEX NAME)




RN 246513-80-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)



RN 246513-84-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-chloro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (14 CITINGS)

L12 ANSWER 43 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1999:350594 CAPLUS

DOCUMENT NUMBER: 131:5186

TITLE: Preparation of (tetrahydro)carbazolecarboxylates as sPLA2 inhibitors

INVENTOR(S): Watanabe, August Masaru

PATENT ASSIGNEE(S): Eli Lilly and Company, USA

SOURCE: PCT Int. Appl., 96 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9925340	A1	19990527	WO 1998-US24258	19981113
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2310250	A1	19990527	CA 1998-2310250	19981113

AU 9914073	A	19990607	AU 1999-14073	19981113
EP 1043991	A1	20001018	EP 1998-957934	19981113
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
JP 2001522884	T	20011120	JP 2000-520774	19981113
US 6514984	B1	20030204	US 2000-529565	20000412
PRIORITY APPLN. INFO.:			US 1997-66035P	P 19971114
			WO 1998-US24258	W 19981113

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): MARPAT 131:5186
 GI




AB Title compds. [e.g., I; R6R7 = CH(COR1)(CH2)3 or C(COR1):CHCH:CH substituted by R21; R1 = NH2 or NHH2; R2 = OH or O(CH2)mR5; R3 = H, halo, alkyl, alkoxy, etc.; R4 = H, (cyclo)alkyl, pyridyl, (un)substituted Ph; R5 = H, CO2H, alkoxycarbonyl, CONH2, tetrazolyl, etc.; R21 = a non-interfering substituent (sic); m = 1-3] were claimed as sPLA2 inhibitors (no data). Thus, 4-[(9-benzyl-4-carbamoyl-1,2,3,4-tetrahydro-6-carbazolyl)oxy]butyric acid was claimed.


IT 207340-86-1P 220862-21-5P 220862-22-6P
 220862-23-7P 220862-24-8P 220862-26-0P
 220862-27-1P 220862-30-6P 220862-31-7P
 220862-32-8P 220862-33-9P 220862-34-0P
 220862-35-1P 220862-36-2P 220862-37-3P
 220862-38-4P 220862-39-5P 220862-40-8P
 220862-41-9P 220862-42-0P 220862-43-1P
 220862-44-2P 220862-45-3P 220862-46-4P
 220862-47-5P 220862-48-6P 220862-49-7P
 220862-50-0P 220862-51-1P 220862-53-3P
 220862-54-4P 220862-55-5P 220862-59-9P
 220862-61-3P 220862-63-5P 220862-66-8P
 220862-68-0P 220862-72-6P 220862-74-8P
 220862-76-0P 220862-84-0P 225653-40-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of (tetrahydro)carbazolecarboxylates as sPLA2 inhibitors)


RN 207340-86-1 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-
 (CA INDEX NAME)




RN 220862-21-5 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-22-6 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-2-methyl-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-23-7 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-24-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[4-(trifluoromethyl)phenyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-26-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-5-[2-[(methylsulfonyl)amino]ethoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-27-1 CAPLUS


CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-[2-[[4-(trifluoromethyl)phenyl]sulfonyl]amino]ethoxy]- (CA INDEX NAME)




RN 220862-30-6 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-pentyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-31-7 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(1-methylethyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-32-8 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-33-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-phenyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-34-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(2-furanyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-35-1 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]-, lithium salt (1:1) (CA INDEX NAME)



● Li


RN 220862-36-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-37-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-phenoxyphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-38-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-39-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-40-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(phenylmethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-41-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-42-0 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(1-naphthalenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-43-1 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-44-2 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-45-3 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-46-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-47-5 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3,5-dimethylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-48-6 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-iodophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-49-7 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-chlorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-50-0 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,3-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-51-1 CAPLUS

CN Acetic acid, 2-[(5-(aminocarbonyl)-9-[(2,6-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-53-3 CAPLUS

CN Acetic acid, 2-[(5-(aminocarbonyl)-9-[(2,6-dichlorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-54-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethoxy)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-55-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-([1,1'-biphenyl]-2-ylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-59-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-61-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-63-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-chloro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-66-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[(2-propen-1-yloxy)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-68-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-(propoxymethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-72-6 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-(cyanomethoxy)-7-methoxy-9-(phenylmethyl)-
(CA INDEX NAME)




RN 220862-74-8 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-(2H-tetrazol-5-ylmethoxy)-
(CA INDEX NAME)




RN 220862-76-0 CAPLUS


CN 9H-Carbazole-4-carboxamide, 5-(2-amino-2-oxoethoxy)-7-methoxy-9-(phenylmethyl)-
(CA INDEX NAME)



RN 220862-84-0 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(4-chlorophenyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 225653-40-7 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 7-methoxy-5-[[5-(methylsulfonyl)amino]methoxy]-9-(phenylmethyl)- (CA INDEX NAME)




OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)
 REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 44 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1999:303240 CAPLUS
 DOCUMENT NUMBER: 130:311699
 TITLE: Preparation of tricyclic compounds as cGMP-PDE inhibitors
 INVENTOR(S): Oku, Teruo; Sawada, Kozo; Kuroda, Akio; Ohne, Kazuhiko
 PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 26 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9921831	A1	19990506	WO 1998-JP4429	19981001
W: CA, CN, JP, KR, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
JP 2002509553	T	20020326	JP 1999-523667	19981001
PRIORITY APPLN. INFO.:			AU 1997-30	A 19971027
			AU 1998-2990	A 19980416
			WO 1998-JP4429	W 19981001
OTHER SOURCE(S):		MARPAT 130:311699		
GI				




AB The title compds. [I; X = halo; Y = lower alkoxy, OH, NH₂; R₁ = H, lower alkyl optionally substituted with a heterocyclyl or aryl; n = 1-2] and their salts, useful in the treatment and prevention of, for example, micturination disorder, or incontinence or storage of urine disorder, were prepared Thus, deprotection of 4-(4-tert-butoxycarbonylamino-2-chlorobenzyl)-3-oxo-1,2,3,4-tetrahydrocyclopent[b]indole-6-carboxamide (preparation given) with F₃CCO₂H in CH₂Cl₂ afforded I [X = Cl; Y = NH₂; R₁ = H; n = 1] which showed IC₅₀ of < 100 nM.

IT 223645-39-4P 223645-40-7P 223645-45-2P
 223645-46-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of tricyclic compds. as cGMP-PDE inhibitors)


RN 223645-39-4 CAPLUS

CN Cyclopent[b]indole-6-carboxamide, 4-[(4-amino-2-chlorophenyl)methyl]-1,2,3,4-tetrahydro-3-oxo- (CA INDEX NAME)



RN 223645-40-7 CAPLUS

CN Cyclopent[b]indole-6-carboxamide, 4-[(4-amino-2-chlorophenyl)methyl]-1,2,3,4-tetrahydro-3-oxo-, hydrochloride (1:1) (CA INDEX NAME)



● HC1


RN 223645-45-2 CAPLUS

CN Cyclopent[b]indole-6-carboxamide, 4-[(4-amino-2-chlorophenyl)methyl]-1,2,3,4-tetrahydro-3-oxo-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 223645-39-4

CMF C19 H16 Cl N3 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 223645-46-3 CAPLUS

CN Cyclopent[b]indole-6-carboxamide, 4-[(4-amino-2-chlorophenyl)methyl]-1,2,3,4-tetrahydro-3-oxo-, sulfate (2:1) (CA INDEX NAME)

CM 1

CRN 223645-39-4

CMF C19 H16 Cl N3 O2




CM 2

CRN 7664-93-9

CMF H2 O4 S



IT 223645-38-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of tricyclic compds. as cGMP-PDE inhibitors)
 RN 223645-38-3 CAPLUS
 CN Carbamic acid, [4-[[6-(aminocarbonyl)-2,3-dihydro-3-oxocyclopent[b]indol-
 4(1H)-yl)methyl]-3-chlorophenyl]-, 1,1-dimethylethyl ester (9CI) (CA
 INDEX NAME)



OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD
 (2 CITINGS)
 REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 45 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1999:233807 CAPLUS
 DOCUMENT NUMBER: 130:267344
 TITLE: Compounds for treatment of cystic fibrosis
 INVENTOR(S): Macias, William Louis
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 260 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9916453	A1	19990408	WO 1998-US19906	19980923
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,			

CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2304482	A1	19990408	CA 1998-2304482	19980923
AU 9896641	A	19990423	AU 1998-96641	19980923
EP 1007056	A1	20000614	EP 1998-950654	19980923
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
JP 2001517707	T	20011009	JP 2000-513587	19980923
US 6576654	B1	20030610	US 2000-508209	20000308
PRIORITY APPLN. INFO.:			US 1997-60128P	P 19970926
			WO 1998-US19906	W 19980923

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 130:267344


AB Title compds., sPLA2 inhibitors (no data), were selected from indoleglyoxylamides, -acetamides, -acetic acid hydrazides, etc. Preparation of [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl-1H-indol-4-yl]oxy]acetic acid was described.

IT 207340-74-7P 207340-75-8P 207340-86-1P
220862-21-5P 220862-22-6P 220862-23-7P
220862-24-8P 220862-26-0P 220862-27-1P
220862-30-6P 220862-31-7P 220862-32-8P
220862-33-9P 220862-34-0P 220862-35-1P
220862-36-2P 220862-37-3P 220862-38-4P
220862-39-5P 220862-40-8P 220862-41-9P
220862-42-0P 220862-43-1P 220862-44-2P
220862-45-3P 220862-46-4P 220862-47-5P
220862-48-6P 220862-49-7P 220862-50-0P
220862-51-1P 220862-53-3P 220862-54-4P
220862-55-5P 220862-59-9P 220862-61-3P
220862-63-5P 220862-66-8P 220862-68-0P
220862-72-6P 220862-74-8P 220862-76-0P
220862-84-0P 222417-25-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(compds. for treatment of cystic fibrosis)


RN 207340-74-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methoxy-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 207340-75-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methoxy-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 207340-86-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-(CA INDEX NAME)




RN 220862-21-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-(CA INDEX NAME)




RN 220862-22-6 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-2-methyl-9H-carbazol-4-yl]oxy]-(CA INDEX NAME)




RN 220862-23-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-24-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[4-(trifluoromethyl)phenyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-26-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-5-[2-[(methylsulfonyl)amino]ethoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-27-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-[[2-[(trifluoromethyl)sulfonyl]amino]ethoxy]- (CA INDEX NAME)




RN 220862-30-6 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-pentyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-31-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(1-methylethyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-32-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-33-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-phenyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-34-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(2-furanyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-35-1 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]-, lithium salt (1:1) (CA INDEX NAME)



● Li


RN 220862-36-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-37-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-phenoxyphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-38-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-39-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-40-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(phenylmethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-41-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-42-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(1-naphthalenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-43-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-44-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-45-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-46-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-47-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3,5-dimethylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-48-6 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-iodophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-49-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-chlorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-50-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,3-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-51-1 CAPLUS

CN Acetic acid, 2-[(5-(aminocarbonyl)-9-[(2,6-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-53-3 CAPLUS

CN Acetic acid, 2-[(5-(aminocarbonyl)-9-[(2,6-dichlorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-54-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethoxy)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-55-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-([1,1'-biphenyl]-2-ylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-59-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-61-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-63-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-chloro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-66-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[(2-propen-1-yloxy)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-68-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-(propoxymethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-72-6 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-(cyanomethoxy)-7-methoxy-9-(phenylmethyl)-
(CA INDEX NAME)




RN 220862-74-8 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-(2H-tetrazol-5-ylmethoxy)-
(CA INDEX NAME)




RN 220862-76-0 CAPLUS


CN 9H-Carbazole-4-carboxamide, 5-(2-amino-2-oxoethoxy)-7-methoxy-9-(phenylmethyl)-
(CA INDEX NAME)



RN 220862-84-0 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(4-chlorophenyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 222417-25-6 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 9-(phenylmethyl)-5-[[[(trifluoromethyl)sulfonyl]amino]methoxy]- (CA INDEX NAME)




OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 46 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1999:172589 CAPLUS
 DOCUMENT NUMBER: 130:196575
 TITLE: Method for treatment of non-rheumatoid arthritis by administration of an sPLA2 inhibitor.
 INVENTOR(S): Macias, William Louis
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 273 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9909978	A1	19990304	WO 1998-US17778	19980827
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2301586	A1	19990304	CA 1998-2301586	19980827
AU 9891231	A	19990316	AU 1998-91231	19980827
EP 1011670	A1	20000628	EP 1998-943430	19980827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI				
JP 2001513555	T	20010904	JP 2000-507368	19980827
ZA 9807867	A	20000228	ZA 1998-7867	19980828
US 20030119860	A1	20030626	US 2000-486472	20000224
US 6610728	B2	20030826		
PRIORITY APPLN. INFO.:			US 1997-57726P	P 19970828
			WO 1998-US17778	W 19980827
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):		MARPAT 130:196575		
GI				



AB A method for treatment of non-rheumatoid arthritis by administration of of an sPLA2 inhibitor is claimed (no data). Thus, preferred compound (I) was prepared in 6 steps via 2-ethyl-4-methoxy-1H-indole.

IT 207340-74-7 207340-75-8 207340-86-1
 220862-21-5 220862-22-6 220862-23-7
 220862-24-8 220862-26-0 220862-27-1
 220862-29-3 220862-30-6 220862-31-7
 220862-32-8 220862-33-9 220862-34-0
 220862-35-1 220862-36-2 220862-37-3
 220862-38-4 220862-39-5 220862-40-8
 220862-41-9 220862-42-0 220862-43-1
 220862-44-2 220862-45-3 220862-46-4
 220862-47-5 220862-48-6 220862-49-7
 220862-50-0 220862-51-1 220862-53-3
 220862-54-4 220862-55-5 220862-59-9


220862-61-3 220862-63-5 220862-66-8
 220862-68-0 220862-72-6 220862-74-8
 220862-76-0 220862-84-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method for treatment of non-rheumatoid arthritis by administration of an sPLA2 inhibitor)


RN 207340-74-7 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methoxy-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 207340-75-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methoxy-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)




RN 207340-86-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-21-5 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-22-6 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-2-methyl-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-23-7 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methyl-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-24-8 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[4-(trifluoromethyl)phenyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-26-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-5-[2-[(methylsulfonyl)amino]ethoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-27-1 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-[2-[[trifluoromethyl)sulfonyl]amino]ethoxy]- (CA INDEX NAME)




RN 220862-29-3 CAPLUS


CN 9H-Carbazole-4-carboxamide, 5-[[[(methylsulfonyl)amino]methoxy]-9-(phenylmethyl)- (CA INDEX NAME)




RN 220862-30-6 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-pentyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-31-7 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(1-methylethyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-32-8 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-33-9 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-phenyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-34-0 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(2-furanyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-35-1 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[[tris(1-methylethyl)silyl]oxy]methyl]-9H-carbazol-4-yl]oxy]-, lithium salt (1:1) (CA INDEX NAME)



● Li


RN 220862-36-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-37-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-phenoxyphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-38-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-fluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-39-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-40-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[2-(phenylmethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-41-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethyl)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-42-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(1-naphthalenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-43-1 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-44-2 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-cyanophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-45-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-46-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-methylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-47-5 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3,5-dimethylphenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-48-6 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(3-iodophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



RN 220862-49-7 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2-chlorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-50-0 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[(2,3-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-51-1 CAPLUS

CN Acetic acid, 2-[(5-(aminocarbonyl)-9-[(2,6-difluorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-53-3 CAPLUS

CN Acetic acid, 2-[(5-(aminocarbonyl)-9-[(2,6-dichlorophenyl)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-54-4 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-[[3-(trifluoromethoxy)phenyl]methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-55-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-([1,1'-biphenyl]-2-ylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-59-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-methyl-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-61-3 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-fluoro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-63-5 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-chloro-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-66-8 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-[(2-propen-1-yloxy)methyl]-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-68-0 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-2-(propoxymethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 220862-72-6 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-(cyanomethoxy)-7-methoxy-9-(phenylmethyl)-
(CA INDEX NAME)




RN 220862-74-8 CAPLUS

CN 9H-Carbazole-4-carboxamide, 7-methoxy-9-(phenylmethyl)-5-(2H-tetrazol-5-ylmethoxy)-
(CA INDEX NAME)




RN 220862-76-0 CAPLUS

CN 9H-Carbazole-4-carboxamide, 5-(2-amino-2-oxoethoxy)-7-methoxy-9-(phenylmethyl)-
(CA INDEX NAME)



RN 220862-84-0 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-(4-chlorophenyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
 (7 CITINGS)
 REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 47 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1998:358667 CAPLUS

DOCUMENT NUMBER: 129:108959

ORIGINAL REFERENCE NO.: 129:22389a,22392a

TITLE: Facile substitution of resin-bound indoles via the
 Mannich reaction

AUTHOR(S): Zhang, Han-Cheng; Brumfield, Kimberly K.; Jaroskova,
 Libuse; Maryanoff, Bruce E.

CORPORATE SOURCE: Drug Discovery, The R. W. Johnson Pharmaceutical
 Research Institute, Spring House, PA, 19477, USA
 SOURCE: Tetrahedron Letters (1998), 39(25), 4449-4452
 CODEN: TELEAY; ISSN: 0040-4039

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 129:108959


AB Mannich reaction of resin-bound indoles provided 3-aminomethylindoles.
 Palladium-mediated heteroannulation of terminal alkynes with resin-bound
 o-iodosulfonamide, followed by Mannich reaction, afforded 2-substituted
 3-aminomethylindoles. Nucleophilic substitution of resin-bound
 3-[(dimethylamino)methyl]indole with KCN or Et 2-nitroacetate gave
 3-substituted indoles.

IT 210052-38-3P 210052-39-4P 210052-40-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (solid phase synthesis of (aminomethyl)indoles)

RN 210052-38-3 CAPLUS


CN 1H-Indole-6-carboxamide, 1-(phenylmethyl)-3-(1-piperidinylmethyl)- (CA

INDEX NAME)




RN 210052-39-4 CAPLUS

CN 1H-Indole-5-carboxamide, 1-[(4-fluorophenyl)methyl]-3-(1-pyrrolidinylmethyl)- (CA INDEX NAME)



RN 210052-40-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-methylphenyl)methyl]-3-(1-piperidinylmethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 72 THERE ARE 72 CAPLUS RECORDS THAT CITE THIS RECORD (72 CITINGS)

REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 48 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1998:293372 CAPLUS

DOCUMENT NUMBER: 129:4575

ORIGINAL REFERENCE NO.: 129:1101a,1104a

TITLE: Preparation and formulation of
4-carbamoyltetrahydrocarbazolyloxyalkanoates and
analogues as secretory phospholipase A2 inhibitors

INVENTOR(S): Bach, Nicholas J.; Dillard, Robert D.; Draheim, Susan
E.; Morin, John M., Jr.

PATENT ASSIGNEE(S): Eli Lilly and Co., USA

SOURCE: PCT Int. Appl., 143 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9818464	A1	19980507	WO 1997-US19183	19971023
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2269203	A1	19980507	CA 1997-2269203	19971023
AU 9851494	A	19980522	AU 1998-51494	19971023
AU 734096	B2	20010607		
CN 1233176	A	19991027	CN 1997-198834	19971023
HU 9903545	A2	20000228	HU 1999-3545	19971023
HU 9903545	A3	20010528		
BR 9713261	A	20000328	BR 1997-13261	19971023
JP 2001503055	T	20010306	JP 1998-520585	19971023
IN 1997CA01995	A	20050311	IN 1997-CA1995	19971023
EP 839806	A1	19980506	EP 1997-308645	19971029
EP 839806	B1	20030709		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 244703	T	20030715	AT 1997-308645	19971029
PT 839806	E	20031128	PT 1997-308645	19971029
ES 2202560	T3	20040401	ES 1997-308645	19971029
TW 513428	B	20021211	TW 1997-116217	19971030
NO 9901831	A	19990621	NO 1999-1831	19990416
NO 314899	B1	20030610		
KR 2000049210	A	20000725	KR 1999-7003309	19990416
PRIORITY APPLN. INFO.:			US 1996-29849P	P 19961030
			WO 1997-US19183	W 19971023
			US 2000-688106	A 20001013

OTHER SOURCE(S): MARPAT 129:4575

GI



I




II


AB Title compds. [e.g., I; R1 = NH2 or NHH2; R2 = OH or O(CH2)mR5; R3 = H,

alkoxy, (amino)alkyl, phenylalkyl, etc.; R4 = H, (cyclo)alkyl, (un)substituted Ph; R5 = H, CO2H, alkoxy, carbonyl, Ph, etc.; m = 1-3; dashed lines = optional addnl. bonds] were prepared. Thus, 4-(MeO)C6H4NHCH2Ph was cyclocondensed with Et 3-bromo-2-oxocyclohexanecarboxylate and the product converted in 3 steps to carbazole II (R2 = OH) which was etherified by Br(CH2)3CO2Et to give, after saponification, II [R2 = O(CH2)4CO2H]. Data for biol. activity of I were given.


IT 207340-73-6P 207340-74-7P 207340-75-8P
 207340-76-9P 207340-84-9P 207340-86-1P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and formulation of 4-carbamoyltetrahydrocarbazolyloxyalkanoates and analogs as secretory phospholipase A2 inhibitors)
 RN 207340-73-6 CAPLUS
 CN Butanoic acid, 4-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-3-yl]oxy]- (CA INDEX NAME)



RN 207340-74-7 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methoxy-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 207340-75-8 CAPLUS
 CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methoxy-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, methyl ester (CA INDEX NAME)



RN 207340-76-9 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-2-methoxy-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]-, sodium salt (1:1) (CA INDEX NAME)



● Na


RN 207340-84-9 CAPLUS

CN Acetic acid, 2-[[5-(aminocarbonyl)-1-methoxy-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




RN 207340-86-1 CAPLUS


CN Acetic acid, 2-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-4-yl]oxy]- (CA INDEX NAME)




IT 207341-21-7P 207341-22-8P 207341-23-9P
 207341-24-0P 207341-25-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and formulation of 4-carbamoyltetrahydrocarbazolyloxyalkanoates
 and analogs as secretory phospholipase A2 inhibitors)
 RN 207341-21-7 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 6-methoxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 207341-22-8 CAPLUS
 CN 9H-Carbazole-4-carboxamide, 6-hydroxy-9-(phenylmethyl)- (CA INDEX NAME)




RN 207341-23-9 CAPLUS
 CN Butanoic acid, 4-[[5-(aminocarbonyl)-9-(phenylmethyl)-9H-carbazol-3-yl]oxy]-, ethyl ester (CA INDEX NAME)



RN 207341-24-0 CAPLUS
CN 9H-Carbazole-4-carboxamide, 5,7-dimethoxy-9-(phenylmethyl)- (CA INDEX NAME)



RN 207341-25-1 CAPLUS
CN 9H-Carbazole-4-carboxamide, 5-hydroxy-7-methoxy-9-(phenylmethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 49 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1998:274848 CAPLUS

DOCUMENT NUMBER: 129:45274

ORIGINAL REFERENCE NO.: 129:9399a,9402a

TITLE: Therapeutic uses and formulations of blood sugar-lowering indoles and their uses in preparation of pharmaceuticals

INVENTOR(S): Oku, Teruo; Sawada, Kozo; Kuroda, Akio; One, Kazuhiko; Yamazaki, Noritsugu; Imoto, Takafumi

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 63 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10114654	A	19980506	JP 1996-268402	19961009
PRIORITY APPLN. INFO.:			JP 1996-268402	19961009

OTHER SOURCE(S): MARPAT 129:45274


AB Pharmaceutical prepsns. containing indoles their pharmacol. acceptable salts are useful for prevention and/or treatment of glucose tolerance disorders, diabetes mellitus, hyperlipidemia, insulin resistance syndrome, cardiovascular disease, or hyperglycemia. The indoles are also useful in preparation of pharmaceuticals. Administration of 6-benzenesulfonylcarbonyl-1-(2-chlorobenzyl)-2-methylindole at 300 mg/kg p.o. to db/db mice showed 70% lowering of blood sugar concns.

IT 184147-58-8P 184147-86-2P 184148-12-7P
 184148-20-7P 184148-72-9P 184148-89-8P
 184150-27-4P 184150-38-7P 184150-41-2P
 205528-05-8P

RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
 USES (Uses)
 (preparation and therapeutic uses of blood sugar-lowering indoles)


RN 184147-58-8 CAPLUS

CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-propyl-
 (CA INDEX NAME)




RN 184147-86-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-(1-oxopropyl)- (CA INDEX NAME)




RN 184148-12-7 CAPLUS

CN Benzoic acid, 2-[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 184148-20-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184148-72-9 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-[(2-nitrophenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184148-89-8 CAPLUS


CN Benzoic acid, 2-[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 184150-27-4 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-formyl- (CA INDEX NAME)




RN 184150-38-7 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-(1-hydroxypropyl)-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 184150-41-2 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-bromophenyl)methyl]-2-propyl- (CA INDEX NAME)



RN 205528-05-8 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-aminophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


IT	184147-65-7P	184147-72-6P	184147-80-6P
	184147-92-0P	184147-98-6P	184148-11-6P
	184148-13-8P	184148-14-9P,	
	1-Benzyl-3-isobutyl-2-propylindole-6-carboxamide	184148-15-0P	
	184148-16-1P	184148-17-2P	184148-19-4P,
	3-Isobutyl-1-phenethyl-2-propylindole-6-carboxamide		
	184148-21-8P	184148-66-1P	184148-67-2P
	184148-68-3P	184148-69-4P	184148-70-7P
	184148-71-8P	184148-73-0P	184148-74-1P
	184148-75-2P	184148-76-3P	184148-77-4P
	184148-78-5P	184148-79-6P	184148-80-9P
	184148-82-1P	184148-83-2P	184148-84-3P
	184148-85-4P	184148-86-5P	184148-87-6P
	184148-90-1P	184149-00-6P	184149-12-0P
	184149-15-3P	184149-16-4P	184149-17-5P
	184149-18-6P	184149-22-2P	184149-23-3P
	184149-24-4P	184149-35-7P	184149-56-2P
	184149-57-3P	184149-58-4P	184149-59-5P
	184149-60-8P	184149-61-9P	184149-62-0P
	184149-63-1P	184149-64-2P	184149-65-3P
	184149-66-4P	184149-67-5P	184150-10-5P
	184150-11-6P	184150-12-7P	184150-13-8P
	184150-14-9P	184150-15-0P	184150-16-1P
	184150-17-2P	184150-18-3P	184150-19-4P
	184150-22-9P	184150-23-0P	184150-24-1P
	184150-25-2P	184150-28-5P	184150-31-0P
	184150-32-1P	184150-34-3P	184150-35-4P
	184150-37-6P	184150-39-8P	184150-40-1P
	184150-42-3P	184150-43-4P	184150-44-5P
	184150-45-6P	184150-46-7P	184150-47-8P
	184150-48-9P	184150-49-0P	184150-50-3P
	184150-53-6P	184150-54-7P	184150-55-8P
	184150-56-9P	184150-57-0P	184150-58-1P
	184150-59-2P	184150-66-1P	184151-83-5P
	184151-84-6P		

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation and therapeutic uses of blood sugar-lowering indoles)

RN 184147-65-7 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184147-72-6 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(1-oxopropyl)-2-propyl- (CA INDEX NAME)



RN 184147-80-6 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-(2-methylpropyl)- (CA INDEX NAME)




RN 184147-92-0 CAPLUS
 CN 1H-Indole-6-carboxamide, 2-acetyl-1-[(2-chlorophenyl)methyl]-3-(2-methylpropyl)- (CA INDEX NAME)




RN 184147-98-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-ethyl-2-(1-oxopropyl)- (CA INDEX NAME)




RN 184148-11-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-chloro-2-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-13-8 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-14-9 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(phenylmethyl)-2-propyl- (CA INDEX NAME)




RN 184148-15-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(3-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-16-1 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-2-propyl-1-[(2-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 184148-17-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-([1,1'-biphenyl]-2-ylmethyl)-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-19-4 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(2-phenylethyl)-2-propyl- (CA INDEX NAME)




RN 184148-21-8 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184148-66-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-67-2 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-bromophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-68-3 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-iodophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-69-4 CAPLUS
 CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-[(2-methylphenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184148-70-7 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-methoxyphenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-71-8 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-cyanophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)



RN 184148-73-0 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2,6-dichlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-74-1 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chloro-4-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-75-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-bromo-2-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-76-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-cyano-2-propyl- (CA INDEX NAME)




RN 184148-77-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-78-5 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-methyl-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-79-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-(methoxymethyl)-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-80-9 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-82-1 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2,3-diethyl- (CA INDEX NAME)




RN 184148-83-2 CAPLUS
 CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-ethyl- (CA INDEX NAME)




RN 184148-84-3 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-formyl-2-propyl- (CA INDEX NAME)




RN 184148-85-4 CAPLUS
 CN 1H-Indole-6-carboxamide, 3-benzoyl-1-[(2-chlorophenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184148-86-5 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-phenylacetyl)-2-propyl- (CA INDEX NAME)




RN 184148-87-6 CAPLUS
 CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-2-propyl- (CA INDEX NAME)



RN 184148-90-1 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[[2-(aminocarbonyl)phenyl]methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184149-00-6 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(1-oxo-2-buten-1-yl)-2-propyl- (CA INDEX NAME)




RN 184149-12-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-hydroxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184149-15-3 CAPLUS

CN 1H-Indole-3-carboxylic acid, 6-(aminocarbonyl)-1-[(2-chlorophenyl)methyl]- (CA INDEX NAME)




RN 184149-16-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-(1-oxopropyl)- (CA INDEX NAME)




RN 184149-17-5 CAPLUS


CN 1H-Indole-6-carboxamide, 3-chloro-1-[(2-chlorophenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184149-18-6 CAPLUS
 CN 1H-Indole-6-carboxamide, 3-bromo-1-[(2-bromophenyl)methyl]-2-propyl- (CA INDEX NAME)



RN 184149-22-2 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-(1-hydroxy-2-methylpropyl)- (CA INDEX NAME)




RN 184149-23-3 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-[1-(hydroxyimino)ethyl]-2-propyl- (CA INDEX NAME)




RN 184149-24-4 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[[2-

[[(methylamino)carbonyl]amino]phenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184149-35-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[[2-(acetylamino)phenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184149-56-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclopropylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-57-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclopropylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-58-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclobutylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-59-5 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclobutylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-60-8 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclopentylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-61-9 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclopentylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-62-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclohexylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-63-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclohexylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-64-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3-methyl-1-oxo-2-buten-1-yl)-2-propyl- (CA INDEX NAME)




RN 184149-65-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(3-methyl-1-oxo-2-buten-1-yl)-2-propyl- (CA INDEX NAME)




RN 184149-66-4 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3-methoxy-1-oxobutyl)-2-propyl- (CA INDEX NAME)




RN 184149-67-5 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(3-methoxy-1-oxobutyl)-2-propyl- (CA INDEX NAME)



RN 184150-10-5 CAPLUS
 CN Benzoic acid, 4-[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]-3-chloro- (CA INDEX NAME)




RN 184150-11-6 CAPLUS
 CN Cyclopent[b]indole-6-carboxamide, 4-[(2-chlorophenyl)methyl]-1,2,3,4-tetrahydro-1-oxo- (CA INDEX NAME)




RN 184150-12-7 CAPLUS

CN 1H-Indole-7-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-13-8 CAPLUS

CN 1H-Indole-5-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-14-9 CAPLUS


CN 1H-Indole-3-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-15-0 CAPLUS
 CN 1H-Indole-4-carboxamide, 1-[(2-chlorophenyl)methyl]-2-propyl- (CA INDEX NAME)



RN 184150-16-1 CAPLUS
 CN 1H-Carbazole-7-carboxamide, 9-[(2-chlorophenyl)methyl]-2,3,4,9-tetrahydro-1-oxo- (CA INDEX NAME)




RN 184150-17-2 CAPLUS
 CN 1H-Carbazole-7-carboxamide, 9-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-2,3,4,9-tetrahydro-1-oxo- (CA INDEX NAME)




RN 184150-18-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-bromo-2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184150-19-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-[2-(4-morpholinyl)acetyl]-2-propyl- (CA INDEX NAME)




RN 184150-22-9 CAPLUS

CN 1H-Indole-3,6-dicarboxamide, 1-[(2-chlorophenyl)methyl]-N3,N3-dimethyl-2-propyl- (CA INDEX NAME)




RN 184150-23-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(4-morpholinylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184150-24-1 CAPLUS

CN 1H-Indole-3,6-dicarboxamide, 1-[(2-chlorophenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184150-25-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-formyl- (CA INDEX NAME)




RN 184150-28-5 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-methyl-3-(1-oxopropyl)- (CA INDEX NAME)




RN 184150-31-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-(benzo[b]thien-5-ylmethyl)-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-32-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2,4-dichlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-34-3 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(1-naphthalenylmethyl)-2-propyl- (CA INDEX NAME)




RN 184150-35-4 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(2-naphthalenylmethyl)-2-propyl- (CA INDEX NAME)




RN 184150-37-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-(1-propen-1-yl)- (CA INDEX NAME)




RN 184150-39-8 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3,3-dimethyl-1-oxobutyl)- (CA INDEX NAME)




RN 184150-40-1 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184150-42-3 CAPLUS
CN 1H-Indole-6-carboxamide, 2-acetyl-1-[(2-chlorophenyl)methyl]-3-methyl- (CA INDEX NAME)



RN 184150-43-4 CAPLUS
CN 1H-Indole-6-carboxamide, 2-chloro-1-[(2-chlorophenyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 184150-44-5 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-(1-oxopropyl)-3-propyl- (CA INDEX NAME)




RN 184150-45-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-(2-methyl-1-oxopropyl)-3-propyl- (CA INDEX NAME)




RN 184150-46-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3-oxo-1-buten-1-yl)- (CA INDEX NAME)




RN 184150-47-8 CAPLUS

CN Cyclopent[b]indole-6-carboxamide, 4-[(2-chlorophenyl)methyl]-1,2,3,4-tetrahydro-3-oxo- (CA INDEX NAME)




RN 184150-48-9 CAPLUS

CN Cyclopent[b]indole-6-carboxamide, 4-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-1,2,3,4-tetrahydro-3-oxo- (CA INDEX NAME)




RN 184150-49-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[[2-chloro-4-[[(phenylsulfonyl)amino]carbonyl]phenyl]methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-50-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-ethoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-53-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-nitro-2-propyl- (CA INDEX NAME)




RN 184150-54-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-chloro-2-fluorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-55-8 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2,4-dichlorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-56-9 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-bromo-2-chlorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-57-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-bromo-2-fluorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-58-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chloro-4-fluorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-59-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-(benzo[b]thien-5-ylmethyl)-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-66-1 CAPLUS


CN Benzoic acid, 4-[[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]-3-chloro-, methyl ester (CA INDEX NAME)



RN 184151-83-5 CAPLUS
 CN 1H-Carbazole-7-carboxamide, 9-[(2-chlorophenyl)methyl]-2,3,4,9-tetrahydro-4-oxo- (CA INDEX NAME)



RN 184151-84-6 CAPLUS
 CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L12 ANSWER 50 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1998:155177 CAPLUS

DOCUMENT NUMBER: 128:275074

ORIGINAL REFERENCE NO.: 128:54365a, 54368a

TITLE: Cyclic nucleotide phosphodiesterase (PDE) inhibitors for prevention and treatment of lupus erythematosus and nephritis, and indoles as cGMP-PDE inhibitors

INVENTOR(S): Nomoto, Atsushi; Hamada, Kaori; Kodama, Hiroshi; Sokabe, Keizo


PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 61 pp.

DOCUMENT TYPE: CODEN: JKXXAF
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: 1 Japanese
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10067682	A	19980310	JP 1997-191618	19970716
PRIORITY APPLN. INFO.:			AU 1996-1188	A 19960723
OTHER SOURCE(S):	MARPAT 128:275074			

GI




AB Prophylactic and therapeutic agents for (systemic) lupus erythematosus and lupus nephritis contain cyclic nucleotide PDE inhibitors as active ingredients. Also claimed are indoles I [R1 = H, halo, NO2, (protected) CO2H, acyl, cyano, hydroxyimino-lower alkyl, (oxo-substituted) lower alkenyl, etc.; R2 = H, halo, lower alkenyl, acyl, (protected) CO2H, lower alkoxy, lower (hydroxy)alkyl; R3 = (un)substituted lower alkenyl, (un)substituted lower alkyl; R4 = (protected) CO2H, acyl, cyano, halo, heterocyclyl, (un)substituted NH2, (un)substituted alkyl; R1CCR2 may form (oxo-substituted) 4- to 7-membered heterocyclic ring] or their medically acceptable salts as cGMP-PDE inhibitors.
 1-(6-Chloro-3,4-methylenedioxybenzyl)-3-methoxyacetyl-2-propylindole-6-carboxamide was effective in treatment of immune-complex nephritis in mice.

IT 184147-65-7P 205527-99-7P
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indoles as cyclic nucleotide PDE inhibitors for treatment of lupus erythematosus and nephritis)

RN 184147-65-7 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 205527-99-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(2-


methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




IT 184147-86-2P 184148-12-7P 184148-89-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of indoles as cyclic nucleotide PDE inhibitors for treatment of lupus erythematosus and nephritis)
 RN 184147-86-2 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-(1-oxopropyl)- (CA INDEX NAME)



RN 184148-12-7 CAPLUS
 CN Benzoic acid, 2-[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]-, methyl ester (CA INDEX NAME)



RN 184148-89-8 CAPLUS
 CN Benzoic acid, 2-[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]- (CA INDEX NAME)




IT	184147-58-8P	184147-72-6P	184147-80-6P
	184147-98-6P	184148-11-6P	184148-13-8P
	184148-14-9P,	1-Benzyl-3-isobutyryl-2-propylindole-6-carboxamide	
	184148-15-0P	184148-16-1P	184148-17-2P
	184148-19-4P,	3-Isobutyryl-1-phenethyl-2-propylindole-6-carboxamide	
	184148-66-1P	184148-67-2P	
	184148-68-3P	184148-69-4P	184148-70-7P
	184148-71-8P	184148-72-9P	184148-73-0P
	184148-74-1P	184148-75-2P	184148-76-3P
	184148-77-4P	184148-78-5P	184148-80-9P
	184148-82-1P	184148-83-2P	184148-84-3P
	184148-85-4P	184148-86-5P	184148-87-6P
	184148-90-1P	184149-00-6P	184149-12-0P
	184149-15-3P	184149-16-4P	184149-17-5P
	184149-18-6P	184149-22-2P	184149-23-3P
	184149-24-4P	184149-56-2P	184149-57-3P
	184149-58-4P	184149-59-5P	184149-60-8P
	184149-61-9P	184149-62-0P	184149-63-1P
	184149-64-2P	184149-65-3P	184149-66-4P
	184149-67-5P	184150-10-5P	184150-11-6P
	184150-12-7P	184150-13-8P	184150-14-9P
	184150-15-0P	184150-16-1P	184150-17-2P
	184150-19-4P	184150-23-0P	184150-24-1P
	184150-25-2P	184150-28-5P	184150-31-0P
	184150-32-1P	184150-34-3P	184150-35-4P
	184150-37-6P	184150-39-8P	184150-40-1P
	184150-42-3P	184150-43-4P	184150-44-5P
	184150-45-6P	184150-46-7P	184150-47-8P
	184150-48-9P	184150-49-0P	184150-50-3P
	184150-53-6P	184150-54-7P	184150-55-8P
	184150-56-9P	184150-57-0P	184150-58-1P
	184150-59-2P	184150-66-1P	184151-83-5P
	184151-84-6P	205527-90-8P	205527-98-6P
	205528-01-4P	205528-05-8P	

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indoles as cyclic nucleotide PDE inhibitors for treatment of lupus erythematosus and nephritis)


RN 184147-58-8 CAPLUS

CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-propyl-
(CA INDEX NAME)




RN 184147-72-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184147-80-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-(2-methylpropyl)- (CA INDEX NAME)



RN 184147-98-6 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-ethyl-2-(1-oxopropyl)- (CA INDEX NAME)



RN 184148-11-6 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(4-chloro-2-fluorophenyl)methyl]-3-(2-methyl-1-

oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-13-8 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-14-9 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(phenylmethyl)-2-propyl- (CA INDEX NAME)




RN 184148-15-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(3-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-16-1 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-2-propyl-1-[(2-(trifluoromethyl)phenyl)methyl]- (CA INDEX NAME)




RN 184148-17-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-([1,1'-biphenyl]-2-ylmethyl)-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-19-4 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(2-phenylethyl)-2-propyl- (CA INDEX NAME)




RN 184148-66-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-67-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-bromophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-68-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-iodophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-69-4 CAPLUS


CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-[(2-methylphenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184148-70-7 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-methoxyphenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-71-8 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-cyanophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-72-9 CAPLUS
 CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-[(2-nitrophenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184148-73-0 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2,6-dichlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-74-1 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chloro-4-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-75-2 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(4-bromo-2-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-76-3 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-cyano-2-propyl- (CA INDEX NAME)



RN 184148-77-4 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-78-5 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-methyl-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-80-9 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-82-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2,3-diethyl- (CA INDEX NAME)




RN 184148-83-2 CAPLUS

CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-ethyl- (CA INDEX NAME)




RN 184148-84-3 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-formyl-2-propyl- (CA INDEX NAME)




RN 184148-85-4 CAPLUS
 CN 1H-Indole-6-carboxamide, 3-benzoyl-1-[(2-chlorophenyl)methyl]-2-propyl-
 (CA INDEX NAME)




RN 184148-86-5 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-phenylacetyl)-2-propyl- (CA INDEX NAME)



RN 184148-87-6 CAPLUS
 CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-2-propyl- (CA INDEX NAME)




RN 184148-90-1 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[[2-(aminocarbonyl)phenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184149-00-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(1-oxo-2-buten-1-yl)-2-propyl- (CA INDEX NAME)




RN 184149-12-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-hydroxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184149-15-3 CAPLUS

CN 1H-Indole-3-carboxylic acid, 6-(aminocarbonyl)-1-[(2-chlorophenyl)methyl]- (CA INDEX NAME)




RN 184149-16-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-(1-oxopropyl)- (CA INDEX NAME)




RN 184149-17-5 CAPLUS

CN 1H-Indole-6-carboxamide, 3-chloro-1-[(2-chlorophenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184149-18-6 CAPLUS

CN 1H-Indole-6-carboxamide, 3-bromo-1-[(2-bromophenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184149-22-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-(1-hydroxy-2-methylpropyl)- (CA INDEX NAME)




RN 184149-23-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-[1-(hydroxyimino)ethyl]-2-propyl- (CA INDEX NAME)




RN 184149-24-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[[2-[[[(methylamino)carbonyl]amino]phenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184149-56-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclopropylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-57-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclopropylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-58-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclobutylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-59-5 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclobutylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-60-8 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclopentylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-61-9 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclopentylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-62-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclohexylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-63-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclohexylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-64-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3-methyl-1-oxo-2-buten-1-yl)-2-propyl- (CA INDEX NAME)




RN 184149-65-3 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(3-methyl-1-oxo-2-buten-1-yl)-2-propyl- (CA INDEX NAME)




RN 184149-66-4 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3-methoxy-1-oxobutyl)-2-propyl- (CA INDEX NAME)



RN 184149-67-5 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(3-methoxy-1-oxobutyl)-2-propyl- (CA INDEX NAME)




RN 184150-10-5 CAPLUS
 CN Benzoic acid, 4-[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]-3-chloro- (CA INDEX NAME)




RN 184150-11-6 CAPLUS

CN Cyclopent[b]indole-6-carboxamide, 4-[(2-chlorophenyl)methyl]-1,2,3,4-tetrahydro-1-oxo- (CA INDEX NAME)




RN 184150-12-7 CAPLUS

CN 1H-Indole-7-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-13-8 CAPLUS

CN 1H-Indole-5-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-14-9 CAPLUS

CN 1H-Indole-5-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-15-0 CAPLUS

CN 1H-Indole-4-carboxamide, 1-[(2-chlorophenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184150-16-1 CAPLUS

CN 1H-Carbazole-7-carboxamide, 9-[(2-chlorophenyl)methyl]-2,3,4,9-tetrahydro-1-oxo- (CA INDEX NAME)




RN 184150-17-2 CAPLUS

CN 1H-Carbazole-7-carboxamide, 9-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-2,3,4,9-tetrahydro-1-oxo- (CA INDEX NAME)




RN 184150-19-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-[2-(4-morpholinyl)acetyl]-2-propyl- (CA INDEX NAME)




RN 184150-23-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(4-morpholinylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184150-24-1 CAPLUS

CN 1H-Indole-3,6-dicarboxamide, 1-[(2-chlorophenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184150-25-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-formyl- (CA INDEX NAME)




RN 184150-28-5 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-methyl-3-(1-oxopropyl)- (CA INDEX NAME)




RN 184150-31-0 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-(benzo[b]thien-5-ylmethyl)-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)



RN 184150-32-1 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2,4-dichlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-34-3 CAPLUS
 CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(1-naphthalenylmethyl)-2-propyl- (CA INDEX NAME)




RN 184150-35-4 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(2-naphthalenylmethyl)-2-propyl- (CA INDEX NAME)




RN 184150-37-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-(1-propen-1-yl)- (CA INDEX NAME)




RN 184150-39-8 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3,3-dimethyl-1-oxobutyl)-2-(1-propen-1-yl)- (CA INDEX NAME)




RN 184150-40-1 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184150-42-3 CAPLUS
CN 1H-Indole-6-carboxamide, 2-acetyl-1-[(2-chlorophenyl)methyl]-3-methyl- (CA INDEX NAME)



RN 184150-43-4 CAPLUS
CN 1H-Indole-6-carboxamide, 2-chloro-1-[(2-chlorophenyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 184150-44-5 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-(1-oxopropyl)-3-propyl- (CA INDEX NAME)




RN 184150-45-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-(2-methyl-1-oxopropyl)-3-propyl- (CA INDEX NAME)




RN 184150-46-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3-oxo-1-buten-1-yl)- (CA INDEX NAME)




RN 184150-47-8 CAPLUS

CN Cyclopent[b]indole-6-carboxamide, 4-[(2-chlorophenyl)methyl]-1,2,3,4-tetrahydro-3-oxo- (CA INDEX NAME)




RN 184150-48-9 CAPLUS

CN Cyclopent[b]indole-6-carboxamide, 4-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-1,2,3,4-tetrahydro-3-oxo- (CA INDEX NAME)




RN 184150-49-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[[2-chloro-4-[(phenylsulfonyl)amino]carbonyl]phenyl]methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-50-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-ethoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-53-6 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-nitro-2-propyl- (CA INDEX NAME)




RN 184150-54-7 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(4-chloro-2-fluorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)



RN 184150-55-8 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2,4-dichlorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-56-9 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(4-bromo-2-chlorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-57-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-bromo-2-fluorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-58-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chloro-4-fluorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-59-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-(benzo[b]thien-5-ylmethyl)-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-66-1 CAPLUS

CN Benzoic acid, 4-[[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]-3-chloro-, methyl ester (CA INDEX NAME)




RN 184151-83-5 CAPLUS

CN 1H-Carbazole-7-carboxamide, 9-[(2-chlorophenyl)methyl]-2,3,4,9-tetrahydro-4-oxo- (CA INDEX NAME)




RN 184151-84-6 CAPLUS

CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-methyl- (CA INDEX NAME)




RN 205527-90-8 CAPLUS


CN 1H-Indole-6-carboxamide, 2-acetyl-1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 205527-98-6 CAPLUS
 CN 1H-Indole-3-acetic acid, 6-(aminocarbonyl)-1-[(2-chlorophenyl)methyl]-2-propyl-, methyl ester (CA INDEX NAME)



RN 205528-01-4 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-methoxy-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 205528-05-8 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-aminophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

IT 184148-20-7 184150-27-4 184150-38-7
184150-41-2

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of indoles as cyclic nucleotide PDE inhibitors for treatment of
lupus erythematosus and nephritis)


RN 184148-20-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methoxyacetyl)-2-
propyl- (CA INDEX NAME)




RN 184150-27-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-formyl- (CA INDEX
NAME)




RN 184150-38-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-(1-hydroxypropyl)-3-
(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 184150-41-2 CAPLUS
CN 1H-Indole-6-carboxamide, 1-[(2-bromophenyl)methyl]-2-propyl- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (6 CITINGS)

L12 ANSWER 51 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1996:746234 CAPLUS

DOCUMENT NUMBER: 126:18786

ORIGINAL REFERENCE NO.: 126:3901a,3904a

TITLE: Indole derivatives as cGMP-PDE inhibitors

INVENTOR(S): Oku, Teruo; Sawada, Kozo; Kuroda, Akio; Ohne, Kazuhiko; Nomoto, Atsushi; Hosogai, Naomi; Nakajima, Yoshimitsu; Nagashima, Akira; Sogabe, Keizo; Amura, Kouichi

PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co, Ltd., Japan

SOURCE: PCT Int. Appl., 211 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9632379	A1	19961017	WO 1996-JP892	19960402
CA 2217707	A1	19961017	CA 1996-2217707	19960402
AU 9651234	A	19961030	AU 1996-51234	19960402
AU 713460	B2	19991202		
EP 820441	A1	19980128	EP 1996-907750	19960402
EP 820441	B1	20020626		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1187812	A	19980715	CN 1996-194691	19960402
JP 11503445	T	19990326	JP 1996-530864	19960402
AT 219765	T	20020715	AT 1996-907750	19960402
ES 2175079	T3	20021116	ES 1996-907750	19960402
ZA 9602859	A	19961011	ZA 1996-2859	19960410
TW 420663	B	20010201	TW 1996-104519	19960416
US 6069156	A	20000530	US 1997-930597	19971210


PRIORITY APPLN. INFO.:

GB 1995-7432	A	19950410
GB 1995-12560	A	19950621
GB 1995-16136	A	19950807
AU 1996-8294	A	19960227
WO 1996-JP892	W	19960402

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 126:18786

GI



AB The invention relates to new indole derivs. I and their pharmaceutically acceptable salts [wherein R¹ = H, halo, NO₂, CO₂H, protected CO₂H, acyl, (un)substituted alk(en)yl, etc.; R² = H, halo, alkenyl, acyl, (un)substituted alkyl, etc.; R³ = (un)substituted alk(en)yl where the substituent is oxo, (un)substituted aryl, or heterocyclyl; R⁴ = CO₂H, protected CO₂H, acyl, cyano, amino, halo, etc.; R¹ and R² may form 4- to 7-membered carboxylic ring (un)substituted with oxo]. I are cyclic nucleotide-PDE inhibitors (specifically cGMP-PDE), and are useful for treating and preventing a variety of conditions, including angina, hypertension, renal failure, atherosclerosis, stroke, asthma, impotence, diabetic complications, and glaucoma. Almost 300 compds. I and numerous intermediates were prepared. For example, Me 3-isobutyryl-2-propylindole-6-carboxylate (preparation given) was N-benzylated by 2-chlorobenzyl bromide using NaH in DMF. The product underwent saponification


with NaOH in aqueous EtOH, followed by amidation of the resultant acid using EDC, HOBT, and aqueous NH₃, to give title amide II. II inhibited human platelet cGMP-PDE in vitro with IC₅₀ <100 nM. I were also active in a variety of other bioassays, including relaxation of isolated rat aorta, inhibition of vascular smooth muscle cell proliferation, inhibition of vasopressin-induced vasospasm, the cyclosporin and FK506 nephritis models, the diabetic glomerulosclerosis model, and several animal impotence models.

IT 184147-65-7P 184148-21-8P
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of indole derivs. as cGMP-PDE inhibitors)

RN 184147-65-7 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-21-8 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




IT 184147-86-2P 184148-72-9P 184148-77-4P
 184148-89-8P 184149-11-9P 184149-15-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of indole derivs. as cGMP-PDE inhibitors)
 RN 184147-86-2 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-(1-oxopropyl)- (CA INDEX NAME)




RN 184148-72-9 CAPLUS
 CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-[(2-nitrophenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184148-77-4 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 184148-89-8 CAPLUS
 CN Benzoic acid, 2-[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 184149-11-9 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-aminophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl-, hydrochloride (1:?) (CA INDEX NAME)



●x HCl

RN 184149-15-3 CAPLUS

CN 1H-Indole-3-carboxylic acid, 6-(aminocarbonyl)-1-[(2-chlorophenyl)methyl]-
(CA INDEX NAME)




IT	184147-58-8P	184147-72-6P	184147-80-6P	
	184147-92-0P	184147-98-6P	184148-11-6P	
	184148-12-7P	184148-13-8P	184148-14-9P,	
	1-Benzyl-3-isobutyryl-2-propylindole-6-carboxamide		184148-15-0P	
	184148-16-1P	184148-17-2P	184148-19-4P,	
	3-Isobutyryl-1-phenethyl-2-propylindole-6-carboxamide			
	184148-20-7P	184148-66-1P	184148-67-2P	
	184148-68-3P	184148-69-4P	184148-70-7P	
	184148-71-8P	184148-73-0P	184148-74-1P	
	184148-75-2P	184148-76-3P	184148-78-5P	
	184148-79-6P	184148-80-9P	184148-82-1P	
	184148-83-2P	184148-84-3P	184148-85-4P	
	184148-86-5P	184148-87-6P	184148-90-1P	
	184149-00-6P	184149-12-0P	184149-16-4P	
	184149-17-5P	184149-18-6P	184149-22-2P	
	184149-23-3P	184149-24-4P	184149-35-7P	
	184149-56-2P	184149-57-3P	184149-58-4P	
	184149-59-5P	184149-60-8P	184149-61-9P	
	184149-62-0P	184149-63-1P	184149-64-2P	
	184149-65-3P	184149-66-4P	184149-67-5P	
	184150-10-5P	184150-11-6P	184150-12-7P	
	184150-13-8P	184150-14-9P	184150-15-0P	
	184150-16-1P	184150-17-2P	184150-18-3P	
	184150-19-4P	184150-22-9P	184150-23-0P	
	184150-24-1P	184150-25-2P	184150-27-4P	
	184150-28-5P	184150-31-0P	184150-32-1P	
	184150-34-3P	184150-35-4P	184150-37-6P	
	184150-38-7P	184150-39-8P	184150-40-1P	
	184150-41-2P	184150-42-3P	184150-43-4P	
	184150-44-5P	184150-45-6P	184150-46-7P	

184150-47-8P	184150-48-9P	184150-49-0P
184150-50-3P	184150-53-6P	184150-54-7P
184150-55-8P	184150-56-9P	184150-57-0P
184150-58-1P	184150-59-2P	184150-66-1P
184150-67-2P	184151-83-5P	184151-84-6P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of indole derivs. as cGMP-PDE inhibitors)


RN 184147-58-8 CAPLUS

CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-propyl-
(CA INDEX NAME)




RN 184147-72-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(1-oxopropyl)-2-propyl-
(CA INDEX NAME)




RN 184147-80-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-(2-methylpropyl)-
(CA INDEX NAME)




RN 184147-92-0 CAPLUS

CN 1H-Indole-6-carboxamide, 2-acetyl-1-[(2-chlorophenyl)methyl]-3-(2-methylpropyl)-
(CA INDEX NAME)




RN 184147-98-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-ethyl-2-(1-oxopropyl)- (CA INDEX NAME)




RN 184148-11-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-chloro-2-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-12-7 CAPLUS

CN Benzoic acid, 2-[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]-, methyl ester (CA INDEX NAME)




RN 184148-13-8 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-14-9 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(phenylmethyl)-2-propyl- (CA INDEX NAME)




RN 184148-15-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(3-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-16-1 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-2-propyl-1-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 184148-17-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-([1,1'-biphenyl]-2-ylmethyl)-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-19-4 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(2-phenylethyl)-2-propyl- (CA INDEX NAME)




RN 184148-20-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184148-66-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-67-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-bromophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-68-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-iodophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184148-69-4 CAPLUS


CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-[(2-methylphenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184148-70-7 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-methoxyphenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 184148-71-8 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-cyanophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-73-0 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2,6-dichlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-74-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chloro-4-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-75-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-bromo-2-fluorophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-76-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-cyano-2-propyl- (CA INDEX NAME)




RN 184148-78-5 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-methyl-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-79-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-(methoxymethyl)-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-80-9 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184148-82-1 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2,3-diethyl- (CA INDEX NAME)




RN 184148-83-2 CAPLUS
 CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-ethyl- (CA INDEX NAME)




RN 184148-84-3 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-formyl-2-propyl- (CA INDEX NAME)




RN 184148-85-4 CAPLUS
 CN 1H-Indole-6-carboxamide, 3-benzoyl-1-[(2-chlorophenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184148-86-5 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-phenylacetyl)-2-propyl- (CA INDEX NAME)




RN 184148-87-6 CAPLUS
 CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-2-propyl- (CA INDEX NAME)



RN 184148-90-1 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[[2-(aminocarbonyl)phenyl]methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184149-00-6 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(1-oxo-2-buten-1-yl)-2-propyl- (CA INDEX NAME)




RN 184149-12-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-hydroxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184149-16-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-(1-oxopropyl)- (CA INDEX NAME)




RN 184149-17-5 CAPLUS

CN 1H-Indole-6-carboxamide, 3-chloro-1-[(2-chlorophenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184149-18-6 CAPLUS

CN 1H-Indole-6-carboxamide, 3-bromo-1-[(2-bromophenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184149-22-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-(1-hydroxy-2-methylpropyl)- (CA INDEX NAME)




RN 184149-23-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-[1-(hydroxyimino)ethyl]-2-propyl- (CA INDEX NAME)




RN 184149-24-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[[2-[(methylamino)carbonylamino]phenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184149-35-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-(acetamino)phenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184149-56-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclopropylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-57-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclopropylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-58-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclobutylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-59-5 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclobutylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-60-8 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclopentylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-61-9 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclopentylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-62-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(cyclohexylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-63-1 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(cyclohexylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184149-64-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3-methyl-1-oxo-2-buten-1-yl)-2-propyl- (CA INDEX NAME)




RN 184149-65-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(3-methyl-1-oxo-2-buten-1-yl)-2-propyl- (CA INDEX NAME)




RN 184149-66-4 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3-methoxy-1-oxobutyl)-2-propyl- (CA INDEX NAME)




RN 184149-67-5 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-3-(3-methoxy-1-oxobutyl)-2-propyl- (CA INDEX NAME)



RN 184150-10-5 CAPLUS
 CN Benzoic acid, 4-[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]-3-chloro- (CA INDEX NAME)




RN 184150-11-6 CAPLUS
 CN Cyclopent[b]indole-6-carboxamide, 4-[(2-chlorophenyl)methyl]-1,2,3,4-tetrahydro-1-oxo- (CA INDEX NAME)




RN 184150-12-7 CAPLUS

CN 1H-Indole-7-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-13-8 CAPLUS

CN 1H-Indole-5-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-14-9 CAPLUS


CN 1H-Indole-3-carboxamide, 1-[(2-chlorophenyl)methyl]-5-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-15-0 CAPLUS
 CN 1H-Indole-4-carboxamide, 1-[(2-chlorophenyl)methyl]-2-propyl- (CA INDEX NAME)



RN 184150-16-1 CAPLUS
 CN 1H-Carbazole-7-carboxamide, 9-[(2-chlorophenyl)methyl]-2,3,4,9-tetrahydro-1-oxo- (CA INDEX NAME)




RN 184150-17-2 CAPLUS
 CN 1H-Carbazole-7-carboxamide, 9-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-2,3,4,9-tetrahydro-1-oxo- (CA INDEX NAME)




RN 184150-18-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(4-bromo-2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)




RN 184150-19-4 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-[2-(4-morpholinyl)acetyl]-2-propyl- (CA INDEX NAME)




RN 184150-22-9 CAPLUS

CN 1H-Indole-3,6-dicarboxamide, 1-[(2-chlorophenyl)methyl]-N3,N3-dimethyl-2-propyl- (CA INDEX NAME)




RN 184150-23-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(4-morpholinylcarbonyl)-2-propyl- (CA INDEX NAME)




RN 184150-24-1 CAPLUS

CN 1H-Indole-3,6-dicarboxamide, 1-[(2-chlorophenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184150-25-2 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-ethyl-3-formyl- (CA INDEX NAME)




RN 184150-27-4 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-formyl- (CA INDEX NAME)



RN 184150-28-5 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-methyl-3-(1-oxopropyl)- (CA INDEX NAME)




RN 184150-31-0 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-(benzo[b]thien-5-ylmethyl)-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-32-1 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2,4-dichlorophenyl)methyl]-3-(2-methyl-1-

oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184150-34-3 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(1-naphthalenylmethyl)-2-propyl- (CA INDEX NAME)




RN 184150-35-4 CAPLUS

CN 1H-Indole-6-carboxamide, 3-(2-methyl-1-oxopropyl)-1-(2-naphthalenylmethyl)-2-propyl- (CA INDEX NAME)




RN 184150-37-6 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-(1-propen-1-yl)- (CA INDEX NAME)




RN 184150-38-7 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-(1-hydroxypropyl)-3-(2-methyl-1-oxopropyl)- (CA INDEX NAME)



RN 184150-39-8 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3,3-dimethyl-1-oxobutyl)- (CA INDEX NAME)




RN 184150-40-1 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-propyl- (CA INDEX NAME)




RN 184150-41-2 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-bromophenyl)methyl]-2-propyl- (CA INDEX NAME)

NAME)




RN 184150-42-3 CAPLUS

CN 1H-Indole-6-carboxamide, 2-acetyl-1-[(2-chlorophenyl)methyl]-3-methyl- (CA INDEX NAME)




RN 184150-43-4 CAPLUS

CN 1H-Indole-6-carboxamide, 2-chloro-1-[(2-chlorophenyl)methyl]-3-ethyl- (CA INDEX NAME)




RN 184150-44-5 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-(1-oxopropyl)-3-propyl- (CA INDEX NAME)




RN 184150-45-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-2-(2-methyl-1-oxopropyl)-3-propyl- (CA INDEX NAME)




RN 184150-46-7 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(3-oxo-1-buten-1-yl)-
(CA INDEX NAME)




RN 184150-47-8 CAPLUS

CN Cyclopent[b]indole-6-carboxamide, 4-[(2-chlorophenyl)methyl]-1,2,3,4-
tetrahydro-3-oxo- (CA INDEX NAME)




RN 184150-48-9 CAPLUS

CN Cyclopent[b]indole-6-carboxamide, 4-[(6-chloro-1,3-benzodioxol-5-
yl)methyl]-1,2,3,4-tetrahydro-3-oxo- (CA INDEX NAME)




RN 184150-49-0 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chloro-4-
 [(phenylsulfonyl)amino]carbonyl]phenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-
 propyl- (CA INDEX NAME)




RN 184150-50-3 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-(2-ethoxyacetyl)-2-
 propyl- (CA INDEX NAME)




RN 184150-53-6 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-chlorophenyl)methyl]-3-nitro-2-propyl- (CA
 INDEX NAME)




RN 184150-54-7 CAPLUS


CN 1H-Indole-6-carboxamide, 1-[(4-chloro-2-fluorophenyl)methyl]-3-(2-
 methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-55-8 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2,4-dichlorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-56-9 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(4-bromo-2-chlorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-57-0 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(4-bromo-2-fluorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-58-1 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-[(2-chloro-4-fluorophenyl)methyl]-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)



RN 184150-59-2 CAPLUS
 CN 1H-Indole-6-carboxamide, 1-(benzo[b]thien-5-ylmethyl)-3-(2-methoxyacetyl)-2-propyl- (CA INDEX NAME)




RN 184150-66-1 CAPLUS
 CN Benzoic acid, 4-[[6-(aminocarbonyl)-3-(2-methyl-1-oxopropyl)-2-propyl-1H-indol-1-yl]methyl]-3-chloro-, methyl ester (CA INDEX NAME)




RN 184150-67-2 CAPLUS

CN 1H-Indole-6-carboxamide, 1-[(2-aminophenyl)methyl]-3-(2-methyl-1-oxopropyl)-2-propyl- (CA INDEX NAME)




RN 184151-83-5 CAPLUS

CN 1H-Carbazole-7-carboxamide, 9-[(2-chlorophenyl)methyl]-2,3,4,9-tetrahydro-4-oxo- (CA INDEX NAME)



RN 184151-84-6 CAPLUS

CN 1H-Indole-6-carboxamide, 3-acetyl-1-[(2-chlorophenyl)methyl]-2-methyl- (CA INDEX NAME)



OS.CITING REF COUNT: 40 THERE ARE 40 CAPLUS RECORDS THAT CITE THIS RECORD (54 CITINGS)

L12 ANSWER 52 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1996:712949 CAPLUS

DOCUMENT NUMBER: 126:54470

ORIGINAL REFERENCE NO.: 126:10586h,10587a

TITLE: Design, Synthesis, and Evaluation of Nonpeptidic Inhibitors of Human Rhinovirus 3C Protease

AUTHOR(S): Webber, Stephen E.; Tikhe, Jayashree; Worland, Stephen T.; Fuhrman, Shella A.; Hendrickson, Thomas F.; Matthews, David A.; Love, Robert A.; Patick, Amy K.; Meador, James W.; et al.

CORPORATE SOURCE: Agouron Pharmaceuticals, San Diego, CA, 92121, USA
SOURCE: Journal of Medicinal Chemistry (1996), 39(26), 5072-5082

CODEN: JMCMAR; ISSN: 0022-2623


PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal


LANGUAGE: English

OTHER SOURCE(S): CASREACT 126:54470


GI



I



II



III

AB The design, synthesis, and biol. evaluation of reversible, nonpeptidic inhibitors of human rhinovirus (HRV) 3C protease (3CP) are reported. A novel series of 2,3-dioxindoles (isatins) were designed that utilized a combination of protein structure-based drug design, mol. modeling, and structure-activity relationship (SAR). The C-2 carbonyl of isatin was envisioned to react in the active site of HRV 3CP with the cysteine

responsible for catalytic proteolysis, thus forming a stabilized transition state mimic. Mol.-modeling expts. using the apo crystal structure of human rhinovirus-serotype 14 (HRV-14) 3CP and a peptide substrate model allowed the authors to design recognition features into the P1 and P2 subsites, resp., from the 5- and 1-positions of isatin. Attempts to optimize recognition properties in the P1 subsite using SAR at the 5-position were performed. In addition, a series of ab initio calcs. were carried out on several 5-substituted isatins to investigate the stability of sulfide adducts at C-3. The inhibitors were prepared by general synthetic methods, starting with com. available 5-substituted isatins in nearly every case. All compds. were tested for inhibition of purified HRV-14 3CP. Compds. I, II, and III were found to have excellent selectivity for HRV-14 3CP compared to other proteolytic enzymes, including chymotrypsin and cathepsin B. Selected compds. were assayed for antiviral activity against HRV-14-infected HI-HeLa cells. A 2.8 Å cocrystal structure of derivative III covalently bound to human rhinovirus-serotype 2 (HRV-2) 3CP was solved and revealed that the isatin was situated in essentially the same conformation as modeled.


IT 184904-90-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease)

RN 184904-90-3 CAPLUS

CN 1H-Indole-5-carboxamide, 2,3-dihydro-1-[(3-methoxyphenyl)methyl]-2,3-dioxo- (CA INDEX NAME)



IT 184904-79-8P 184904-80-1P 184904-81-2P

184904-82-3P 184904-86-7P 184904-88-9P

184904-92-5P 184904-94-7P 184904-95-8P


184904-96-9P 184904-97-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease)


RN 184904-79-8 CAPLUS

CN 1H-Indole-5-carboxamide, 2,3-dihydro-2,3-dioxo-1-(3-phenylpropyl)- (CA INDEX NAME)




RN 184904-80-1 CAPLUS

CN 1H-Indole-5-carboxamide, 2,3-dihydro-2,3-dioxo-1-(phenylmethyl)- (CA INDEX NAME)




RN 184904-81-2 CAPLUS

CN 1H-Indole-5-carboxamide, 1-([1,1'-biphenyl]-4-ylmethyl)-2,3-dihydro-2,3-dioxo- (CA INDEX NAME)




RN 184904-82-3 CAPLUS

CN 1H-Indole-5-carboxamide, 2,3-dihydro-1-(2-naphthalenylmethyl)-2,3-dioxo- (CA INDEX NAME)




RN 184904-86-7 CAPLUS

CN 1H-Indole-5-carboxamide, 2,3-dihydro-1-[(4-methylphenyl)methyl]-2,3-dioxo- (CA INDEX NAME)




RN 184904-88-9 CAPLUS

CN 1H-Indole-5-carboxamide, 1-[(3,4-dimethylphenyl)methyl]-2,3-dihydro-2,3-dioxo- (CA INDEX NAME)




RN 184904-92-5 CAPLUS

CN 1H-Indole-5-carboxamide, 1-[(3,5-dimethoxyphenyl)methyl]-2,3-dihydro-2,3-dioxo- (CA INDEX NAME)




RN 184904-94-7 CAPLUS

CN 1H-Indole-5-carboxamide, 2,3-dihydro-1-[(6-methoxy-2-naphthalenyl)methyl]-2,3-dioxo- (CA INDEX NAME)




RN 184904-95-8 CAPLUS

CN 1H-Indole-5-carboxamide, 2,3-dihydro-1-[(3-hydroxyphenyl)methyl]-2,3-dioxo- (CA INDEX NAME)




RN 184904-96-9 CAPLUS

CN 1H-Indole-5-carboxamide, 1-[(3,5-dihydroxyphenyl)methyl]-2,3-dihydro-2,3-dioxo- (CA INDEX NAME)




RN 184904-97-0 CAPLUS
 CN 1H-Indole-5-carboxamide, 2,3-dihydro-1-[(6-hydroxy-2-naphthalenyl)methyl]-
 2,3-dioxo- (CA INDEX NAME)




IT 184905-09-7P
 RL: BYP (Byproduct); PREP (Preparation)
 (design, synthesis, and evaluation of nonpeptidic inhibitors of human
 rhinovirus 3C protease)

RN 184905-09-7 CAPLUS
 CN 1H-Indole-5-carboxamide, 2,3-dihydro-3-hydroxy-2-oxo-1-(3-phenylpropyl)-
 (CA INDEX NAME)



IT 184905-07-5P
 RL: PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); PREP
 (Preparation); RACT (Reactant or reagent)
 (design, synthesis, and evaluation of nonpeptidic inhibitors of human
 rhinovirus 3C protease)

RN 184905-07-5 CAPLUS
 CN 1H-Indole-5-carboxamide, 2,3-dihydro-3,3-dimethoxy-1-(2-
 naphthalenylmethyl)-2-oxo- (CA INDEX NAME)



OS.CITING REF COUNT: 97 THERE ARE 97 CAPLUS RECORDS THAT CITE THIS
 RECORD (98 CITINGS)
 REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 53 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1995:621499 CAPLUS
 DOCUMENT NUMBER: 123:32954
 ORIGINAL REFERENCE NO.: 123:6087a,6090a

TITLE: Preparation of 1H-indole-3-acetamides as sPLA2 inhibitors.

INVENTOR(S): Bach, Nicholas James; Dillard, Robert Delane; Draheim, Susan Elizabeth; Hermann, Robert Bell; Schevitz, Richard Walter

PATENT ASSIGNEE(S): Eli Lilly and Co., USA

SOURCE: Eur. Pat. Appl., 123 pp.
CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 620215	A1	19941019	EP 1994-302666	19940414
EP 620215	B1	19990818		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
HU 70836	A2	19951128	HU 1994-1060	19940413
CA 2121323	A1	19941017	CA 1994-2121323	19940414
BR 9401482	A	19941018	BR 1994-1482	19940414
AT 183503	T	19990915	AT 1994-302666	19940414
ES 2138648	T3	20000116	ES 1994-302666	19940414
CZ 289750	B6	20020313	CZ 1994-893	19940414
FI 9401767	A	19941017	FI 1994-1767	19940415
NO 9401361	A	19941017	NO 1994-1361	19940415
AU 9459492	A	19941020	AU 1994-59492	19940415
AU 676884	B2	19970327		
JP 07025850	A	19950127	JP 1994-77650	19940415
CN 1098715	A	19950215	CN 1994-104434	19940415
CN 1068588	C	20010718		
ZA 9402615	A	19951016	ZA 1994-2615	19940415
RU 2162463	C2	20010127	RU 1994-12930	19940415
PL 181319	B1	20010731	PL 1994-303028	19940415
US 5684034	A	19971104	US 1995-435256	19950505
US 6252084	B1	20010626	US 1997-962603	19971031
GR 3031783	T3	20000229	GR 1999-402875	19991108
PRIORITY APPLN. INFO.:			US 1993-48629	A 19930416
			US 1994-208721	A 19940315
			US 1995-435256	A1 19950505

OTHER SOURCE(S): MARPAT 123:32954

GI



I

AB Title compds. [I; R1 = (cyclo)alkyl, alkenyl, aryl, alkylamino, etc.; R2 = H, halo, alkyl, alkoxy, etc.; R3 = H, halo, Me; R4-R7 = H, (cyclo)alkyl, aryl(alkyl), alkoxy, etc.; X = O or S] were prepared Thus, 1-(2-tert-butoxycarbonylamino-5-methoxyphenyl)-2-butanone (preparation from 4-methoxy-2-methylaniline given) was cyclized and the product alkylated by

BrCH₂CO₃Me to give, in 4 addnl. steps, I (R₁ = CH₂Ph, R₂ = Et, R₃ = R₄ = R₆ = R₇ = H, R₅ = OR, X = O) (II; R = H) which was condensed with Br(CH₂)₃P(O)(OMe)₂ to give, after saponification, II [R = (CH₂)₃P(O)(OH)₂].

The

latter had IC₅₀ of 0.02μM against human sPLA₂ in vitro.

IT

164084-35-9P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1H-indole-3-acetamides as sPLA₂ inhibitors.)

RN

164084-35-9 CAPLUS

CN

1H-Indole-3-acetamide, 5-(aminocarbonyl)-2-methyl-1-(phenylmethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS RECORD (50 CITINGS)

L12 ANSWER 54 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1995:374622 CAPLUS

DOCUMENT NUMBER: 123:143924

ORIGINAL REFERENCE NO.: 123:25645a,25648a

TITLE: Preparation of indolylalkyl derivatives of pyrimidinylpiperazine for treating vascular headache
INVENTOR(S): Smith, David W.; Yocca, Frank D.; Yevich, Joseph P.; Mattson, Ronald J.; Williams, Andrew; Ruediger, Edward H.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Co., USA
SOURCE: U.S., 27 pp. Cont.-in-part of U.S. Ser. No. 680,208, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5300506	A	19940405	US 1992-960063	19921013
CA 2043709	A1	19911230	CA 1991-2043709	19910531
CA 2043709	C	20020122		
ZA 9104804	A	19930224	ZA 1991-4804	19910621
ES 2066278	T3	19950301	ES 1991-110376	19910624
FI 9103142	A	19911230	FI 1991-3142	19910627
FI 101224	B1	19980515		
AU 9179416	A	19920102	AU 1991-79416	19910627
AU 643038	B2	19931104		
JP 04230378	A	19920819	JP 1991-183911	19910628
PRIORITY APPLN. INFO.:			US 1990-546122	B2 19900629
			US 1991-680208	B2 19910404

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 123:143924

GI




AB Title compds. [I; R1 = H, halo, alkyl, alkoxy, (substituted) phenylalkoxy, amino, cyano, OH, OCH2CN, CO2R9, Q1, etc.; R2 = H, halo, alkyl, alkoxy, CO2R9; R3, R5, R6 = H, alkyl; R4 = alkyl; R9 = alkyl, (substituted) phenylalkyl], were prepared Thus, 1-[3-(5-benzyloxy-1H-indol-3-yl)propyl]-4-(5-methoxy-4-pyrimidinyl)piperazine (preparation given) was hydrogenolyzed in EtOH over Pd(OH)2 to give 1-[3-(5-hydroxy-1H-indol-3-yl)propyl]-4-(5-methoxy-4-pyrimidinyl)piperazine. The latter showed a 5-HT1d binding site affinity of 0.8 nM.

IT 161108-37-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of, as intermediate for pyrimidinylpiperazinylpropylindole serotonin 5-HT1d agonist for treatment of vascular headache)

RN 161108-37-8 CAPLUS

CN 1H-Indole-5-carboxamide, 3-(3-hydroxypropyl)-1-(phenylmethyl)- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 55 OF 55 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1980:532369 CAPLUS


DOCUMENT NUMBER: 93:132369

ORIGINAL REFERENCE NO.: 93:21105a,21108a


TITLE: Indole compounds and pharmaceutical compositions containing them

INVENTOR(S): Webb, Colin Frederick
 PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
 SOURCE: Ger. Offen., 102 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2940687	A1	19800430	DE 1979-2940687	19791008
DE 2940687	C2	19910801		
ZA 7905239	A	19801126	ZA 1979-5239	19791002
FI 7903071	A	19800413	FI 1979-3071	19791004
DK 7904255	A	19800413	DK 1979-4255	19791009
AU 7951657	A	19800417	AU 1979-51657	19791010
AU 531783	B2	19830908		
GB 2035310	A	19800618	GB 1979-35208	19791010
GB 2035310	B	19821222		
US 4252803	A	19810224	US 1979-83343	19791010
AT 7906605	A	19840815	AT 1979-6605	19791010
AT 377511	B	19850325		
SE 7908443	A	19800413	SE 1979-8443	19791011
SE 448628	B	19870309		
SE 448628	C	19870618		
CH 646151	A5	19841115	CH 1979-9194	19791011
BE 879381	A1	19800201	BE 1979-197621	19791012
NL 7907583	A	19800415	NL 1979-7583	19791012
FR 2438651	A1	19800509	FR 1979-25446	19791012
FR 2438651	B1	19830304		
JP 55062063	A	19800510	JP 1979-130944	19791012
JP 63058817	B	19881117		
CA 1146550	A1	19830517	CA 1979-337443	19791012
PRIORITY APPLN. INFO.:			GB 1978-40279	A 19781012
OTHER SOURCE(S):	MARPAT 93:132369			
GI				



I



II


AB The indole derivs. I [R, R1, R2, R3 = H, (substituted) alkyl, cycloalkyl, aryl, or aralkyl; RR1N, and R2R3N = ring; R4 = H, C1-3 alkyl, aryl; R5 = H, alkyl, aralkyl; Z = C1-4 alkylene; X = O, S] and their salts were prepared for use in treatment of hypertension and migraines (no data). Thus, II (R6 = CO2CH2Ph, R7 = OH) reacted with PhCH2NH2 in the presence of 2-chloro-1-methylpyridinium iodide to give II (R6 = CO2CH2Ph, R7 = NHCH2Ph), which was hydrogenated over Pd-C to give I (R6 = H, R7 = NHCH2Ph), isolated as compound with creatinine sulfate.

IT 74885-49-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 74885-49-7 CAPLUS


CN 1H-Indole-5-carboxamide, 3-(2-aminoethyl)-1-(phenylmethyl)-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1
 CRN 74885-48-6
 CMF C18 H19 N3 O



CM 2
 CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



OS.CITING REF COUNT: 29 THERE ARE 29 CAPLUS RECORDS THAT CITE THIS RECORD (30 CITINGS)

=> log hold
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
337.40	988.64

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
 CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
-48.72	-57.42

SESSION WILL BE HELD FOR 120 MINUTES
 STN INTERNATIONAL SESSION SUSPENDED AT 10:06:58 ON 25 MAY 2011

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACDR1614

PASSWORD:

***** RECONNECTED TO STN INTERNATIONAL *****
 SESSION RESUMED IN FILE 'CAPLUS' AT 10:32:25 ON 25 MAY 2011
 FILE 'CAPLUS' ENTERED AT 10:32:25 ON 25 MAY 2011
 COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	337.40	988.64
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	-48.72	-57.42
=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
FULL ESTIMATED COST	ENTRY	SESSION
	337.92	989.16
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
CA SUBSCRIBER PRICE	ENTRY	SESSION
	-48.72	-57.42

FILE 'REGISTRY' ENTERED AT 10:32:44 ON 25 MAY 2011
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAY 2011 HIGHEST RN 1299596-13-6
 DICTIONARY FILE UPDATES: 24 MAY 2011 HIGHEST RN 1299596-13-6

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH January 14, 2011.


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdnoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10598281FOAM1c.str



```

chain nodes :
10 19 20 21 22 23 24 25
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16
chain bonds :
2-22 3-21 4-19 5-20 9-10 10-12 23-24 23-25
ring bonds :
1-2 1-6 1-9 2-3 3-4 4-5 5-6 6-7 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16
exact/norm bonds :
1-9 4-19 6-7 7-8 8-9 23-24 23-25
exact bonds :
2-22 3-21 5-20 9-10 10-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16

```

G1:OH,NH2

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 19:CLASS 20:CLASS 21:CLASS
22:CLASS 23:CLASS 24:CLASS 25:CLASS 27:Atom

```

L13 STRUCTURE UPLOADED

=> d l13

L13 HAS NO ANSWERS

L13 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l13 sss sam

SAMPLE SEARCH INITIATED 10:33:07 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 30556 TO ITERATE

100.0% PROCESSED 30556 ITERATIONS

16 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 600658 TO 621582

PROJECTED ANSWERS: 80 TO 560

L14 16 SEA SSS SAM L13

=> s l13 sss full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 196.35 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SEARCH INITIATED 10:33:12 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 615882 TO ITERATE

100.0% PROCESSED 615882 ITERATIONS

443 ANSWERS

SEARCH TIME: 00.00.02

L15 443 SEA SSS FUL L13

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

196.86

1186.02

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

0.00

-57.42

FILE 'CAPLUS' ENTERED AT 10:33:17 ON 25 MAY 2011

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 May 2011 VOL 154 ISS 22

FILE LAST UPDATED: 24 May 2011 (20110524/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2011

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2011

Caplus now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l15

L16 97 L15

=> d ibib abs hitstr 97

L16 ANSWER 97 OF 97 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1965:488799 CAPLUS

DOCUMENT NUMBER: 63:88799

ORIGINAL REFERENCE NO.: 63:16308a-h,16309a-c

TITLE: Indolyl aliphatic acids

INVENTOR(S): Sarett, Lewis H.; Shen, Tsung Y.

PATENT ASSIGNEE(S): Merck & Co., Inc.

SOURCE: 23 pp.

DOCUMENT TYPE: Patent

LANGUAGE: Unavailable

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3196162		19650720	US 1961-94995	19590903
PRIORITY APPLN. INFO.:			US	19590903

GI For diagram(s), see printed CA Issue.

AB The title compds. (Ia) are antiinflammatory and sunscreens agents, some of which have antipyretic action p-Methoxyphenyl-hydrazine-HCl (25 g.) and 20 g. Et α -methyllevulinate in 250 ml. 2N ethanolic HCl was refluxed to give Et α -(2-methyl-5-methoxy-3-indolyl)propionate (I), b0.25 150-3° m. 53-5.5°. Et α -(2,5-dimethyl-3-indolyl)propionate, b1 150-170° (bath temperature), m. 88-8.5° (petroleum ether), was similarly prepared I was hydrolyzed to the free acid, m. 163-5° (aqueous EtOH). I (13 g.) in 75 ml. dimethylformamide (II) was added to a stirred suspension of 2.5 g. of a NaH-mineral oil dispersion (containing 52 weight-% NaH) in 100 ml. II. The mixture was stirred at room temperature for 1 hr., then 8 g. o-chlorobenzyl chloride was added slowly. The resulting mixture kept at room temperature 14 hrs.


gave Et α -(1-o-chlorobenzyl-2-methyl-5-methoxy-3-indolyl)propionate (III), 118-122°. III was saponified to give the free acid, m. 191-2° (benzene). In a similar manner, the following Ia (R1 = R6 = H, R2 = R3 = Me), were prepared (R, R4, R5, and m.p. given): H, OCH3, m-Cl, 191-2°; Et OCH3, o,p-di-Cl, 130°; H, OCH3, o,p-di-Cl 184-6°; Et CH3, p-Cl, 89-90°; H, CH3, p-Cl, 185-6°; H, OCH3, p-OCH3, 153-3.5°; H, OCH3, p-F, 164-5°; Et, OCH3, p-SCHF2, -, H, OCH3, p-SCHF2, 132-3°; Et, OCH3, p-OCHF2, -, H, OCH3, p-OCHF2, 144-6°; H, OCH3, p-Cl, 163-5°; H, OCH3, p-SCH3, 170-1°; H, OCH3, p-SCH2Ph, 150-3°; H, OCH3, p-SH, 161-4°; H, OCH3, p-SOCH3, 194-6°; H, OCH3, p-SOCH3, 98-101°; Et, CH3, p-SCH3, 111-13°; H, CH3, p-SCH3, 184-7°; H, OCH3, p-CF3, 176-80°; Et, OCH3, p-CN, 72°; H, OCH3, p-CN, 197-200°; H, OCH3, p-COOH, 230-4°; Et, OCH3, p-NO2, 102-3°; H, OCH3, p-NO2, 188-90°; H, OCH3, p-N(CH3)2, 193-4°; Et, OCH3, p-SO2N- (CH3)2, 140°; H, OCH3, p-SO2N(CH3)2, 156.5-8.5°; H, OCH3, p-Set, 126-33°. α -(1-p-Methylthiobenzyl-2-methyl-5-methoxy-3-indolyl)propionic acid (IV) (8.8 g.) and 14 g. urea was heated at 190-200° for 1.5 hrs. to

give the amide of IV m. 143-4°. IV (4.45 g.) was slurried in 12 ml. MeOH, 5.2 ml. 2.21N NaOCH₃ in MeOH was added under N and the solution was concentrated to a sirup to give the Na salt of IV. The Al salt of IV was also prepared in the preparation of α -(1-p-chlorobenzyl-2-methyl-5-methylthio-3-indolyl)propionic acid (V), N-p-chlorobenzylidene-4-mercaptoaniline (VI) was prepared from 53.3 g. p-aminothiophenol in 200 ml. EtOH and 60.2 g. p-chlorobenzaldehyde in 200 ml. EtOH. VI (58.2 g.) was treated with 11.52 g. NaH (52% in mineral oil) in 400 ml. II and 35 g. CHI₃ in 100 ml. II to give N-p-chlorobenzylidene-4-methylthioaniline (VII). VII was treated with NaBH₄ to give N-p-chlorobenzyl-4-methylthioaniline. The corresponding nitroso derivative was prepared and reduced to give N'-p-chlorobenzyl-4-methylthiophenylhydrazine-HCl m. 140.5° (EtOH). Ring closure of the hydrazine with Et α -methyllevulinate gave the Et ester of V as a yellow sirup. The ester was saponified to V, m. 154-60° (acetone). The following intermediates were also prepared: p-difluoromethylthiotoluene, b_{0.35} 32-4°, n_D 1.5092; p-difluoromethylthiobenzyl bromide, b_{0.3} 74°, n_D 1.5622; p-difluoromethoxytoluene, b. 165-7°; p-difluoromethoxybenzyl bromide, b_{0.2} 50-2° n_D 1.5170; p-methylthiobenzyl chloride b₁ 99°; p-trifluoromethylbenzaldehyde, b₁₂ 64°, n_D 1.4633; p-trifluoromethylbenzyl chloride, b₁₂ 68°, n_D 1.4622; p-trifluoromethylbenzyl alcohol, b₁₂ 85-8°, n_D 1.4562; N'-(p-nitrobenzyl)-N-(p-methoxyphenyl)hydrazine-HCl, 147-150°; NN-dimethyl-p-bromomethylbenzenesulfonamide, 85-108°; p-ethylthiobenzyl chloride, b. 92-103°/250-400 μ ; phenylthiobenzyl chloride (39%, by analysis), b. 85-145°/50 μ ; N-(o,p-dimethoxybenzyl)-p-methoxyaniline, 126-7°; N'-(o,p-dimethoxybenzyl)-N-(p-methoxyphenyl)hydrazine-HCl, 136-9°. Also prepared were the following Ia (R₃ = R₆ = H) (R, R₁, R₂, R₄, R₅, and m.p. given): H, H, H, OCH₃, p-Cl, 144-8°; H, H, CF₃, OCH₃, p-SCH₃, 168-72°; H, H, CH₃, OCH₃, p-SCH₃, 155-6.5°; Et, H, CH₃, OCH₃, p-SCH₃, 94-5°; H, H, H, OCH₃, p-Cl, 146-8°; H, H, COOH, OCH₃, p-Cl, 213-18°; Et, H, COOH, OCH₃, p-Cl, 214-16°; H, H, H, OCH₃, p-Cl, 146-8°. The following intermediates were prepared: 2-ethyl-5-methylindole, 72-4°; 2-ethyl-5-gramine, m. 100-3°; α -(2-ethyl-5-methyl-3-indolyl)acetic acid, m. 137-8°; Et 2-methyl-5-chloro-3-indolylacetate, m. 85°. Oxalyl chloride (19 g.) in 25 ml. ether was added rapidly to an ice cold mixture of 35.7 g. 1-p-chlorobenzyl-2-methyl-5-methoxyindole in 900 ml. ether and the mixture stirred for 2 hrs.; the solid recovered was added to 660 ml. EtOH and treated with 0.12 moles NaCl. After being stirred 1 hr., the mixture was poured into an equal volume of H₂O containing 10 ml. acetic

acid

to give Et α -(1-p-chlorobenzyl-2-methyl-5-methoxy-3-indolyl)oxoacetate (VIII), m. 113°. VIII (38 g.) in 260 ml. benzene and 500 ml. dry ether was added to a mixture of 500 ml. dry ether, 36.02 g. triphenylphosphonium bromide, and 94.36 ml. 1.10N BuLi under N. After stirring 1 hr., the mixture was heated in a closed flask at 65-70° for 5 hrs. to give Et α -(1-p-chlorobenzyl-2-methyl-5-methoxy-3-indolyl)acrylate (IX), m. 94-5°. The free acid m. 187-8° (EtOH). IX (1.8 g.) in 10 ml. dry tetrahydrofuran was added to 4 g. diiodomethane, 1.25 g. Zn-Cu couple, and 0.2 g. iodine in 20 ml. dry tetrahydrofuran. The mixture was refluxed to give Et α -(1-p-chlorobenzyl-2-methyl-5-methoxy-3-indolyl)cyclopropa-necarboxylate (X). X was hydrolyzed to the free acid, m. 220-4°. In addition, racemic and optically active forms were prepared: (+)- α -(1-p-methylthiobenzyl-2-methyl-5-methoxy-3-indolyl)propionic acid (+)- α -phenethylamine salt m. 170-2°, [α]_D 22 D 38.5° (c 1, MeOH); the free acid of the preceding salt, m. 118°, [α]_D 22 D 62.4° (c 0.94, EtOH); (+)- α -(1-p-chlorobenzyl-2-methyl-5-methoxy-3-indolyl)propionic acid (+)- α -phenethylamine salt, m. 148-9°, [α]_D 22 D

43° (c 1, MeOH); the free acid (XI) of the preceding salt m.
 156-7°, [α]_D²² 60° (c 1, EtOH); the dl form of XI;
 the (-) form of XI, m. 153-4°, [α]_D²³ -58° (c 1,
 EtOH); (-)-α-(1-p-chlorobenzyl-2-methyl-5-methoxy-3-
 indolyl)propionic acid (-)-α-phenethylamine salt. Racemic forms of
 α-[1-p-fluoro(and methoxy)benzyl-2-methyl-5-methoxy-3-
 indolyl]propionic acids and of 1-(1-p-methylthio-benzyl-2,5-dimethyl-3-
 indolyl)propionic acid were also prepared
 IT 3447-34-5P, Indole-3-acetic acid,
 1-(p-carboxybenzyl)-5-methoxy-α,2-dimethyl-
 RL: PREP (Preparation)
 (preparation of)
 RN 3447-34-5 CAPLUS
 CN 1H-Indole-3-acetic acid, 1-[(4-carboxyphenyl)methyl]-5-methoxy-α,2-
 dimethyl- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
 (5 CITINGS)

=> file reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

6.48	1192.50
------	---------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-0.87	-58.29
-------	--------

FILE 'REGISTRY' ENTERED AT 10:33:42 ON 25 MAY 2011

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 24 MAY 2011 HIGHEST RN 1299596-13-6

DICTIONARY FILE UPDATES: 24 MAY 2011 HIGHEST RN 1299596-13-6

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

TSCA INFORMATION NOW CURRENT THROUGH January 14, 2011.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10598281FOAM1d.str



```
chain nodes :
10 19 20 21 22 23 24 25 28 29
ring nodes :
1 2 3 4 5 6 7 8 9 11 12 13 14 15 16
chain bonds :
2-22 3-21 4-19 5-20 7-28 8-29 9-10 10-12 23-24 23-25
ring bonds :
1-2 1-6 1-9 2-3 3-4 4-5 5-6 6-7 7-8 8-9 11-12 11-16 12-13 13-14 14-15
15-16
exact/norm bonds :
1-9 4-19 6-7 7-8 8-9 23-24 23-25
exact bonds :
2-22 3-21 5-20 7-28 8-29 9-10 10-12
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 11-12 11-16 12-13 13-14 14-15 15-16
```

G1:OH,NH2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 19:CLASS 20:CLASS 21:CLASS
22:CLASS 23:CLASS 24:CLASS 25:CLASS 27:Atom 28:CLASS 29:CLASS

L17 STRUCTURE UPLOADED

=> d l17

L17 HAS NO ANSWERS

L17 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> d hist

(FILE 'HOME' ENTERED AT 09:52:54 ON 25 MAY 2011)

FILE 'REGISTRY' ENTERED AT 09:53:16 ON 25 MAY 2011

L1 STRUCTURE UPLOADED

L2 0 S L1 SSS SAM

L3 18 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 09:53:51 ON 25 MAY 2011

L4 1 S L3

FILE 'REGISTRY' ENTERED AT 09:54:29 ON 25 MAY 2011

L5 STRUCTURE UPLOADED

L6 0 S L5 SSS SAM

L7 30 S L5 SSS FULL

FILE 'CAPLUS' ENTERED AT 09:57:16 ON 25 MAY 2011

L8 9 S L7

FILE 'REGISTRY' ENTERED AT 09:57:41 ON 25 MAY 2011

FILE 'REGISTRY' ENTERED AT 10:02:11 ON 25 MAY 2011

L9 STRUCTURE UPLOADED

L10 24 S L9 SSS SAM

L11 446 S L9 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:02:39 ON 25 MAY 2011

L12 55 S L11

FILE 'REGISTRY' ENTERED AT 10:32:44 ON 25 MAY 2011

L13 STRUCTURE UPLOADED

L14 16 S L13 SSS SAM

L15 443 S L13 SSS FULL

FILE 'CAPLUS' ENTERED AT 10:33:17 ON 25 MAY 2011

L16 97 S L15

FILE 'REGISTRY' ENTERED AT 10:33:42 ON 25 MAY 2011

L17 STRUCTURE UPLOADED

=> s l17 sub=115 sss sam

SAMPLE SUBSET SEARCH INITIATED 10:35:00 FILE 'REGISTRY'

SAMPLE SUBSET SCREEN SEARCH COMPLETED - 16 TO ITERATE

100.0% PROCESSED

16 ITERATIONS

6 ANSWERS

SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):	ONLINE	**COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):	80 TO	560
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):	6 TO	266

L18 6 SEA SUB=L15 SSS SAM L17

=> s l17 sub=l15 sss full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 46.85 U.S. DOLLARS

DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

FULL SUBSET SEARCH INITIATED 10:35:07 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 443 TO ITERATE

100.0% PROCESSED	443 ITERATIONS	145 ANSWERS
SEARCH TIME: 00.00.01		

L19 145 SEA SUB=L15 SSS FUL L17

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	47.87	1240.37

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	0.00	-58.29

FILE 'CAPLUS' ENTERED AT 10:35:10 ON 25 MAY 2011

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 25 May 2011 VOL 154 ISS 22

FILE LAST UPDATED: 24 May 2011 (20110524/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2011

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2011

CPlus now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>


This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l19


L20 23 L19

=> d ibib abs hitstr 1-23

L20 ANSWER 1 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2009:904814 CAPLUS
 DOCUMENT NUMBER: 151:381220
 TITLE: FXR agonist activity of conformationally constrained analogs of GW 4064
 AUTHOR(S): Akwabi-Ameyaw, Adwoa; Bass, Jonathan Y.; Caldwell, Richard D.; Caravella, Justin A.; Chen, Lihong; Creech, Katrina L.; Deaton, David N.; Madauss, Kevin P.; Marr, Harry B.; McFadyen, Robert B.; Miller, Aaron B.; Navas, Frank; Parks, Derek J.; Spearing, Paul K.; Todd, Dan; Williams, Shawn P.; Bruce Wisely, G.
 CORPORATE SOURCE: Department of Medicinal Chemistry, GlaxoSmithKline, Research Triangle Park, NC, 27709, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2009), 19(16), 4733-4739
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 151:381220
 GI




AB Two series of conformationally constrained analogs of the FXR agonist GW 4064 were prepared Replacement of the metabolically labile stilbene with either benzothiophene or naphthalene rings led to the identification of potent full agonists I and II.
 IT 1097778-44-3P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (FXR agonist activity of conformationally constrained analogs of GW 4064)
 RN 1097778-44-3 CAPLUS
 CN Benzoic acid, 3-[[5-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)



IT 1097776-81-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (FXR agonist activity of conformationally constrained analogs of GW
 4064)

RN 1097776-81-2 CAPLUS

CN Benzoic acid, 4-[[5-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-
 isoxazolyl]methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
 (4 CITINGS)
 REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 2 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2009:793237 CAPLUS

DOCUMENT NUMBER: 151:123969

TITLE: Preparation of
 1,2,3,4-tetrahydro-1H-pyrido[4,3-b]indoles and
 1,2,3,4,5,6-hexahydroazepino[4,3-b]indoles as ligands
 for α -adrenoceptors and for dopamine, histamine,
 imidazoline and serotonin receptors and their use in
 treatment of CNS diseases

INVENTOR(S): Ivashchenko, Andrey Alexandrovich; Ivashchenko,
 Alexander Vasilievich; Lavrovsky, Yan Vadimovich;
 Mitkin, Oleg Dmitrievich; Savchuk, Nikolay
 Filippovich; Tkachenko, Sergey Yevgenievich; Okun,
 Ilya Matusovich

PATENT ASSIGNEE(S): Alla Chem, LLC, USA

SOURCE: PCT Int. Appl., 151pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: Russian


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009082268	A2	20090702	WO 2008-RU780	20081219
WO 2009082268	A3	20090820		
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 2236511	A2	20101006	EP 2008-864305	20081219
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS			
RU 2407744	C2	20101227	RU 2008-150397	20081219
JP 2011507835	T	20110310	JP 2010-539344	20081219
US 20110039825	A1	20110217	US 2010-810013	20100621
PRIORITY APPLN. INFO.:			RU 2007-147347	A 20071221
			RU 2007-147349	A 20071221
			RU 2007-147351	A 20071221
			RU 2007-147352	A 20071221
			RU 2007-147355	A 20071221
			RU 2007-147356	A 20071221
			RU 2007-147358	A 20071221
			RU 2007-147361	A 20071221
			RU 2007-147363	A 20071221
			RU 2007-147365	A 20071221
			RU 2007-147367	A 20071221
			RU 2007-147368	A 20071221
			RU 2007-147370	A 20071221
			RU 2007-147371	A 20071221
			RU 2007-147372	A 20071221
			RU 2007-147374	A 20071221
			RU 2007-147375	A 20071221
			RU 2007-147376	A 20071221
			RU 2008-137937	A 20080924
			WO 2008-RU780	W 20081219
OTHER SOURCE(S):	MARPAT 151:123969			
GI				



I



II

AB Ligands I; R1 = H, (un)substituted C1-4 alkyl, acyl, heterocyclyl, alkoxy carbonyl substituted sulfonyl; R2 = H, halo, (un)substituted C1-4 alkyl, CF3 CN, alkoxy, alkoxy carbonyl, carboxyl, heterocyclyl, substituted sulfonyl; R3 = (un)substituted aryl, possibly annelated with heterocyclyl or (un)substituted heterocyclyl; W = (un)substituted (CH2)m, (un)substituted CH:CH, (un)substituted CH2CH:CH, (un)substituted C.tplbond.C, SO2; n = 1, 2; m = 1-3; the continuous line together with a dotted line represents a single or a double bond] as free bases, geometric isomers, racemic mixts. or individual optical isomers and also as pharmaceutically acceptable salts and/or hydrates, the broad spectrum of which simultaneously comprises α -adrenoceptors, dopamine receptors, histamine receptors, imidazoline receptors and serotonin receptors, including 5-HT7 serotonin receptors, are claimed, as are processes for their preparation Medicinal substances, pharmaceutical compns. containing

ligands

I as medicinal substances, novel medicinal agents which were used for treating diseases and states of the central nervous system of human beings and warm-blooded animals, are also claimed. E.g., II.2HCl (preparation given) gave 100% inhibition of histamine H1 receptors, and 98% inhibition of histamine H2 receptors.


IT 1009632-22-7P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of tetrahydro-1H-pyrido[4,3-b]indoles and hexahydroazepino[4,3-b]indoles as ligands for α -adrenoceptors and other receptors for treatment of CNS diseases)

RN 1009632-22-7 CAPLUS

CN Benzoic acid, 4-[[[(5aR,10bR)-2,3,4,5,5a,10b-hexahydro-2,9-dimethylazepino[4,3-b]indol-6(1H)-yl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



IT 1166848-57-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of tetrahydro-1H-pyrido[4,3-b]indoles and hexahydroazepino[4,3-b]indoles as ligands for α -adrenoceptors and other receptors for treatment of CNS diseases)

RN 1166848-57-2 CAPLUS

CN Benzoic acid, 4-[[[(5aR,10bR)-2,3,4,5,5a,10b-hexahydro-2,9-dimethylazepino[4,3-b]indol-6(1H)-yl]methyl]-, hydrochloride (1:?), rel- (CA INDEX NAME)

Relative stereochemistry.



●x HCl

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L20 ANSWER 3 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2009:20122 CAPLUS

DOCUMENT NUMBER: 150:121632

TITLE: Preparation of isoxazoles as farnesoid x receptor agonists

INVENTOR(S): Akwabi-Ameyaw, Adwoa A.; Deaton, David Norman;

Mcfadyen, Robert Blount; Navas, Frank, III



PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA

SOURCE: PCT Int. Appl., 299pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009005998	A1	20090108	WO 2008-US66817	20080613
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2008270784	A1	20090108	AU 2008-270784	20080613
CA 2690406	A1	20090108	CA 2008-2690406	20080613
EP 2173174	A1	20100414	EP 2008-770928	20080613
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, AL, BA, MK, RS			
KR 2010044810	A	20100430	KR 2010-7002455	20080613
JP 2010532363	T	20101007	JP 2010-514955	20080613
CN 101877966	A	20101103	CN 2008-80104790	20080613
MX 2009013946	A	20100310	MX 2009-13946	20091217
IN 2009KN04405	A	20100521	IN 2009-KN4405	20091218
US 20110034507	A1	20110210	US 2010-665772	20101021
PRIORITY APPLN. INFO.:			US 2007-947548P	P 20070702
			WO 2008-US66817	W 20080613
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): CASREACT 150:121632; MARPAT 150:121632				
GI				




AB The invention is related to isoxazoles I [A = (un)substituted Ph, 5-6 membered heteroaryl containing 1-3 heteroatoms selected from N, O and S; R1 = CO2H, CONH2, alkoxycarbonyl, CH2CH2CO2H, CH2CH2CO2alkyl, NHCOCH3, NHSO2CF3, etc.; Z1 = (Z1')a; Z1' = CH2, CO, NH, S, SO, SO2; a = 0-1; B = 3-oxo-3,4-dihydro-2(1H)-3,6-isoquinolinylenes, 2,6-benzothiazolylene, 2,5-1H-indolylene, etc.; Z2 = O, S, CH2, NR5, R5 = H, alkyl; R6 = alkyl, 2,2,2-trifluoroethyl, cycloalkyl, alkenyl, cycloalkenyl and fluoro-substituted cycloalkyl; R7 = (R7')d; R7' = alkylene; Z3 = (Z3')e; Z3' = O, S(O)0-2, NH; d, e = both 0, or d = 1 and e = 0-1; D = cycloalkyl, (un)substituted Ph, pyridin-4-yl, 1H-imidazol-2-yl, etc.] and their pharmaceutically acceptable salts as farnesoid x receptor (FXR) agonists, and their pharmaceutical compns. useful for treating a condition mediated by decreased FXR activity, such as obesity, diabetes, cholestatic liver disease, liver fibrosis, and metabolic syndrome. Thus, oxidation of ethylene glycol tert-Bu ether, oximation of the aldehyde (no data) with NH2OH·HCl, cyclization of the oxime with Me isobutanoylacetate, reduction of Me 3-[[[(1,1-dimethylethyl)oxy]methyl]-5-(1-methylethyl)isoxazole-4-carboxylate, chlorination of the alc. with thionyl chloride, treatment with Me 3-[(5-hydroxy-1H-indol-1-yl)methyl]benzoate, cleavage of the tert-Bu group, reaction of the alc. with 2,6-dimethylphenol and saponification of the Me ester gave acid II. In an FXR cofactor binding assay, II showed FXR agonistic activity with a PEC50 in the range of 6 to 6.99.

IT 1097776-13-OP, 3-[[[5-[[[3-[[[(2,6-Dimethylphenyl)oxy]methyl]-5-(1-methylethyl)-4-isoxazolyl]methyl]oxy]-1H-indol-1-yl]methyl]benzoic acid 1097776-31-2P, 3-[[[5-[[[5-(1-Methylethyl)-3-[[[(2,4,6-trifluorophenyl)oxy]methyl]-4-isoxazolyl]methyl]oxy]-1H-indol-1-yl]methyl]benzoic acid 1097776-37-8P, 3-[[[5-[[[5-(1-Methylethyl)-3-[[[(2,4,6-trichlorophenyl)oxy]methyl]-4-isoxazolyl]methyl]oxy]-1H-indol-1-yl]methyl]benzoic acid 1097776-40-3P, 3-[[[5-[[[3-[[[(2,6-Dichlorophenyl)amino]methyl]-5-(1-methylethyl)-4-isoxazolyl]methyl]oxy]-1H-indol-1-yl]methyl]benzoic acid 1097776-44-7P, 3-[[[5-[[[3-[[[(2,6-Dibromophenyl)oxy]methyl]-5-(1-methylethyl)-4-isoxazolyl]methyl]oxy]-1H-indol-1-yl]methyl]benzoic acid 1097776-46-9P, 3-[[[5-[[[5-(1-Methylethyl)-3-[[[(1,3-thiazol-2-yl)thio]methyl]-4-isoxazolyl]methyl]oxy]-1H-indol-1-yl]methyl]benzoic acid

1097776-49-2P, 3-[[5-[[[5-(1-Methylethyl)-3-[2-
 [(trifluoromethyl)oxy]phenyl]-4-isoxazolyl]methyl]oxy]-1H-indol-1-
 yl]methyl]benzoic acid 1097776-81-2P,
 4-[[5-[[[3-(2,6-Dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methyl]oxy]-
 1H-indol-1-yl]methyl]benzoic acid 1097776-83-4P,
 3-[[5-[[[3-[[2,6-Dichloro-4-fluorophenyl]oxy]methyl]-5-(1-methylethyl)-4-
 isoxazolyl]methyl]oxy]-1H-indol-1-yl]methyl]benzoic acid
 1097776-85-6P, 3-[[5-[[[3-[[2,6-Dichlorophenyl]oxy]methyl]-5-(1-
 methylethyl)-4-isoxazolyl]methyl]oxy]-1H-indol-1-yl]methyl]benzoic acid
 1097778-00-1P, 5-[[5-[[[3-(2,6-Dichlorophenyl)-5-(1-methylethyl)-4-
 isoxazolyl]methyl]oxy]-1H-indol-1-yl]methyl]-2-methylbenzoic acid
 1097778-44-3P, 3-[[5-[[[3-(2,6-Dichlorophenyl)-5-(1-methylethyl)-4-
 isoxazolyl]methyl]oxy]-1H-indol-1-yl]methyl]benzoic acid
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (drug candidate; preparation of isoxazoles as farnesoid x receptor agonists)
 RN 1097776-13-0 CAPLUS
 CN Benzoic acid, 3-[[5-[[3-[(2,6-dimethylphenoxy)methyl]-5-(1-methylethyl)-4-
 isoxazolyl]methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 1097776-31-2 CAPLUS
 CN Benzoic acid, 3-[[5-[[5-(1-methylethyl)-3-[(2,4,6-trifluorophenoxy)methyl]-
 4-isoxazolyl]methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 1097776-37-8 CAPLUS

CN Benzoic acid, 3-[[5-[[5-(1-methylethyl)-3-[(2,4,6-trichlorophenoxy)methyl]-4-isoxazolyl]methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 1097776-40-3 CAPLUS

CN Benzoic acid, 3-[[5-[[3-[(2,6-dichlorophenyl)amino]methyl]-5-(1-methylethyl)-4-isoxazolyl]methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 1097776-44-7 CAPLUS

CN Benzoic acid, 3-[[5-[[3-[(2,6-dibromophenoxy)methyl]-5-(1-methylethyl)-4-isoxazolyl]methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 1097776-46-9 CAPLUS

CN Benzoic acid, 3-[[5-[[5-(1-methylethyl)-3-[(2-thiazolylthio)methyl]-4-isoxazolyl]methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 1097776-49-2 CAPLUS

CN Benzoic acid, 3-[[5-[[5-(1-methylethyl)-3-[2-(trifluoromethoxy)phenyl]-4-isoxazolyl]methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 1097776-81-2 CAPLUS

CN Benzoic acid, 4-[[5-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 1097776-83-4 CAPLUS

CN Benzoic acid, 3-[[5-[[3-[(2,6-dichloro-4-fluorophenoxy)methyl]-5-(1-methylethyl)-4-isoxazolyl]methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 1097776-85-6 CAPLUS

CN Benzoic acid, 3-[[5-[[3-[(2,6-dichlorophenoxy)methyl]-5-(1-methylethyl)-4-isoxazolyl]methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 1097778-00-1 CAPLUS

CN Benzoic acid, 5-[[5-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]-1H-indol-1-yl]methyl]-2-methyl- (CA INDEX NAME)



RN 1097778-44-3 CAPLUS
 CN Benzoic acid, 3-[[5-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4-isoxazolyl]methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
 REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 4 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2008:609524 CAPLUS

DOCUMENT NUMBER: 148:561890

TITLE: Preparation of derivatives of pyrrolo[4,3-b]indoles, γ -carbolines and azepino[4,3-b]indoles as ligands of 5-HT6 receptors for treating CNS diseases and pharmaceutical compositions containing them
 INVENTOR(S): Ivashchenko, Andrey Alexandrovich; Ivashchenko, Alexandr Vasilievich; Tkachenko, Sergey Yevgenievich; Okun, Ilya Matusovich; Savchuk, Nikolay Filippovich
 PATENT ASSIGNEE(S): Alla Chem, LLC, USA
 SOURCE: PCT Int. Appl., 66pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: Russian

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008060190	A2	20080522	WO 2007-RU624	20071115
WO 2008060190	A3	20080724		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR,

TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
 BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW,
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

RU 2329044 C1 20080720 RU 2006-140353 20061116

EP 2184064 A2 20100512 EP 2007-861047 20071115

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR



US 20110046368 A1 20110224 US 2010-741006 20101018

PRIORITY APPLN. INFO.: RU 2006-140353 A 20061116

WO 2007-RU624 W 20071115

OTHER SOURCE(S): CASREACT 148:561890; MARPAT 148:561890

GI



AB Azaheterocycles that are derivs. of pyrrolo[4,3-b]indoles, γ-carbolines or azepino[4,3-b]indoles [I; Z = (CH2)_n, n = 1-3; k = 1-3, R1 = H, (un)substituted C1-5 alkyl, C1-5 alkoxy, C1-5 alkenyl, halo, CF3, CN, (un)substituted aryl, (un)substituted heterocyclyl, substituted sulfonyl, (un)substituted carboxyl; R2, R3 = H, substituted carbonyl, substituted aminocarbonyl, substituted aminothiocarbonyl, substituted sulfonyl, C1-5 alkyl, (un)substituted C6-10 aryl, (un)substituted heterocyclyl, C6-10 (arylamino)carbonyl, C6-10 (arylamino)thiocarbonyl, C5-10 azaheteroaryl, (un)substituted carboxyl, CN, (un)substituted aryl; the dotted line next to the solid line represents a single or a double bond;] or their racemates or optical or geometric isomers or pharmaceutically acceptable salts and/or hydrates are claimed as ligands for 5-HT6 receptors, as are pharmaceutical compns. containing them for treating diseases and conditions of the central nervous system in humans, in the pathogenesis of which neurotransmitter systems modulated by 5-HT6 receptors play a substantial role. A focused chemical library containing 3537

I, their geometric isomers and pharmaceutically acceptable salts were tested for ligand activity toward 5-HT6 receptors. Thus, tetrahydro-γ-carboline derivative II was 100% effective in binding with 5-HT6 receptors, with an IC50 = 0.074 μM.


IT 1009632-22-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(preparation of azaheterocycles, derivs. of pyrrolo[4,3-b]indoles, γ-carbolines and azepino[4,3-b]indoles, as ligands of 5-HT6

receptors for treating CNS diseases)
 RN 1009632-22-7 CAPLUS
 CN Benzoic acid, 4-[[[(5aR,10bR)-2,3,4,5,5a,10b-hexahydro-2,9-dimethylazepino[4,3-b]indol-6(1H)-yl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
 (3 CITINGS)

L20 ANSWER 5 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2008:249120 CAPLUS

DOCUMENT NUMBER: 148:308318

TITLE: Preparation of hydrogenated, substituted azepino[4,3-b]indoles for treatment of neurodegenerative or autoimmune diseases and allergies by reduction of azepino[4,3-b]indol-1-ones and subsequent reaction with electrophiles

INVENTOR(S): Ivashchenko, Andrey Alexandrovich; Frolov, Yevgeniy Borisovich; Tkachenko, Sergey Yevgenievich; Khvat, Alexander Viktorovich; Malyarchuk, Sergey Viktorovich; Mitkin, Oleg Dmitrievich; Okun, Ilya Matusovich; Kyselev, Alexandr Sergeevich; Savchuk, Nikolay Filippovich; Ivashchenko, Alexandr Vasilievich

PATENT ASSIGNEE(S): Alla Chem, LLC, USA

SOURCE: PCT Int. Appl., 91pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Russian

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008024029	A1	20080228	WO 2007-RU436	20070808
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

RU 2317989	C1	20080227	RU 2006-130505	20060824
EP 2062895	A1	20090527	EP 2007-834964	20070808

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

PRIORITY APPLN. INFO.: RU 2006-130505 A 20060824
WO 2007-RU436 W 20070808

OTHER SOURCE(S): CASREACT 148:308318; MARPAT 148:308318
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Hydrogenated, substituted azepino[4,3-b]indoles I; the dotted line with a solid line associated with it = a single or double bond; R1, R2 = H, (un)substituted C1-8 alkyl, possibly substituted by aryl, 5-6-membered azaheterocyclyl; C1-8 alkoxy carbonyl; (un)substituted Ph; (un)substituted carbonylamino or thiocarbonylamino; substituted acyl, C1-8 alkylsulfonyl, (un)substituted arylsulfonyl; substituents on R1, R2 are selected from C1-8 alkyl, halo, nitro, carboxy, alkoxy, aryl; Rin = ≥ 1 substituents selected from H, C1-8 alkyl, C6-10 aryl, halo, 5-6-membered azaheterocyclyl and their racemates, optical and geometric isomers and pharmaceutically acceptable salts and/or hydrates are claimed. Synthesis of compds. I as novel physiol. active substances, lead compds., mol. tools and drug candidates produced by screening combinatorial and focused libraries of compds., a pharmaceutical composition and methods for their production and use are also claimed. I are prepared by reduction of the corresponding azepino[4,3-b]indol-1-ones with LiAlH₄, BH₃ or other borane compds. and subsequent reaction with electrophiles such as aldehydes, alkyl halides, alkenes, iso(thio)cyanates, etc. I are biol. active in treatment of neurodegenerative or autoimmune diseases and allergies. E.g., II (preparation given) showed memory-enhancing activity in doses of 1 mg/kg and 5 mg/kg.

IT 1009632-22-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of hydrogenated, substituted azepino[4,3-b]indoles for treatment of neurodegenerative or autoimmune diseases and allergies)

RN 1009632-22-7 CAPLUS

CN Benzoic acid, 4-[[[5aR,10bR)-2,3,4,5,5a,10b-hexahydro-2,9-dimethylazepino[4,3-b]indol-6(1H)-yl]methyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 6 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2007:619459 CAPLUS
 DOCUMENT NUMBER: 147:52913
 TITLE: Fused pyrimidines as growth factor receptor tyrosine kinase inhibitors, their preparation, pharmaceutical compositions, and use in therapy
 INVENTOR(S): Ishikawa, Tomoyasu; Miwa, Kazuhiro; Seto, Masaki; Banno, Hiroshi; Kawakita, Youichi
 PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan
 SOURCE: PCT Int. Appl., 643pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007064045	A1	20070607	WO 2006-JP324499	20061201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006319787	A1	20070607	AU 2006-319787	20061201
CA 2631066	A1	20070607	CA 2006-2631066	20061201
AR 57961	A1	20071226	AR 2006-105330	20061201
EP 1957495	A1	20080820	EP 2006-834254	20061201
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009517333	T	20090430	JP 2008-520459	20061201
ZA 2008005009	A	20091028	ZA 2008-5009	20061201
MX 2008007019	A	20080618	MX 2008-7019	20080530
US 20100216788	A1	20100826	US 2008-95543	20080530
IN 2008KN02251	A	20090116	IN 2008-KN2251	20080604
NO 2008002870	A	20080901	NO 2008-2870	20080624
KR 2008084823	A	20080919	KR 2008-7016193	20080702
CN 101370812	A	20090218	CN 2006-80052319	20080804
PRIORITY APPLN. INFO.:			JP 2005-349858	A 20051202
			JP 2006-60648	A 20060307
			WO 2006-JP324499	W 20061201


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): CASREACT 147:52913; MARPAT 147:52913
 GI

AB The invention relates to pyrrolo[3,2-d]pyrimidines represented by formula I and related derivs., which are inhibitors of growth factor receptor tyrosine kinase. In compds. I, R1 is H; R2 is carbonylamino-substituted C1-6 alkyl; R3 is H or C1-6 alkyl; R4 and R5 are independently halo or C1-6 alkyl; and X is H or halo; including salts and prodrugs thereof; with several compds. excluded. The invention also relates to the preparation of I, pharmaceutical compns. comprising a compound I, a related compound or a salt or prodrug thereof, as well as to the use of the compns. for the prophylaxis or treatment of cancer. Coupling of the dihydrochloride of amine II with 2-methyl-2-(methylsulfonyl)propanoic acid gave pyrrolopyrimidine III. The compds. of the invention are inhibitors of growth factor receptor tyrosine kinases, e.g., compound III expressed 98% inhibition of HER2 kinase at 1 μ M and IC50 value below 100 nM in an assay for inhibition of breast cancer cell proliferation.

IT 940308-58-7P, 3-[(5-Nitro-1H-indol-1-yl)methyl]benzoic acid
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of fused pyrimidines as growth factor receptor tyrosine kinase inhibitors)

RN 940308-58-7 CAPLUS

CN Benzoic acid, 3-[(5-nitro-1H-indol-1-yl)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2007:512060 CAPLUS

DOCUMENT NUMBER: 146:501049

TITLE: Preparation of benzimidazolyl and indolyl amide derivatives as modulators of 11 β -hydroxysteroid dehydrogenase type 1

INVENTOR(S): Kilburn, John Paul; Andersen, Henrik Sune; Kampen, Gita Camilla Tejlgaard; Ebdrup, Soeren

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 126 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007051811	A2	20070510	WO 2006-EP68017	20061101
WO 2007051811	A3	20080124		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,

IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU 2006310519	A1	20070510	AU 2006-310519	20061101
CA 2627307	A1	20070510	CA 2006-2627307	20061101
EP 1945207	A2	20080723	EP 2006-807711	20061101

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
 BA, HR, MK, RS

JP 2009513611	T	20090402	JP 2008-537122	20061101
MX 2008005653	A	20080722	MX 2008-5653	20080430
KR 2008069189	A	20080725	KR 2008-7011701	20080516
IN 2008DN04561	A	20080815	IN 2008-DN4561	20080528
CN 101355938	A	20090128	CN 2006-80050238	20080701
US 20090118259	A1	20090507	US 2008-92223	20081023

PRIORITY APPLN. INFO.: EP 2005-110226 A 20051101
 WO 2006-EP68017 W 20061101

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OTHER SOURCE(S): CASREACT 146:501049; MARPAT 146:501049
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB Title compds. I [R1 = substituted alkyl; R2 = H, halo, alkyl, etc.; X = N
 or CR3, wherein R3 = H, CN, alkyl, etc.; if R4 is absent, A and N together
 form an (un)substituted and saturated heterobicyclic or heterotricyclic ring;
 if R4 = H or alkyl, A = (un)substituted adamantyl], and their
 pharmaceutically acceptable salts, are prepared and disclosed as modulators
 of 11 β -hydroxysteroid dehydrogenase type 1 (11 β HSD1). Thus,
 e.g., II was prepared by acylation of trifluoroacetate salt of III with
 2-furoic acid. Details for bioassays are described (no data). As
 modulators of 11 β HSD1, I should prove useful for the treatment and
 prevention of medical disorders where a decreased intracellular concentration

of active glucocorticoid is desirable.

IT 936348-04-8P 936348-06-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of benzimidazolyl and indolyl amide derivs. as modulators of
 11 β -hydroxysteroid dehydrogenase type 1)


RN 936348-04-8 CAPLUS

CN Benzoic acid, 3-[[5-[(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-
 yl)carbonyl]-1H-indol-1-yl)methyl]- (CA INDEX NAME)



RN 936348-06-0 CAPLUS


CN Benzoic acid, 4-[[5-[(1,3,3-trimethyl-6-azabicyclo[3.2.1]oct-6-
 yl)carbonyl]-1H-indol-1-yl)methyl]- (CA INDEX NAME)



L20 ANSWER 8 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2007:284092 CAPLUS
 DOCUMENT NUMBER: 146:341023
 TITLE: Photoelectric conversion material, semiconductor electrode, and photoelectric converter thereof
 INVENTOR(S): Torizuka, Koichi
 PATENT ASSIGNEE(S): Mitsubishi Paper Mills, Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 31pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007066689	A	20070315	JP 2005-251019	20050831

PRIORITY APPLN. INFO.:
 OTHER SOURCE(S): MARPAT 146:341023
 GI



AB The photoelec. conversion material uses a compound represented by I (R1, R8 = (substituted) alkyl, aralkyl, alkenyl, aryl, or heterocyclic group; R2-7 = H, halo, lower alkyl, or lower alkoxy group; R9-10 = H, (substituted) alkyl, aralkyl, aryl, acyl, cyano, carboxyl, carboxy alkyl, carbamoyl, sulfamoyl, or heterocyclic group; X = single bond or divalent connecting group; Y1, Y2 = divalent group selected from ketone, amide, sulfone, sulfoxide, or ester; Z1, Z2 = residue forming five-membered, six-membered, or heterocyclic ring by connecting 2 Carbon of N-containing heterocyclic ring; m, n = 0 or 1; and ≥1 of R1, R8, R9, and R10 contains carboxyl group), or II (R1-4, R9, X, Y1, Z1, and m are same as I). The semiconductor electrode has a semiconductor layer coated on a

surface-conductive substrate, and a pigment using the above photoelec. conversion material and adsorbed on the semiconductor layer. The photoelec. converter uses the above semiconductor electrode.


IT 929519-25-5 929519-31-3

RL: TEM (Technical or engineered material use); USES (Uses)
(comps. of pigments for semiconductor electrodes in photoelec. converters)


RN 929519-25-5 CAPLUS

CN 1,2-Benzenedicarboxylic acid, 4,4'-[1,4-phenylenebis[2-(methylamino)carbonyl]-3-oxo-1-butene-4,1-diyl] (2,3,3a,8b-tetrahydrocyclopent[b]indole-7,4(1H)-diyl)methylene]]bis- (CA INDEX NAME)

PAGE 1-A





PAGE 1-B



RN 929519-31-3 CAPLUS

CN Benzoic acid, 4,4'-[1,4-phenylenebis[methyleneoxy(2-cyano-3-oxo-1-propene-3,1-diyl)] (2,3,3a,8b-tetrahydrocyclopent[b]indol-7,4(1H)-diyl)-2,1-ethanediyl]]bis- (CA INDEX NAME)



L20 ANSWER 9 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2007:197836 CAPLUS
 DOCUMENT NUMBER: 146:252104
 TITLE: Preparation of substituted indoles and their use as
 PAI-1 inhibitors
 INVENTOR(S): Hu, Baihua; Jetter, James W.
 PATENT ASSIGNEE(S): Wyeth, USA
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007022321	A2	20070222	WO 2006-US32066	20060816
WO 2007022321	A3	20070510		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

AU 2006279496	A1	20070222	AU 2006-279496	20060816
CA 2617372	A1	20070222	CA 2006-2617372	20060816
US 20070043101	A1	20070222	US 2006-505527	20060816
US 7683091	B2	20100323		
EP 1919866	A2	20080514	EP 2006-801683	20060816

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

JP 2009504762	T	20090205	JP 2008-527122	20060816
BR 2006014340	A2	20110412	BR 2006-14340	20060816
IN 2008DN01072	A	20080620	IN 2008-DN1072	20080207
MX 2008002117	A	20080926	MX 2008-2117	20080213
CN 101263115	A	20080910	CN 2006-80029894	20080215
US 20100137363	A1	20100603	US 2010-696648	20100129

PRIORITY APPLN. INFO.:

US 2005-708834P	P	20050817
US 2006-505527	A1	20060816
WO 2006-US32066	W	20060816

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 146:252104; MARPAT 146:252104

GI



I

AB The invention relates to indole derivs. I [R is p-R2C6H4(CH2)1-4, where R2 is alkyl, and R1 is a sulfonylamino or ureido group; or R is R3C6H4(CH2)0-4CHR4, where R3 is H, a carboxyalkoxy, carbamoyl, or carbonyl-amino acid group and R4 is H, CO2H, or CONHNH2 and R1 is a sulfonylamino group; or R is R5CO(CH2)1-4, where R5 is OH, alkoxy, or an amino acid residue and R1 is a sulfonylamino group] for use as PAI-1 inhibitors. Thus, N-[[[1-(4-tert-butylbenzyl)-1H-indol-5-yl]amino]carbonyl]-L-phenylalanine was prepared by treating 1-(4-tert-butylbenzyl)-1H-indol-5-amine (preparation given) with 2-isocyanato-3-phenylpropionic acid Et ester.


IT 926025-13-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of substituted indoles and their use as PAI-1 inhibitors)

RN 926025-13-0 CAPLUS

CN Benzoic acid, 4-[(5-nitro-1H-indol-1-yl)methyl]- (CA INDEX NAME)



L20 ANSWER 10 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2005:1176261 CAPLUS

DOCUMENT NUMBER: 143:440259

TITLE: Preparation of indolyl hexafluoropropanols as Live-X-Receptor (LXR) modulators for the treatment of diabetes and related diseases

INVENTOR(S): Dehmloew, Henrietta; Kuhn, Bernd; Panday, Narendra; Ratni, Hasane; Schulz-Gasch, Tanja; Wright, Matthew Blake

PATENT ASSIGNEE(S): Hoffmann-La Roche Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 45 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050245515	A1	20051103	US 2005-115942	20050427
US 7173048	B2	20070206		
AU 2005238176	A1	20051110	AU 2005-238176	20050426
CA 2564563	A1	20051110	CA 2005-2564563	20050426
WO 2005105791	A1	20051110	WO 2005-EP4454	20050426
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1756096	A1	20070228	EP 2005-751959	20050426
EP 1756096	B1	20090812		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
CN 1950365	A	20070418	CN 2005-80014206	20050426
BR 2005010599	A	20071120	BR 2005-15099	20050426
JP 2007536300	T	20071213	JP 2007-511949	20050426
JP 4682192	B2	20110511		
AT 439357	T	20090815	AT 2005-751959	20050426
RU 2368612	C2	20090927	RU 2006-142746	20050426
PT 1756096	E	20091016	PT 2005-751959	20050426
ES 2329489	T3	20091126	ES 2005-751959	20050426
NZ 550447	A	20100625	NZ 2005-550447	20050426
AR 49497	A1	20060809	AR 2005-101717	20050429
TW 287537	B	20071001	TW 2005-113966	20050429
ZA 2006008886	A	20080625	ZA 2006-8886	20061025
MX 2006012683	A	20070116	MX 2006-12683	20061101
KR 2007008678	A	20070117	KR 2006-7023014	20061102


KR 893449	B1	20090417		
IN 2006DN06980	A	20070615	IN 2006-DN6980	20061122
NO 2006005503	A	20070124	NO 2006-5503	20061129
US 20070099916	A1	20070503	US 2006-636925	20061211
US 7485652	B2	20090203		

PRIORITY APPLN. INFO.: EP 2004-101889 A 20040503
WO 2005-EP4454 W 20050426
US 2005-115942 A3 20050427

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:440259; MARPAT 143:440259
GI



I




II

AB The invention relates to compds. I [wherein R1 - R6 = H, alkyl, etc.; A = (un)substituted aryl or heterocyclyl; m, p = 0-3; n = 0 or 1; R3 and R4 are absent when a is a double bond, with limitations, and pharmaceutically acceptable salts and esters thereof], their pharmaceutical compns., processes for their preps., and their use in the treatment and prophylaxis of diseases modulated by LXRA and/or LXRβ agonists, such as diabetes. For instance, II, which showed IC50 values of 0.02 μM and 0.006 μM against LXRA and LXRβ, resp., in the binding assay, was synthesized in multiple steps from 2-methyl-2,3-dihydro-1H-indole, hexafluoroacetone sesquihydrate and Me 3-(chloromethyl)benzoate.

IT 868750-83-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(modulator; preparation of indolyl hexafluoropropanols as Live-X-Receptor (LXR) modulators)

RN 868750-83-8 CAPLUS

CN Benzoic acid, 3-[[[2,3-dihydro-2-methyl-5-[[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L20 ANSWER 11 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 2005:1042216 CAPLUS
 DOCUMENT NUMBER: 143:347050
 TITLE: Preparation of
 4-(5-(aminomethyl)indole-1-ylmethyl)benzamide
 derivatives as opioid receptor antagonists for the
 treatment of obesity
 INVENTOR(S): Benesh, Dana Rae; Blanco-Pillado, Maria-Jesus
 PATENT ASSIGNEE(S): Eli Lilly and Company, USA
 SOURCE: PCT Int. Appl., 52 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005090303	A1	20050929	WO 2005-US7702	20050309
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2558030	A1	20050929	CA 2005-2558030	20050309
EP 1751103	A1	20070214	EP 2005-725070	20050309
EP 1751103	B1	20090114		
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
JP 2007529523	T	20071025	JP 2007-503959	20050309
AT 420858	T	20090115	AT 2005-725070	20050309
ES 2318472	T3	20090501	ES 2005-725070	20050309
US 20070155793	A1	20070705	US 2006-598281	20060823
PRIORITY APPLN. INFO.:			US 2004-553176P	P 20040315
			WO 2005-US7702	W 20050309

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): CASREACT 143:347050; MARPAT 143:347050

GI




AB Title comps. represented by the formula I [wherein X1 = CH2, CH or N; X2 = CH or N; R1, R2 = independently H, alkyl(aryl), alkenyl, etc.; R3, R3' = independently H, alkyl, alkynyl, etc.; R4, R5 = independently H, (halo)alkyl, aryl, etc.; m = 0-2; n = 0-2; p = 0-2; and pharmaceutically acceptable salts, solvates, prodrugs, enantiomers, racemates, diastereomers and diastereomeric mixture thereof] were prepared as opioid receptor antagonists. For example, II was provided in a multi-step synthesis starting from the reaction of 5-formylindole with 4-bromomethylbenzonitrile. I were tested for antagonistic activity of mu-, gamma- and delta-opioid receptor in SPA-based GTPyS binding assay, and their pharmaceutical formulations were also presented. Thus, I and their pharmaceutical comps. are useful as opioid receptor antagonists for the treatment of obesity (no data).

IT 865542-83-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of 4-(5-(aminomethyl)indole-1-ylmethyl)benzamide derivs. as opioid receptor antagonists for treatment of obesity)

RN 865542-83-2 CAPLUS

CN Benzamide, 4-[[5-[[[2-(2-thienyl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]-
(CA INDEX NAME)



IT 865542-80-9P 865542-82-1P 865542-84-3P

865542-85-4P 865542-86-5P 865542-87-6P

865542-88-7P 865542-89-8P 865542-90-1P

865542-91-2P 865542-92-3P 865542-93-4P


865542-94-5P 865542-95-6P 865542-96-7P

865542-97-8P 865542-98-9P 865542-99-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-(5-(aminomethyl)indole-1-ylmethyl)benzamide derivs. as opioid receptor antagonists for treatment of obesity)


RN 865542-80-9 CAPLUS
 CN Benzamide, 4-[[5-[(3-methylbutyl)amino]methyl]-1H-indol-1-yl]methyl]-
 (CA INDEX NAME)




RN 865542-82-1 CAPLUS
 CN Benzamide, 4-[[5-formyl-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-84-3 CAPLUS
 CN Benzamide, 4-[[5-[(3,3-dimethylbutyl)amino]methyl]-1H-indol-1-yl]methyl]-
 (CA INDEX NAME)




RN 865542-85-4 CAPLUS
 CN Benzamide, 4-[[2,3-dihydro-5-[[2-(2-thienyl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-86-5 CAPLUS
 CN Benzamide, 4-[[2,3-dihydro-5-[(3-methylbutyl)amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-87-6 CAPLUS
 CN Benzamide, 4-[[5-[[(3,3-dimethylbutyl)amino]methyl]-2,3-dihydro-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-88-7 CAPLUS
 CN Benzamide, 4-[[5-[(hexylamino)methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)



RN 865542-89-8 CAPLUS
 CN Benzamide, 4-[[5-[[(3-phenylpropyl)amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-90-1 CAPLUS
 CN Benzamide, 4-[[5-[[[2-(2-fluorophenyl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-91-2 CAPLUS

CN Benzamide, 4-[[5-[[[(2-hydroxyethyl)amino]methyl]-1H-indol-1-yl]methyl]-
(CA INDEX NAME)




RN 865542-92-3 CAPLUS

CN Benzamide, 4-[[5-[[[2-(4-methoxyphenyl)ethyl]amino]methyl]-1H-indol-1-
yl]methyl]- (CA INDEX NAME)




RN 865542-93-4 CAPLUS

CN Benzamide, 4-[[5-[[[(2-chloro-6-fluorophenyl)methyl]amino]methyl]-1H-indol-1-
yl]methyl]- (CA INDEX NAME)




RN 865542-94-5 CAPLUS

CN Benzamide, 4-[[5-[[[2-(3-pyridinyl)ethyl]amino]methyl]-1H-indol-1-
yl]methyl]- (CA INDEX NAME)




RN 865542-95-6 CAPLUS


CN Benzamide, 4-[[5-[[[2-(2-ethoxyphenyl)ethyl]amino]methyl]-1H-indol-1-
yl]methyl]- (CA INDEX NAME)




RN 865542-96-7 CAPLUS
 CN Benzamide, 4-[[5-[[[2-(4-ethoxyphenyl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 865542-97-8 CAPLUS
 CN Benzamide, 4-[[5-[[[2-(1-cyclohexen-1-yl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)



RN 865542-98-9 CAPLUS
 CN Benzamide, 4-[[5-[[[2-(3-fluorophenyl)ethyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)



RN 865542-99-0 CAPLUS
 CN Benzamide, 4-[[5-[[[2-(ethylbutyl)amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 12 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2004:927166 CAPLUS

DOCUMENT NUMBER: 141:395428

TITLE: Biaryl methyl indolines, indoles, and tetrahydroquinolines, useful as serine protease inhibitors, and particularly as anticoagulants, and their preparation, pharmaceutical compositions, and use.

INVENTOR(S): Smallheer, Joanne M.; Quan, Mimi L.; Wang, Shuaige; Bisacchi, Gregory S.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 153 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094372	A2	20041104	WO 2004-US11856	20040415
WO 2004094372	A3	20050602		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 20040220206	A1	20041104	US 2004-824025	20040414
US 7129264	B2	20061031		
EP 1633716	A2	20060315	EP 2004-750251	20040415
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
JP 2006523716	T	20061019	JP 2006-513080	20040415
PRIORITY APPLN. INFO.:			US 2003-463452P	P 20030416
			US 2004-824025	A 20040414
			WO 2004-US11856	W 20040415

OTHER SOURCE(S): MARPAT 141:395428

GI



AB The invention provides compds. I or stereoisomers, pharmaceutically acceptable salts or hydrates, or prodrugs thereof (wherein: W = (un)substituted CH₂CH₂, CH:CH, CH:N, or CH₂CH₂CH₂; L₁ = CH₂, CH₂CH₂, CH₂S(O)0-2, or CH₂C(O); L₂ = bond, (un)substituted CH₂, CH₂CH₂, O, NH, C(O), S(O)0-2, CH₂C(O), C(O)CH₂, CH₂O, OCH₂, CH₂NH, NHCH₂, CH₂S(O)0-2, S(O)0-2CH₂, C(O)O, OC(O), C(O)NH, NHC(O), S(O)NH, S(O)2NH, NHS(O), or NHS(O)2; A = (un)substituted C3-10 carbocycle or 5- to 12-membered heterocycle with 1-4 N/O/S(O)0-2 heteroatoms; B = (un)substituted alk(en/yn)yl, C3-10 carbocycle, or 5- to 12-membered heterocycle with 1-4 N/O/S(O)0-2 heteroatoms; X = (independently) (un)substituted CH or N]. I are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, the invention relates to compds. that are selective factor XIa inhibitors. This invention also relates to pharmaceutical compns. comprising I, and methods of treating thromboembolic and/or inflammatory disorders using I. I had K_i values of ≤ 15 μM in assays for Factor XIa and plasma kallikrein, thereby confirming their utility as effective inhibitors of these entities. Approx. 115 compds. I and various intermediates were prepared. For instance, 5-cyanoindoline was reduced to 5-cyanoindoline with NaBH₃CN (40%) or with Et₃SiH (77%). Then, Suzuki coupling of 2-IC₆H₄CO₂Me with 2-OCHC₆H₄B(OH)₂ gave 83% 2-OCHC₆H₄-C₆H₄CO₂Me-2, which underwent reductive alkylation with 5-cyanoindoline (86%). The obtained 1-substituted 5-cyanoindoline was converted to the corresponding 5-amidoxime, which was reduced by Zn in AcOH to give the 5-amidine (18.5%). Alkaline saponification of the ester moiety gave

invention compound II, isolated as the bis(trifluoroacetate) salt.

IT 787630-52-8P, 2-(Benzyloxy)-5-(5-carbamimidoyl-2,3-dihydroindol-1-ylmethyl)benzoic acid 787630-53-9P, 2-(Benzyloxy)-3-(5-(5-carbamimidoyl-2,3-dihydroindol-1-ylmethyl)benzoic acid 787630-69-7P, 6'-((5-Carbamidimidoyl-2,3-dihydroindol-1-ylmethyl)-4-methoxybiphenyl-2,3'-dicarboxylic acid


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(drug candidate; preparation of biarylmethyl indolines, indoles, and tetrahydroquinolines as serine protease inhibitors and anticoagulants)


RN 787630-52-8 CAPLUS

CN Benzoic acid, 5-[[5-(aminoiminomethyl)-2,3-dihydro-1H-indol-1-yl]methyl]-2-(phenylmethoxy)- (CA INDEX NAME)




RN 787630-53-9 CAPLUS

CN Benzoic acid, 3-[[5-(aminoiminomethyl)-2,3-dihydro-1H-indol-1-yl]methyl]-2-(phenylmethoxy)- (CA INDEX NAME)



RN 787630-69-7 CAPLUS

CN [1,1'-Biphenyl]-2,3'-dicarboxylic acid, 6'-[[5-(aminoiminomethyl)-2,3-dihydro-1H-indol-1-yl]methyl]-4-methoxy- (CA INDEX NAME)




IT 787631-72-5P, 2'-(5-Cyano-2,3-dihydroindol-1-ylmethyl)-5'-carboxybiphenyl-2-carboxylic acid methyl ester 787631-85-0P, 3-[2-[(Benzyloxy)carbonyl]-4-methylphenyl]-4-[(5-cyano-2,3-dihydro-1-indolyl)methyl]benzoic acid
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of biarylmethyl indolines, indoles, and tetrahydroquinolines as serine protease inhibitors and anticoagulants)


RN 787631-72-5 CAPLUS

CN [1,1'-Biphenyl]-2,3'-dicarboxylic acid,

6'-[(5-cyano-2,3-dihydro-1H-indol-1-yl)methyl]-, 2-methyl ester (CA INDEX NAME)



RN 787631-85-0 CAPLUS
 CN [1,1'-Biphenyl]-2,3'-dicarboxylic acid,
 6'-[(5-cyano-2,3-dihydro-1H-indol-1-yl)methyl]-4-methyl-, 2-(phenylmethyl)
 ester (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
 (7 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 13 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2003:784629 CAPLUS

DOCUMENT NUMBER: 139:292147

TITLE: Preparation of indole derivatives as phospholipase
 enzyme inhibitors

INVENTOR(S): Seehra, Jasbir S.; Kaila, Neelu; McKew, John C.;

Bemis, Jean E.; Xiang, Yibin; Chen, Lihren

PATENT ASSIGNEE(S): Genetics Institute LLC, USA

SOURCE: U.S., 81 pp., Cont.-in-part of U.S. Ser. No. 30,102.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6630496	B1	20031007	US 2000-645042	20000824
BR 9909242	A	20001114	BR 1999-9242	19990217
PRIORITY APPLN. INFO.:			US 1997-918400	B2 19970826
			US 1998-30102	B2 19980225
			WO 1999-IS3388	W 19990217

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB The indole derivs. (I), (II), and (III) [where A = CH₂ or CH₂CH₂; B = (CH₂)_n, (CH₂O)_n, (CH₂S)_n, (OCH₂)_n, (SCH₂)_n, (CH=CH)_n, (C.tplbond.C)_n, CONR₆, NR₆CO, O, S, or NR₆; R₁ = H, OH, halo, etc.; R₂, R₃ = H, CO₂H, alkyl, aryl, etc.; R₄, R₅ = H, OH, CN, CO₂H, etc.; n = 0-4] and pharmaceutically acceptable salts thereof, were prepared. Thus, 2,4-thiazolidinedione and K₂CO₃ followed by NaOH were added to 5-(benzyloxy)-1-(4-([3,5-bis(trifluoromethyl)phenoxy]methyl)benzyl)-1H-indole-2-carboxaldehyde in EtOH to form the 2,4-thiazolidinedione-4-ylidene derivative. The ylidene was dissolved in a solution of DMF and NaH, reacted

with an alkyl ester of 4-(bromomethyl)benzoic acid, and deesterified with HF to yield the acid, (E)-(IV). The title compds. are useful as phospholipase enzyme inhibitors, especially cytosolic phospholipase A₂ (cPLA₂), for treatment of inflammatory conditions and pain, particularly where inhibition of production of prostaglandins, leukotrienes, and PAF are all desired. Eighty-seven compds. of the invention were tested for phospholipase enzyme inhibiting activity in the LysoPC and/or Coumarine assay. IC₅₀ values ranged from 0.081 μM to >50 μM for the LysoPC assay and from 2.5 μM to >64 μM for the Coumarine assay. Selected compds. were tested for in vivo activity in the carrageenan-induced rat paw edema test, and showed 4.2% to 34.2% inhibition. Forty-eight compds. of the invention were tested for cPLA₂ enzyme activity, and exhibited 25% to 95% inhibition at concns. of 3 μM to 100 μM. Pharmaceutical composition comprising the compound I was claimed.

IT 204017-06-1P 204017-07-2P 204017-08-3P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indole derivs. as phospholipase enzyme inhibitors for treatment of inflammatory conditions)


RN 204017-06-1 CAPLUS

CN Benzoic acid, 4-[[2-[[[2,4-bis(trifluoromethyl)phenyl]methoxy]methyl]-2,3-dihydro-5-(phenylmethoxy)-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 204017-07-2 CAPLUS

CN Benzoic acid, 4-[[2,3-dihydro-2-[(2-naphthalenylmethoxy)methyl]-5-(phenylmethoxy)-1H-indol-1-yl]methyl]- (CA INDEX NAME)



RN 204017-08-3 CAPLUS
 CN Benzoic acid, 4-[[2-[[[4-[[3,5-bis(trifluoromethyl)phenoxy]methoxy]methyl]phenyl]methoxy]methyl]-2,3-dihydro-5-(phenylmethoxy)-1H-indol-1-yl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
 REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 14 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2001:137021 CAPLUS

DOCUMENT NUMBER: 134:193347

TITLE: Preparation of indol-1-yl(or quinolin-1-yl)methyl benzoic acids as peroxisome proliferator activated receptor (PPAR) agonists

INVENTOR(S): Hargreaves, Rodney Brian; Whittamore, Paul Robert Owen

PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; AstraZeneca UK Limited

SOURCE: PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012187	A2	20010222	WO 2000-GB3140	20000814
WO 2001012187	A3	20010607		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				

	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,	
	CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG	
CA 2380775	A1 20010222	CA 2000-2380775 20000814
BR 2000013368	A 20020507	BR 2000-13368 20000814
EP 1210343	A2 20020605	EP 2000-953320 20000814
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,		
	IE, SI, LT, LV, FI, RO, MK, CY, AL	
JP 2003507327	T 20030225	JP 2001-516533 20000814
NZ 517059	A 20040528	NZ 2000-517059 20000814
ZA 2002000669	A 20030424	ZA 2002-669 20020124
MX 2002001598	A 20020702	MX 2002-1598 20020214
NO 2002000765	A 20020417	NO 2002-765 20020215
PRIORITY APPLN. INFO.:		
	GB 1999-19411 A 19990818	
	WO 2000-GB3140 W 20000814	
OTHER SOURCE(S):	MARPAT 134:193347	
GI		



AB The title compds. [I; X, Y, Z = a bond, atom or groups of atoms such that X, Y and Z together with the nitrogen atom = 5-6 membered (non)aromatic ring; R1 = alkyl, halo, haloalkyl, etc.; n = 0-2; R2 = (un)substituted hydrocarbyl, halo, CN, etc.; l = 0-1; Q = a bond, alkylene, alkenylene; R3 = alkyl, halo, haloalkyl, etc.; m = 0-2] which act as peroxisome proliferator activated receptor (PPAR) agonists, in particular gamma receptors (PPAR γ) (data given), and so are useful in the treatment of states of insulin resistance, including type 2 diabetes mellitus, were prepared. E.g., a multi-step synthesis of II was given.

IT 327043-57-2P 327043-61-8P 327043-63-0P
327043-65-2P 327043-68-5P 327043-70-9P
327043-71-0P 327043-72-1P 327043-73-2P
327043-74-3P 327043-77-6P 327043-79-8P
327043-80-1P 327043-81-2P 327043-82-3P
327043-83-4P 327043-84-5P 327043-85-6P
327043-86-7P 327043-87-8P 327043-88-9P
327043-89-0P 327043-90-3P 327043-91-4P
327043-94-7P 327043-95-8P 327043-96-9P
327043-98-1P 327043-99-2P 327044-00-8P
327044-01-9P 327044-02-0P 327044-09-7P
327044-10-0P 327044-11-1P 327044-12-2P


327044-13-3P	327044-14-4P	327044-15-5P
327044-16-6P	327044-17-7P	327044-18-8P
327044-19-9P	327044-20-2P	327044-21-3P
327044-22-4P	327044-23-5P	327044-24-6P
327044-25-7P	327044-26-8P	327044-27-9P
327044-28-0P	327044-29-1P	327044-30-4P
327044-31-5P	327044-32-6P	327044-33-7P
327044-34-8P	327044-35-9P	327044-36-0P
327044-37-1P	327044-38-2P	327044-39-3P
327044-40-6P	327044-41-7P	327044-42-8P
327044-43-9P	327044-44-0P	327044-45-1P
327044-46-2P		

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indol-1-yl(or quinolin-1-yl)methyl benzoic acids as peroxisome proliferator activated receptor (PPAR) agonists)


RN 327043-57-2 CAPLUS

CN Benzoic acid, 2-[[5-[2-(2-quinolinyl)ethenyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-61-8 CAPLUS

CN Benzoic acid, 2-[[5-(2-naphthalenylmethoxy)-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-63-0 CAPLUS

CN Benzoic acid, 2-[[5-[(methyl-2-pyridinylamino)methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-65-2 CAPLUS


CN Benzoic acid, 2-[[5-[(1,1'-biphenyl)-4-ylmethoxy)-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-68-5 CAPLUS
 CN Benzoic acid, 2-[(5-phenoxy-1H-indol-1-yl)methyl]- (CA INDEX NAME)




RN 327043-70-9 CAPLUS
 CN Benzoic acid, 2-[[5-(4-morpholinylcarbonyl)-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-71-0 CAPLUS
 CN Benzoic acid, 2-[[5-(carboxymethoxy)-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-72-1 CAPLUS
 CN Benzoic acid, 2-[(5-nitro-1H-indol-1-yl)methyl]- (CA INDEX NAME)




RN 327043-73-2 CAPLUS
 CN Benzoic acid, 2-[[5-[[[(2-methoxyphenyl)methyl]amino]carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-74-3 CAPLUS
 CN Benzoic acid, 2-[[5-[(4-chlorophenyl)methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-77-6 CAPLUS
 CN Benzoic acid, 2-[[5-(1,3-benzodioxol-5-ylmethoxy)-1H-indol-1-yl]methyl]- (CA INDEX NAME)



RN 327043-79-8 CAPLUS
 CN Benzoic acid, 2-[[5-[(phenylamino)carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-80-1 CAPLUS
 CN Benzoic acid, 2-[[5-[(3-phenoxyphenyl)methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-81-2 CAPLUS

CN Benzoic acid, 2-[[5-[[4-(1-methylethyl)phenyl]methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-82-3 CAPLUS

CN Benzoic acid, 2-[[5-[[4-(methylsulfonyl)phenyl]methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-83-4 CAPLUS

CN Benzoic acid, 2-[[5-[[2,3,4-trimethoxyphenyl]methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-84-5 CAPLUS


CN Benzoic acid, 2-[[5-[[[1,1'-biphenyl]-4-ylmethyl]amino]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-85-6 CAPLUS
 CN Benzoic acid, 2-[[5-[[[(phenylmethyl)amino]carbonyl]amino]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-86-7 CAPLUS
 CN Benzoic acid, 2-[[5-[[[(phenylmethyl)amino]thioxomethyl]amino]-1H-indol-1-yl]methyl]- (CA INDEX NAME)



RN 327043-87-8 CAPLUS
 CN Benzoic acid, 2-[[5-[(2-phenylacetyl)amino]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-88-9 CAPLUS
 CN Benzoic acid, 2-[[5-[(butylamino)carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-89-0 CAPLUS

CN Benzoic acid, 2-[[5-[(diphenylamino)carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-90-3 CAPLUS

CN Benzoic acid, 2-[[5-[[1,3-benzodioxol-5-ylmethyl]amino]carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-91-4 CAPLUS

CN Benzoic acid, 2-[[5-[[2-thienylmethyl]amino]carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-94-7 CAPLUS

CN Benzoic acid, 2-[[5-[[4-(trifluoromethyl)phenyl]methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-95-8 CAPLUS

CN Benzoic acid, 2-[[5-[[2-methylpropoxy]carbonyl]amino]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-96-9 CAPLUS

CN Benzoic acid, 2-[[5-[(2-[1,1'-biphenyl]-4-yl-2-oxoacetyl)amino]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-98-1 CAPLUS

CN Benzoic acid, 2-[[5-[[[(phenylmethyl)amino]carbonyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327043-99-2 CAPLUS

CN Benzoic acid, 2-[[5-[[[(phenylmethyl)amino]thioxomethyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-00-8 CAPLUS

CN Benzoic acid, 2-[[5-[[[(2-methylpropoxy)carbonyl]amino]methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-01-9 CAPLUS

CN Benzoic acid, 2-[[5-[[[(2,3-dihydro-1H-inden-2-yl)amino]carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-02-0 CAPLUS

CN Benzoic acid, 2-[[5-[[[(4-nitrophenyl)methyl]amino]carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-09-7 CAPLUS

CN Benzoic acid, 2-[[5-[(6-quinolinylamino)carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-10-0 CAPLUS

CN 1H-Indole-5-carboxylic acid, 1-[(2-carboxyphenyl)methyl]- (CA INDEX NAME)




RN 327044-11-1 CAPLUS

CN Benzoic acid, 2-[[5-[(3-quinolinylamino)carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-12-2 CAPLUS

CN Benzoic acid, 2-[[5-[[[(phenylmethyl)sulfonyl]amino]-1H-indol-1-yl]methyl]-
(CA INDEX NAME)




RN 327044-13-3 CAPLUS

CN Benzoic acid, 2-[[5-[[[(1,1'-biphenyl)-4-ylcarbonyl]amino]methyl]-1H-indol-
1-yl]methyl]- (CA INDEX NAME)




RN 327044-14-4 CAPLUS

CN Benzoic acid, 2-[[5-[[[(phenylmethyl)sulfonyl]amino]methyl]-1H-indol-1-
yl]methyl]- (CA INDEX NAME)




RN 327044-15-5 CAPLUS

CN Benzoic acid, 2-[[5-[[[(2-phenylacetyl)amino]methyl]-1H-indol-1-yl]methyl]-
(CA INDEX NAME)




RN 327044-16-6 CAPLUS


CN Benzoic acid, 2-[[5-[(benzoylamino)methyl]-1H-indol-1-yl]methyl]- (CA
INDEX NAME)




RN 327044-17-7 CAPLUS
 CN Benzoic acid, 2-[[5-[[[(benzoylamino)thioxomethyl]amino)methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-18-8 CAPLUS
 CN Benzoic acid, 2-[[5-[2-oxo-2-[(phenylmethyl)amino]ethoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-19-9 CAPLUS
 CN Benzoic acid, 2-[[5-[2-oxo-2-[(4-fluorophenyl)methyl]amino]-2-oxoethoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-20-2 CAPLUS
 CN Benzoic acid, 2-[[5-[2-oxo-2-[(2-phenylethyl)amino]ethoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-21-3 CAPLUS
 CN Benzoic acid, 2-[[5-[2-[(1-naphthalenylmethyl)amino]-2-oxoethoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-22-4 CAPLUS
 CN Benzoic acid, 2-[[5-[2-oxo-2-[[4-(phenylmethoxy)phenyl]amino]ethoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-23-5 CAPLUS
 CN Benzoic acid, 2-[[5-[2-oxo-2-(phenylamino)ethoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-24-6 CAPLUS
 CN Benzoic acid, 2-[[5-[2-[[4-(4-methoxyphenyl)methyl]amino]-2-oxoethoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-25-7 CAPLUS
 CN Benzoic acid, 2-[[5-[6-(4-bromophenyl)-2-methyl-3-pyridinyl]methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-26-8 CAPLUS
 CN Benzoic acid, 2-[[5-[(1,2-dihydro-1-methyl-2-oxo-3-quinolinyl)methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-27-9 CAPLUS
 CN Benzoic acid, 2-[[5-[(3-(4-chlorophenyl)-5-isoxazolyl)methoxy]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-28-0 CAPLUS
 CN Benzoic acid, 2-[[5-(3-quinolinylmethoxy)-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-29-1 CAPLUS
 CN Benzoic acid, 2-[[5-(3-isoquinolinylmethoxy)-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-30-4 CAPLUS
 CN Benzoic acid, 2-[[5-[(6-fluoro-1,2-dihydro-1-methyl-2-oxo-3-quinolinyl)methoxy]-1H-indol-1-yl)methyl]- (CA INDEX NAME)




RN 327044-31-5 CAPLUS
 CN Benzoic acid, 2-[[5-[[[3-(1H-imidazol-1-yl)propyl]amino]carbonyl]-1H-indol-1-yl)methyl]- (CA INDEX NAME)




RN 327044-32-6 CAPLUS
 CN Benzoic acid, 2-[[5-[[[phenylmethyl]amino]carbonyl]-1H-indol-1-yl)methyl]- (CA INDEX NAME)



RN 327044-33-7 CAPLUS
 CN Benzoic acid, 2-[[5-[[[(4-methoxyphenyl)methyl]amino]carbonyl]-1H-indol-1-yl)methyl]- (CA INDEX NAME)




RN 327044-34-8 CAPLUS
 CN Benzoic acid, 2-[[5-[[[(4-chlorophenyl)methyl]amino]carbonyl]-1H-indol-1-yl)methyl]- (CA INDEX NAME)




RN 327044-35-9 CAPLUS

CN Benzoic acid, 2-[[5-[[[(3-chlorophenyl)methyl]amino]carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-36-0 CAPLUS

CN Benzoic acid, 2-[[5-[[[(2-chlorophenyl)methyl]amino]carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-37-1 CAPLUS

CN Benzoic acid, 2-[[5-[[[(3-methoxyphenyl)methyl]amino]carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-38-2 CAPLUS


CN Benzoic acid, 2-[[5-[[[(2-phenylethyl)amino]carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-39-3 CAPLUS
 CN Benzoic acid, 2-[[5-[[[(3,4-dimethoxyphenyl)methyl]amino]carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-40-6 CAPLUS
 CN Benzoic acid, 2-[[5-[[[4-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-41-7 CAPLUS
 CN Benzoic acid, 2-[[5-[[[2-(naphthalenyl)methyl]amino]carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-42-8 CAPLUS
 CN Benzoic acid, 2-[[5-[[[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-43-9 CAPLUS
 CN Benzoic acid, 2-[[5-[[[3-(trifluoromethyl)phenyl]methyl]amino]carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 327044-44-0 CAPLUS
 CN Benzoic acid, 2-[[5-[(2,3-dihydro-1,4-benzodioxin-6-yl)amino]carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)



RN 327044-45-1 CAPLUS
 CN Benzoic acid, 2-[[5-[(cyclohexylamino)carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)



RN 327044-46-2 CAPLUS
 CN Benzoic acid, 2-[[5-[[[1,1'-biphenyl]-4-yl]carbonyl]amino]-1H-indol-1-yl]methyl]- (CA INDEX NAME)




OS.CITING REF COUNT: 23 THERE ARE 23 CAPLUS RECORDS THAT CITE THIS
 RECORD (24 CITINGS)
 REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 15 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN
 ACCESSION NUMBER: 1999:566043 CAPLUS
 DOCUMENT NUMBER: 131:199620

TITLE: Preparation of indole derivatives as phospholipase enzyme inhibitors
 INVENTOR(S): Seehra, Jasbir S.; Xiang, Yibin; Bemis, Jean; McKew, John; Kaila, Neel; Chen, Lihren
 PATENT ASSIGNEE(S): Genetics Institute, Inc., USA
 SOURCE: PCT Int. Appl., 225 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9943672	A1	19990902	WO 1999-US3388	19990217
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2322163	A1	19990902	CA 1999-2322163	19990217
AU 9932970	A	19990915	AU 1999-32970	19990217
BR 9909242	A	20001114	BR 1999-9242	19990217
TR 2000002445	T2	20001221	TR 2000-2445	19990217
EP 1062216	A1	20001227	EP 1999-936073	19990217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
HU 2001000156	A2	20010730	HU 2001-156	19990217
JP 2002504551	T	20020212	JP 2000-533428	19990217
EE 2000000522	A	20020215	EE 2000-522	19990217
HR 2000000513	A2	20011231	HR 2000-513	20000731
NO 2000004217	A	20001023	NO 2000-4217	20000823
MX 2000008294	A	20020327	MX 2000-8294	20000824
BG 104781	A	20011031	BG 2000-104781	20000919
PRIORITY APPLN. INFO.:			US 1998-30102	A 19980225
			WO 1999-IS3388	W 19990217
			WO 1999-US3388	W 19990217
OTHER SOURCE(S):		MARPAT 131:199620		
GI				



AB Indole derivs. (I), (II), and (III) [where A = CH₂ or CH₂CH₂; B = (CH₂)_n, (CH₂O)_n, (CH₂S)_n, (OCH₂)_n, (SCH₂)_n, (CH=CH)_n, (C.tplbond.C)_n, CON(R₆), N(R₆)CO, O, S, or N(R₆); R₁ and R₅ = independently H, OH, halogen, CN, NO₂, C1-5 alkyl, alkenyl, alkynyl, or (un)substituted aryl, etc.; R₂ and R₃ = independently H, CO₂H, COR₅, CONR₅R₆, (CH₂)_nW(CH₂)_mZR₅, (CH₂)_nWR₅, ZR₅, C1-10 alkyl, alkenyl, or substituted aryl; R₄ = H, OH, OR₆, SR₆, CN, COR₆, NHR₆, CO₂H, COR₆R₇, NO₂, (un)substituted sulfamidocarbonyl, C1-5 alkyl, alkenyl, or substituted aryl; R₆, R₇ = H, C1-5 alkyl, alkenyl, alkynyl, or (un)substituted aryl; W = O, S, CH₂, CH=CH, C.tplbond.C, or N(R₆); X = O, S, N(R₆); Z = CH₂, O, S, N(R₆), CO, CON(R₆), N(R₆)CO; m and n = independently 0-4] and pharmaceutically acceptable salts thereof, were prepared. Thus, 2,4-thiazolidinedione and K₂CO₃ followed by NaOH were added to 5-(benzyloxy)-1-(4-{[3,5-bis(trifluoromethyl)phenoxy]methyl}benzyl)-1H-indole-2-carboxaldehyde in EtOH to form the 2,4-thiazolidinedione-4-ylidene derivative. The ylidene was dissolved in a solution of DMF and NaH, reacted


with an alkyl ester of 4-(bromomethyl)benzoic acid, and deesterified with HF to yield the acid, (E)-(IV). The title compds. are useful as phospholipase enzyme inhibitors, especially cytosolic phospholipase A₂ (cPLA₂), for treatment of inflammatory conditions, particularly where inhibition of production of prostaglandins, leukotrienes, and PAF are all desired. Eighty-seven compds. of the invention were tested for phospholipase enzyme inhibiting activity in the LysoPC and/or Coumarine assay. IC₅₀ values ranged from 0.081 μM to >50 μM for the LysoPC assay and from 2.5 μM to >64 μM for the Coumarine assay. Selected compds. were tested for *in vivo* activity in the carrageenan-induced rat paw edema test, and showed 4.2% to 34.2% inhibition. Forty-eight compds. of the invention were tested for cPLA₂ enzyme activity, and exhibited 25% to 95% inhibition at concns. of 3 μM to 100 μM.

IT 204017-06-1P 204017-07-2P 204017-08-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of indole derivs. as phospholipase enzyme inhibitors for treatment of inflammatory conditions)


RN 204017-06-1 CAPLUS

CN Benzoic acid, 4-[[2-[[[2,4-bis(trifluoromethyl)phenyl]methoxy]methyl]-2,3-dihydro-5-(phenylmethoxy)-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 204017-07-2 CAPLUS

CN Benzoic acid, 4-[[2,3-dihydro-2-[(2-naphthalenylmethoxy)methyl]-5-(phenylmethoxy)-1H-indol-1-yl]methyl]- (CA INDEX NAME)



RN 204017-08-3 CAPLUS

CN Benzoic acid, 4-[[2-[[[4-[[[3,5-bis(trifluoromethyl)phenoxy]methyl]phenyl]methoxy]methyl]-2,3-dihydro-5-(phenylmethoxy)-1H-indol-1-yl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 27


THERE ARE 27 CAPLUS RECORDS THAT CITE THIS RECORD (31 CITINGS)

REFERENCE COUNT: 5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 1998:163566 CAPLUS
 DOCUMENT NUMBER: 128:204806
 ORIGINAL REFERENCE NO.: 128:40503a,40506a
 TITLE: Preparation of indole derivatives as phospholipase enzyme inhibitors
 INVENTOR(S): Xiang, Yibin; Bemis, Jean; McKew, John; Kaila, Neelu
 PATENT ASSIGNEE(S): Genetics Institute, Inc., USA
 SOURCE: PCT Int. Appl., 115 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9808818	A1	19980305	WO 1997-US14943	19970826
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2264020	A1	19980305	CA 1997-2264020	19970826
AU 9740862	A	19980319	AU 1997-40882	19970826
AU 717430	B2	20000323		
EP 922028	A1	19990616	EP 1997-938589	19970826
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000516958	T	20001219	JP 1998-511798	19970826
PRIORITY APPLN. INFO.: US 1996-703115 A 19960826 WO 1997-US14943 W 19970826				
OTHER SOURCE(S): MARPAT 128:204806				




AB Title compds. I, II, III (A is independent of any other group and is selected from the group consisting of -CH₂- and -CH₂-CH₂-; B is independent of any other group and is selected from the group consisting of -(CH₂)_n-, -(CH₂O)_n-, -(CH₂S)_n-, -(OCH₂)_n-, -(SCH₂)_n-, -(CH=CH)_n-, -(C.tplbond.C)_n-, -CON(R₆)-, -N(R₆)CO-, -O-, -S- and -N(R₆)-; R₂ is independent of any other R group and is selected from the group consisting of -H, -COOH, -COR₅, -CONR₅R₆, -(CH₂)_n-W-(CH₂)_m-Z-R₅, -(CH₂)_n-W-R₅, -Z-R₅, C₁-C₁₀ alkyl, alkenyl and substituted aryl; R₃ is independent of any other R group and is selected from the group consisting of -H, -COOH, -COR₅, -CONR₅R₆, -(CH₂)_n-W-(CH₂)_m-Z-R₅, -(CH₂)_n-W-R₅, -Z-R₅ wherein: C₁-C₁₀ alkyl, alkenyl and substituted aryl) and a pharmaceutically acceptable salt thereof; which inhibit the activity of phospholipase enzymes, particularly cytosolic phospholipase A₂ were prepared Pharmaceutical compns. comprising such compds. and methods of treatment using such compns. are also disclosed.

IT 204017-06-1P 204017-07-2P 204017-08-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of indole derivs. as phospholipase enzyme inhibitors)


RN 204017-06-1 CAPLUS

CN Benzoic acid, 4-[[2-[[[2,4-bis(trifluoromethyl)phenyl]methoxy]methyl]-2,3-dihydro-5-(phenylmethoxy)-1H-indol-1-yl]methyl]- (CA INDEX NAME)




RN 204017-07-2 CAPLUS

CN Benzoic acid, 4-[[2-[[[2,3-dihydro-2-((2-naphthalenylmethoxy)methyl)-5-(phenylmethoxy)-1H-indol-1-yl]methyl]- (CA INDEX NAME)



RN 204017-08-3 CAPLUS

CN Benzoic acid, 4-[[2-[[[4-[[[3,5-bis(trifluoromethyl)phenoxy]methyl]phenyl]methoxy]methyl]-2,3-dihydro-5-(phenylmethoxy)-1H-indol-1-yl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 29 THERE ARE 29 CAPLUS RECORDS THAT CITE THIS RECORD (33 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 17 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1995:230091 CAPLUS

DOCUMENT NUMBER: 122:23227

ORIGINAL REFERENCE NO.: 122:4397a,4400a

TITLE: Derivation of a 3D pharmacophore model for the angiotensin-II site one receptor

AUTHOR(S): Prendergast, Kristine; Adams, Kym; Greenlee, William J.; Nachbar, Robert B.; Patchett, Arthru A.; Underwood, Dennis J.

CORPORATE SOURCE: Mol. Systems Dep., Merck Res. Lab., Rahway, NJ, 07065, USA

SOURCE: Journal of Computer-Aided Molecular Design (1994), 8(5), 491-512

CODEN: JCADEQ; ISSN: 0920-654X

PUBLISHER: ESCOM

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A systematic search has been use to derive a hypothesis for the receptor-bound conformation of A-II antagonists at the AT1 receptor. The validity of the pharmacophore hypothesis has been tested using CoMFA, which included 50 diverse A-II antagonists, spanning four orders of magnitude in activity. The resulting cross-validated R2 or 0.64 (conventional R2 of 0.76) is indicative of a good predictive model of activity, and has been used to estimate potency for a variety of non-peptidyl antagonists. The structural model for the non-peptide has been compared with respect to the natural substrate, A-II, by generating peptide to non-peptide overlays.


IT 145303-68-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(derivation of a 3D pharmacophore model for the angiotensin-II site one receptor)

RN 145303-68-0 CAPLUS

CN Benzoic acid, 2-[[5-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-1H-indol-1-yl)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 35 THERE ARE 35 CAPLUS RECORDS THAT CITE THIS RECORD (35 CITINGS)

L20 ANSWER 18 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1995:67127 CAPLUS

DOCUMENT NUMBER: 122:23206

ORIGINAL REFERENCE NO.: 122:4393a,4396a

TITLE: Nonpeptide angiotensin II (AII) receptor antagonists: N-substituted indole, dihydroindole, phenylaminophenylacetic acid and acylsulfonamide-based AII receptor antagonists

AUTHOR(S): Dhanoa, D. S.; Bagley, S. W.; Chang, R. S. L.; Lotti, V. J.; Chen, T.; Kivlighn, S. D.; Zingaro, G.; Siegl, P. K. S.; Greenlee, W. J.

CORPORATE SOURCE: Merck Res. Lab., Rahway, NJ, 07065, USA

SOURCE: Pept.: Chem., Struct. Biol., Proc. Am. Pept. Symp., 13th (1994), Meeting Date 1993, 296-8. Editor(s): Hodges, Robert S.; Smith, John A. ESCOM: Leiden, Neth.

CODEN: 60LXAW

DOCUMENT TYPE: Conference

LANGUAGE: English


AB The design and biol. activity of new series of angiotensin II receptor antagonists derived from N-substituted indole, dihydroindole, phenylaminophenylacetic acid and acylsulfonamide are presented.

IT 145303-68-0

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (structure-activity relationships of nonpeptide angiotensin II receptor antagonists)

RN 145303-68-0 CAPLUS

CN Benzoic acid, 2-[[5-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-1H-indol-1-yl)methyl]- (CA INDEX NAME)



L20 ANSWER 19 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1994:217425 CAPLUS

DOCUMENT NUMBER: 120:217425

ORIGINAL REFERENCE NO.: 120:38604h,38605a

TITLE: Non-peptide angiotensin II receptor antagonists. 1. Design, synthesis, and biological activity of N-substituted indoles and dihydroindoles

AUTHOR(S): Dhanoa, Daljit S.; Bagley, Scott W.; Chang, Raymond S. L.; Lotti, Victor J.; Chen, Tsing Bau; Kivlighn, Salah D.; Zingaro, Gloria J.; Siegl, Peter K. S.; Patchett, Arthur A.; Greenlee, William J.

CORPORATE SOURCE: Merck Res. Lab., Rahway, NJ, 07065, USA

SOURCE: Journal of Medicinal Chemistry (1993), 36(26), 4230-8
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 120:217425

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *


AB A series of N-acylated indoles, N-alkylated indoles, N-acylated dihydroindoles, and N-alkylated dihydroindoles were synthesized and evaluated in the in vitro AT1 (rabbit aorta) and AT2 (rat midbrain) binding assay. The carboxylic acid 3-[[N-(2-carboxy-3,6-dichlorobenzoyl)-5-indolyl]methyl]-5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine (I, R = 3,6-Cl₂, R₁ = CO₂H) was found to be the most potent AT1 (IC₅₀ = 0.8 nM) antagonist in the N-acylated indole series and displayed a 25-fold higher potency than the parent unsubstituted derivative I (R = H, R₁ = CO₂H) (AT1 IC₅₀ = 20 nM) and a 22-fold greater potency than the corresponding dihydroindole analog II (AT1 IC₅₀ = 18 nM). Replacement of the terminal carboxyl (COOH) of I (R = H, R₁ = CO₂H) with the bioisostere tetrazole I (R = H, R₁ = tetrazol-5-yl) (AT1 IC₅₀ = 5 nM, AT2 IC₅₀ = 130 nM) not only improved the AT1 potency by 4-fold but also resulted in a 50-fold increase in AT2 activity. In the N-alkylated indole series, the tetrazole 3-[[N-(2-tetrazol-5-yl-6-chlorobenzyl)-5-indolyl]methyl]-5,7-dimethyl-2-ethyl-3H-imidazo[4,5-b]pyridine (III, R₁ = tetrazol-5-yl) exhibited the highest AT1 (IC₅₀ = 1 nM) activity, revealing a 230-fold increase in AT1 activity as a result of the incorporation of the isosteric tetrazole for the carboxyl (COOH) of and a nearly 9-fold increase over the corresponding deschloro analog (AT1 IC₅₀ = 8.7 nM). Tetrazole IV (R₁ = tetrazol-5-yl) was identified as the most potent (AT1 IC₅₀ = 18 nM) AT1 receptor antagonist in a structurally distinct series of compds. derived from N-alkylation of the corresponding dihydroindole. A new class of highly potent [I (R = 3,6-Cl₂, R₁ = CO₂H), AT1 IC₅₀ = 0.8 nM; III (R₁ = tetrazol-5-yl), AT1 IC₅₀ = 1 nM] AT1-selective non-peptide AII receptor antagonists derived from N-substituted indoles and dihydroindoles is disclosed. Tetrazole III (R₁ = tetrazol-5-yl) of the N-alkylated indole series displayed good in vivo activity by blocking the AII-induced pressor response for 5.5 h after i.v. administration in conscious normotensive rats at a 1.0 mg/kg dose level.

IT 145303-68-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as angiotensin II receptor antagonist)

RN 145303-68-0 CAPLUS

CN Benzoic acid, 2-[[5-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-1H-indol-1-yl)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 15 THERE ARE 15 CAPLUS RECORDS THAT CITE THIS RECORD (15 CITINGS)

L20 ANSWER 20 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1993:449404 CAPLUS

DOCUMENT NUMBER: 119:49404

ORIGINAL REFERENCE NO.: 119:8969a,8972a

TITLE: Angiotensin II antagonists incorporating a substituted indole or dihydroindole

INVENTOR(S): Bagley, Scott; Greenlee, William J.; Dhanoa, Daljit S.; Patchett, Arthur A.

PATENT ASSIGNEE(S): Merck and Co., Inc., USA

SOURCE: Eur. Pat. Appl., 104 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 517357	A1	19921209	EP 1992-303080	19920407
R: CH, DE, FR, GB, IT, LI, NL				
US 5175164	A	19921229	US 1991-710413	19910605
CA 2065078	A1	19921206	CA 1992-2065078	19920403
JP 05247030	A	19930924	JP 1992-133093	19920408
JP 08026015	B	19960313		

PRIORITY APPLN. INFO.: US 1991-710413 A 19910605

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 119:49404

GI



AB Title compds. I (R = N heterocyclic; R1R2 = O, S, H2; R1 = H, R2 = CO2H, alkoxycarbonyl, cyano, tetrazolyl, sulfonylamino carbonyl; R3 = Ph,


substituted Ph; R4, R5 = H, halo, nitro, alkyl etc.) and their 2,3-dihydro analogs were prepared as angiotensin II inhibitors and for the treatment of ocular hypertension (no data). Thus, 5-methylindole was N-benzoylated, brominated and treated with 2-butyl-6-methyl-4(1H)-quinazolinone to give the product II.

IT 148029-19-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 148029-19-0 CAPLUS

CN Benzoic acid, 2-[[5-[(2-butyl-6-methyl-4-oxo-3(4H)-quinazolinyl)methyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 6 THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD
(9 CITINGS)

L20 ANSWER 21 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1993:80938 CAPLUS

DOCUMENT NUMBER: 118:80938

ORIGINAL REFERENCE NO.: 118:14245a,14248a

TITLE: Preparation of
3-[(N-benzoylindol-5-yl)methyl]-3H-imidazo[4,6-b]pyridines and analogs as angiotensin II antagonists
Bagley, Scott; Greenlee, William J.; Dhanoa, Daljit S.; Patchett, Arthur A.

INVENTOR(S): Merck and Co., Inc., USA

PATENT ASSIGNEE(S): U.S., 35 pp.

SOURCE: CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5151435	A	19920929	US 1991-681793	19910408
CA 2065049	A1	19921009	CA 1992-2065049	19920403
EP 508723	A1	19921014	EP 1992-303073	19920407
R: CH, DE, FR, GB, IT, LI, NL				
JP 05247031	A	19930924	JP 1992-133094	19920408
JP 07039414	B	19950501		

PRIORITY APPLN. INFO.: US 1991-681793 A 19910408

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 118:80938

GI




AB Title compds. [I; A = atoms to complete a (substituted) (N-containing) aromatic ring, dioxopiperazine ring, etc.; E = bond, O, SOn(CH2)s; R = (substituted) Ph; R1 = (cyclo)alkyl, alkenyl, Ph, heteroaryl, perfluoroalkyl, etc.; R9, R10 = H, halo, (cyclo)alkyl, alkoxy, aryl, etc.; X = O, H2, H and 1 of CO2H, cyano, alkoxycarbonyl, tetrazolyl, etc.; n = 0-2; s = 0-5; dashed line = optional bond] were prepared as angiotensin II antagonists (no data). Thus, 2-amino-4,6-dimethylpyridine was converted in 4 steps to 5,7-dimethyl-2-ethylimidazo[4,5-b]pyridine which was condensed with N-benzoyl-5-(bromomethyl)indole (preparation given) to give title compound II.

IT 145303-68-0P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of, as angiotensin II antagonist)

RN 145303-68-0 CAPLUS

CN Benzoic acid, 2-[[5-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-1H-indol-1-yl)methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 14 THERE ARE 14 CAPLUS RECORDS THAT CITE THIS RECORD (17 CITINGS)

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 22 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 1992:469879 CAPLUS

DOCUMENT NUMBER: 117:69879

ORIGINAL REFERENCE NO.: 117:12299a,12302a

TITLE: Preparation of 5-(heterocyclylmethoxy)indoles as lipoxigenase inhibitors

INVENTOR(S): Stevens, Rodney William; Morita, Hiromasa; Nakane, Masami

PATENT ASSIGNEE(S): Pfizer Inc., USA


SOURCE: PCT Int. Appl., 32 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9206088	A1	19920416	WO 1991-US7045	19911001
W: CA, FI, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
JP 04145079	A	19920519	JP 1990-265687	19901003
JP 07064841	B	19950712		
CA 2092404	A1	19920404	CA 1991-2092404	19911001
EP 544821	A1	19930609	EP 1991-917500	19911001
EP 544821	B1	19950111		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
ES 2067248	T3	19950316	ES 1991-917500	19911001
US 5290788	A	19940301	US 1992-848941	19920421
PRIORITY APPLN. INFO.:			JP 1990-265687	A 19901003
			WO 1991-US7045	W 19911001
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S): MARPAT 117:69879				
GI				




AB The title compds. [I; R = naphthyl, quinolyl, pyridyl, etc.; R1 = H, C1-4 alkyl; R2 = H, C1-4 alkyl, pyridylvinylene, (un)substituted benzoyl, (un)substituted benzyl; R3 = H, HO, C1-3 alkyl, pyridyl, thienyl, carboxy, amino, (un)substituted Ph, etc.; Z = CH2, CO; m = 1, 2; n = 0-3; with a proviso], antiallergics and antiinflammatories (no data for specific I given), useful for the prevention and treatment of bronchial asthma, arthritis, thrombosis, etc., were prepared Stirring of 5-hydroxyindole 5.0, 2-(chloromethyl)quinoline 7.0, and Na2CO3 10.0 g in DMF for 4 h at 80° gave 5.0 g of the appropriate (quinolylmethoxy)indole which (2.5 g) in DMF was added to a suspension of NaH in DMF at 0°. The mixture was treated by 1.54 g 4-ClC6H4CH2Cl in DMF and the whole stirred 30 min at that temperature for 30 min to give 3.0 g title compound [I; R(CH2)mO = 5-(2-quinolylmethoxy), R1 = R2 = H, R3 = 4-ClC6H4, Z = CH2, n = 1]. Preferred (unspecified) I had IC50 of 0.1-30 µM in a lipoxigenase inhibition test.

IT 142403-22-3P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as lipoxigenase inhibitor)

RN 142403-22-3 CAPLUS

CN Benzoic acid, 4-[[5-(2-quinolinylmethoxy)-1H-indol-1-yl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD
(9 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 23 OF 23 CAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 1986:626346 CAPLUS
DOCUMENT NUMBER: 105:226346
ORIGINAL REFERENCE NO.: 105:36543a,36546a
TITLE: Heterocyclic amides
INVENTOR(S): Brown, Frederick Jeffrey; Bernstein, Peter Robert;
Yee, Ying Kwong
PATENT ASSIGNEE(S): ICI Americas, Inc., USA
SOURCE: Eur. Pat. Appl., 137 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 179619	A1	19860430	EP 1985-307498	19851017
EP 179619	B1	19900905		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
FI 8504024	A	19860420	FI 1985-4024	19851016
ZA 8507952	A	19860528	ZA 1985-7952	19851016
HU 38905	A2	19860728	HU 1985-4007	19851016
HU 194163	B	19880128		
AU 8548814	A	19860424	AU 1985-48814	19851017
AU 583062	B2	19890420		
DD 253618	A5	19880127	DD 1985-281838	19851017
SU 1545940	A3	19900223	SU 1985-3970050	19851017
AT 56205	T	19900915	AT 1985-307498	19851017
DK 8504793	A	19860420	DK 1985-4793	19851018
DK 169541	B1	19941128		
NO 8504163	A	19860421	NO 1985-4163	19851018
JP 61178963	A	19860811	JP 1985-231457	19851018
JP 07045466	B	19950517		
IL 76756	A	19890515	IL 1985-76756	19851018
CA 1273934	A1	19900911	CA 1985-493372	19851018
US 4997844	A	19910305	US 1985-788807	19851018
CN 85108623	A	19860730	CN 1985-108623	19851019
ES 554579	A5	19880714	ES 1986-554579	19860430
SU 1595338	A3	19900923	SU 1987-4202434	19870424

US 5234942
PRIORITY APPLN. INFO.:

A 19930810

US 1990-628787

19901217

GB 1984-26474

A 19841019

GB 1985-7305

A 19850321

GB 1985-7861

A 19850326

GB 1985-7862

A 19850326

EP 1985-307498



A 19851017

US 1985-788807

A3 19851018

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 105:226346
GI




AB Title compds. I [Z1 = CH, N; Z2 = alkylene, alkenylene; Z3 = bond, O, S, phenylene, etc.; Z4 = CH2, CH:CH, bond; R1 = CO2H, 5-tetrazolyl, N-(organosulfonyl)carbamoyl, etc.; R2 = H, Me, halo, alkanoyl, etc.; R3 = H, halo, alkyl, alkoxy; R4 = acylamino, esterified NHC(=O)2H, substituted ureido, H2NCO, etc.] were prepared for treatment of allergic and inflammatory diseases. Indolamine II (R5 = H) was treated with hexanoyl chloride and Et3N to give II (R5 = hexanoyl). Selected I showed leukotriene antagonism in guinea-pigs at 5-50 mg orally. Capsules were prepared containing I 10, lactose 488.5, and Mg stearate 1.5 mg.

IT 104448-20-6P 104448-22-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as a drug)


RN 104448-20-6 CAPLUS

CN Benzoic acid, 3-methoxy-4-[[5-[(2-methylpropyl)amino]carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)



RN 104448-22-8 CAPLUS

CN Benzoic acid, 3-methoxy-4-[[5-[(pentylamino)carbonyl]-1H-indol-1-yl]methyl]- (CA INDEX NAME)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)

=> log hold

COST IN U.S. DOLLARS

SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST

137.60 1377.97

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL

ENTRY SESSION

CA SUBSCRIBER PRICE

-20.01 -78.30

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 10:36:03 ON 25 MAY 2011